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Abstract
Expression and purification of the metal-containing
monooxygenases tryptophan hydroxylase and dopamine
β-hydroxylase
Tryptophan hydroxylase (TPH) and dopamine β-hydroxylase (DβH) are two
metal-containing monooxygenases that both function e.g. in the brain where they
are involved in the biosynthesis of neurotransmitters. TPH catalyse the rate-
limiting step in the biosynthesis of serotonin, namely the conversion of tryptophan
to 5-OH-tryptophan, whereas DβH catalyse the conversion of dopamine into nore-
pinephrine in the catecholamine neurotransmitter synthesis and thereby control
the levels of both these neurotransmitters.
With these functions both TPH and DβH are involved in a range of neuro-
logical disorders related to abnormal levels of the neurotransmitters serotonin,
dopamine and norepinephrine and the regulation of tryptophan hydroxylase and
dopamine β-hydroxylase. These include depression, anxiety disorders, obsessive-
compulsive disorder (OCD), schizophrenia, Parkinson’s disease and attention defi-
cit-hyperactive disorder (ADHD) among others. Since all these diseases are the
cause of huge economical and personal costs it is very important to gain more
knowledge of TPH and DβH since these two enzymes could be possible targets for
medicine against the diseases mentioned above.
TPH a three-domain, iron-containing enzyme which belongs to the aromatic
amino acid hydroxylase (AAAH) family. It exist in two isoforms, TPH1 and TPH2,
which are expressed in different tissues and have different properties. TPH is
known as a very difficult protein to work with especially due to instability and only
truncated forms of TPH1 have been purified and crystallized. This project concern
the human neuronal TPH or TPH2. In an attempt to overcome the problems with
recombinant TPH two stability and solubility optimized variants of TPH2 are
designed. Escherichia coli (E. coli) expression strains for these variants and full
length human TPH2 are constructed and the expression levels analysed. Moreover
purification of the three TPH2 variants are compared. As earlier reported in other
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studies, TPH2 expressed in this project was also unstable and only partly soluble,
and these properties were not improved by the introduction of mutations.
Since expression of TPH in E. coli systems seems not to be feasible, it was
decided to try expression of TPH2 in an eukaryote expression system, namely
Drosophila melanogaster (D. melanogaster) S2 cells. Stable transfected S2 cell
lines with human TPH2 with and without the secretion signal BiP were con-
structed, but also in this system TPH2 was problematic. No expression of TPH2
was detected from the S2/BiP-TPH2 cell line whereas TPH2 was found in the
insoluble fraction when expressed from the S2/TPH2 cell line.
Dopamine β-hydroxylase contains two copper ions in the active site and be-
longs to the family of ascorbate dependent type II Cu monooxygenases. Very little
knowledge exist on DβH and most of it comes from investigations of related pro-
teins. Attempts to express human DβH in bacterial systems have been done in
the Metalloprotein Chemistry and Engineering Group, but at present no system
expressing high amounts of soluble DβH have been found. On the other hand
expression of DβH in D. melanogaster S2 was earlier reported and it was decided
to use this system.
Stable transfected cell lines for human DβH with and without the BiP se-
cretion signal were constructed. From the S2/BiP-DβH cell line DβH was suc-
cessfully expressed and secreted in spinner cultures. An improved purification
procedure for glycosylated DβH was developed and up to 1.4 mg/l culture glyco-
sylated tetrameric DβH and 1.0 mg/l glycosylated dimeric DβH were obtained.
The oligomerisation states were determined by mass spectrometry analysis.
Tetrameric DβH was deglycosylated and separated from the deglycosylation
enzyme in another purification step. 0.2 mg/l culture deglycosylated DβH was
obtained after this step and it was used for screening of crystallization conditions.
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Dansk resume´
Ekspression og oprensning af de metal-holdige
mono-oxygenaser tryptophan hydroxylase og dopamin
β-hydroxylase
Tryptophan hydroxylase (TPH) og dopamin β-hydroxylase (DβH) er to metal-
holdige mono-oxygenaser som begge har deres virkning bl.a. i hjernen, hvor de
er involveret i biosyntesen af neurotransmittere. TPH katalyserer omdannelsen
af tryptophan til 5-OH-tryptophan, som er det hastighedsbestemmende trin i
biosyntesen af serotonin, mens DβH katalyserer omdannelsen af dopamin til nore-
pinephrin (noradrenalin) i katekolamin-biosyntesen og kontrollerer dermed mæng-
den af begge disse neurotransmittere.
Med s˚adanne funktioner er b˚ade TPH og DβH involveret i en række neurol-
ogiske sygdomme forbundet med unormale niveauer af neurotransmitterne sero-
tonin, dopamin og norepinephrin samt reguleringen af tryptophan hydroxylase
og dopamin β-hydroxylase. Disse sygdomme inkluderer blandt andre depression,
angst sygdomme, tvangstanker og -handlinger (OCD), skizofreni, Parkinsons syg-
dom og ADHD (attention deficit-hyperactive disorder). Alle disse sygdomme har
store økonomiske og personlige omkostninger, og derfor er det meget vigtigt at
opn˚a større viden om TPH og DβH, idet disse enzymer er mulige m˚al for medicin
mod de førnævnte sygdomme.
TPH er et jern-holdigt enzym best˚aende af tre domæner, som tilhører fam-
ilien af aromatiske aminosyre hydroxylaser (AAAH). Det findes i to isoformer,
TPH1 og TPH2, som udtrykkes i forskellige væv og har forskellige egenskaber.
TPH er kendt som et meget svært protein at arbejde med især pga. ustabilitet,
og kun trunkerede TPH varianter er blevet oprenset og krystalliseret. Dette pro-
jekt omhandler human neuronal TPH ogs˚a kaldet TPH2. I et forsøg p˚a at løse
problemerne med rekombinant TPH er to stabilitets- og opløselighedsoptimerede
varianter af TPH2 blevet designet. Der er blevet fremstillet ekspressionsstammer
for disse varianter samt fuldlængde human TPH2 i Escherichia coli (E. coli) og
udtrykkelsesniveauerne er blevet analyseret. Herudover er alle tre TPH2 varianter
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blevet oprenset og oprensningerne sammenlignet. Ligesom i andre publikationer
har TPH2 i dette projekt været ustabilt og kun delvist opløseligt, og disse egen-
skaber blev ikke forbedret af introduktionen af mutationer.
P˚a grund af problemerne med TPH b˚ade i dette og andre projekter blev det
besluttet at forsøge at udtrykke TPH2 i et eukaryot system, nemlig Drosophila
melanogaster (D. melanogaster) S2 celler. Stabil-transfekterede S2 cellelinier til
udtrykkelse af human TPH2 med eller uden secernerings-signalet BiP blev frem-
stillet, men ogs˚a i dette system var der problemer med TPH2. Fra S2/BiP-TPH2
cellelinien blev der ikke detekteret TPH2 udtrykkelse, hvorimod TPH2 blev fundet
i den uopløselige fraktion efter udtrykkelse i cellelinien S2/TPH2.
Dopamin β-hydroxylase indeholder to kobber-ioner i det aktive site og tilhører
familien af ascorbat afhængige type II Cu monooxygenaser. Der findes meget lidt
viden om DβH, og det meste kommer fra undersøgelser af beslægtede proteiner.
I Metalloproteinkemi gruppen har vi forsøgt at udtrykke DβH i bakterielle syste-
mer, men har p˚a nuværende tidspunkt ikke fundet et system, der udtrykker store
mængder af opløseligt DβH. Derimod er det tidligere blevet rapporteret at DβH
kunne udtrykkes i D. melanogaster S2 celler, og det blev besluttet at benytte dette
system.
Der er lavet stabil-transfekterede cellelinier for human DβH med og uden
secernerings-signalet BiP. Succesfuld udtrykkelse af secerneret DβH blev opn˚aet
med S2/BiP-DβH cellelinien. Der er fundet en forbedret oprensningsprocedure for
glykosyleret DβH med udbytter p˚a op til 1,4 mg/l kultur glykosyleret tetramert
DβH og 1,0 mg/l glykosyleret dimert DβH. De oligomere tilstande er bestemt ved
massespektrometrisk analyse.
Tetramert DβH blev deglykosyleret og adskilt fra deglykosyleringsenzymet i
et efterfølgende oprensningstrin, hvor udbyttet var 0,2 mg/l kultur deglykosyleret
DβH. Det deglykosylerede dopamin β-hydroxylase blev brugt til screening for krys-
tallisationsbetingelser.
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Abbreviations
4-OH-BH4 4a-hydroxy-tetrahydrobiopterin/4a-tetrahydro-BH4
5-OH-Trp 5-hydroxytryptophan
AAAH Aromatic amino acid hydroxylases
ADHD Attention deficit-hyperactivity disorder
Amp Ampicillin
BH2 7,8-dihydrobiopterin
BH4 5,6,7,8-tetrahydrobiopterin
BiP Immunoglobulin binding protein
BiP-DβH Dopamine β-hydroxylase with BiP signal sequence
BiP-TPH2 Tryptophan hydroxylase 2 with BiP signal sequence
Bis-tris buffer Bis-(2-hydroxyethyl)imino-tris(hydroxymethyl)methane
buffer
bp Basepairs
BSD Blasticidin S deaminase
CAPS N-Cyclohexyl-3-aminopropanesulfonic acid
ccPHM Catalytic core of peptidyl α-hydroxylating
monooxygenase
CE Cation exchange
DF Dilution factor
CHES 2-(N-cyclohexylamino)ethane sulfonic acid
CIP Calf intestinal alkaline phosphatase
CNS Central nervous system
cTPH Catalytic domain of tryptophan hydroxylase
cv Canonical variable
CV Column volume
DβH Dopamine β-hydroxylase
D. melanogaster Drosophila melanogaster
DEAE-dextran Diethylaminoethyl-dextran
DIWV Dipeptide instability weight value
VII
DMPD N,N’-dimethyl-1,4-phenylenediamine
DMSO Dimethylsulfoxide
DOPA Dihydroxyphenylalanine
E. coli Escherichia coli
EPR Electron paramagnetic resonance
ER Endoplasmatic reticulum
EtBr Ethidium bromide
EXAFS Extended x-ray absorption fine structure spectroscopy
FBS Fetal bovine serum
GF Gel filtration
HBS HEPES buffered saline
HEPES 2-(4-(2-Hydroxyethyl)-1-piperazinyl)ethanesulfonic acid
HPLC High performance liquid chromatography
huTPH2 Human TPH2
II Instability index
IPTG Isopropyl β-D-1-thiogalactopyranoside
Kan Kanamycin sulfate
KAV Gel phase distribution coefficient
kb Kilobases
LB Luria-Broth
m3tTPH2 tetramerisation domain of tryptophan hydroxylase 2
containing three mutations
m9TPH2 Tryptophan hydroxylase 2 containing nine mutations
m9rTPH2 Regulatory domain of tryptophan hydroxylase 2
containing nine mutations
m12TPH2 Tryptophan hydroxylase 2 containing 12 mutations
m/z Mass-to-charge ratio
MES 2-(N-morpholino)ethanesulfonic acid
MIB buffer Malonic acid, imidazole and boric acid buffer
MOX Monooxygenase X
MMT buffer Malic acid, MES and tris buffer
MPD 2,4-methyl pentanediol
MW Molecular weight
MWCO Molecular weight cut off
NAD+ Nicotinamide-adenine dinucleotide
Na HEPES 2-(4-(2-Hydroxyethyl)-1-piperazinyl)ethanesulfonic acid
sodium salt
NMWL Nominal molecular weight limit
OCD Obsessive-compulsive disorder
PAH Phenylalanine hydroxylase
PAL Peptidyl-α-hydroxyglycine α-amidating lyase
PAM Peptidylglycine α-amidating monooxygenase
PES Polyethersulfone
PBS Phosphate buffered saline
PCR Polymerase chain reaction
PCTP buffer Propionic acid, cacodylate and bis-tris propane buffer
PEG Polyethylene glycol
VIII
Pen/strep Penicillin/streptomycin
PES Polyethersulfone
PHM Peptidyl α-hydroxylating monooxygenase
PKU Phenylketonuria
PVDF Polyvinylidene fluoride
rpm Rounds per minute
rTPH Regulatory domain of tryptophan hydroxylase
S2 (D. melanogaster) Schneider 2 cells
SDS-Page Sodium dodecyl sulfate polyacrylamide gel
electrophoresis
SPG buffer Succinic acid, phosphate and glycine buffer
T-20 Tween 20
TβM Tyramine β-monooxygenase
TBE Tris-boric acid-EDTA buffer
TH Tyrosine hydroxylase
Tm Annealing temperature
TPH(2) Tryptophan hydroxylase (isoform 2)
Tris 2-amino-2-(hydroxymethyl)propane-1,3-diol
tTPH tetramerisation domain of tryptophan hydroxylase
Ub Ubiquitin
UV-light Ultra violet light
V 0 Void volume
V c Geometric column volume
V e Elution volume
WB Western blotting
X-gal 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside
For amino acids standard abbreviations are used.
IX
X
Contents
Part I:
Metal-containing monooxygenases 1
Introduction to part I 3
1 Metal-containing monooxygenases 5
1.1 The biogenic amines . . . . . . . . . . . . . . . . . . . . . . . . . . 6
2 Tryptophan hydroxylase 9
2.1 Biosynthesis of serotonin . . . . . . . . . . . . . . . . . . . . . . . . 9
2.2 The aromatic amino acid hydroxylases . . . . . . . . . . . . . . . . 10
2.2.1 Phenylalanine hydroxylase . . . . . . . . . . . . . . . . . . . 10
2.2.2 Tyrosine hydroxylase . . . . . . . . . . . . . . . . . . . . . . 10
2.3 The two isoforms of tryptophan hydroxylase . . . . . . . . . . . . . 10
2.4 The TPH sequence . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
2.5 Three-dimensional structure of TPH . . . . . . . . . . . . . . . . . 13
2.6 Reaction mechanism for TPH . . . . . . . . . . . . . . . . . . . . . 15
2.7 The neurotransmitter serotonin . . . . . . . . . . . . . . . . . . . . 17
2.8 Disorders related to TPH and serotonin . . . . . . . . . . . . . . . . 17
3 Dopamine β-hydroxylase 19
3.1 The catecholamine neurotransmitters . . . . . . . . . . . . . . . . . 20
3.2 The DβH sequence . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
3.3 Ascorbate dependent type II Cu monooxygenases . . . . . . . . . . 22
3.3.1 Copper centres in proteins . . . . . . . . . . . . . . . . . . . 24
3.4 The catalytic activity of DβH . . . . . . . . . . . . . . . . . . . . . 24
3.4.1 Regulation of DβH activity . . . . . . . . . . . . . . . . . . 25
3.5 The structure of dopamine β-hydroxylase . . . . . . . . . . . . . . . 25
3.5.1 3D structure of PHM . . . . . . . . . . . . . . . . . . . . . . 25
3.5.2 The active site coppers . . . . . . . . . . . . . . . . . . . . . 26
XI
3.6 Proposed mechanisms for the DβH reaction . . . . . . . . . . . . . 27
3.7 Disorders related to dopamine β-hydroxylase . . . . . . . . . . . . . 29
Part II:
Production of tryptophan hydroxylase 2 variants
in a bacterial expression system 31
Introduction to part II 33
4 Stability and solubility optimized variants of TPH 35
4.1 Instability index and solubility . . . . . . . . . . . . . . . . . . . . . 35
4.1.1 Design of the mutated TPH2 sequence . . . . . . . . . . . . 37
4.2 Construction of huTPH2 expression vector . . . . . . . . . . . . . . 41
4.3 Construction of m9TPH2 and m12TPH2 expression vectors . . . . . 42
5 E. coli expression strains for TPH2 - experimental 47
5.1 Construction of E. coli expression strains . . . . . . . . . . . . . . . 47
5.1.1 Polymerase chain reaction . . . . . . . . . . . . . . . . . . . 48
5.1.2 Agarose gel electrophoresis . . . . . . . . . . . . . . . . . . . 49
5.1.3 Extraction of DNA fragment from gel material . . . . . . . . 50
5.1.4 Ligation in PCR vector . . . . . . . . . . . . . . . . . . . . . 50
5.1.5 Transformation of constructs . . . . . . . . . . . . . . . . . . 50
5.1.6 Overnight cultures . . . . . . . . . . . . . . . . . . . . . . . 51
5.1.7 Preparation of bacterial stocks . . . . . . . . . . . . . . . . . 51
5.1.8 Purification of DNA from bacteria . . . . . . . . . . . . . . . 51
5.1.9 Preparation of DNA for sequencing . . . . . . . . . . . . . . 52
5.1.10 Digestion with restriction enzymes . . . . . . . . . . . . . . 52
5.1.11 Ligation of insert and vector DNA . . . . . . . . . . . . . . 53
6 Construction of E. coli TPH2 expression strains 55
6.1 Construction of huTPH2 expression strain . . . . . . . . . . . . . . 55
6.2 Construction of m9TPH2 expression strain . . . . . . . . . . . . . . 56
6.3 Construction of m12TPH2 expression strain . . . . . . . . . . . . . 57
6.4 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
7 Production and purification of TPH2 variants 59
7.1 Protein production in E. coli . . . . . . . . . . . . . . . . . . . . . . 59
7.2 Purification of TPH2 variants . . . . . . . . . . . . . . . . . . . . . 60
7.3 Preparation of cell extract . . . . . . . . . . . . . . . . . . . . . . . 60
7.4 Purification of huTPH2 . . . . . . . . . . . . . . . . . . . . . . . . . 61
7.5 Purification of m9TPH2 . . . . . . . . . . . . . . . . . . . . . . . . 61
7.6 Purification of m12TPH2 . . . . . . . . . . . . . . . . . . . . . . . . 61
7.7 Protein characterization . . . . . . . . . . . . . . . . . . . . . . . . 61
7.7.1 Sodium dodecyl sulfate polyacrylamide gel electrophoresis . 61
7.7.2 TPH activity assay . . . . . . . . . . . . . . . . . . . . . . . 62
7.7.3 TPH activity measurements . . . . . . . . . . . . . . . . . . 63
XII
8 Production and purification of huTPH2, m9TPH2 and m12TPH2 65
8.1 Expression and purification of huTPH2 . . . . . . . . . . . . . . . . 65
8.2 Expression and purification of m9TPH2 . . . . . . . . . . . . . . . . 67
8.3 Expression and purification of m12TPH2 . . . . . . . . . . . . . . . 69
8.4 Overall discussion of the expression and purification of TPH2 variants 72
9 Concluding remarks on part II 73
9.1 Further work on TPH2 . . . . . . . . . . . . . . . . . . . . . . . . . 73
Part III:
TPH2 and DβH production
in an eukaryotic expression system 75
Introduction to part III 77
10 Strategy for expression in Drosophila Melanogaster cells 79
10.1 Eukaryote expression host . . . . . . . . . . . . . . . . . . . . . . . 79
10.2 Drosophila melanogaster Schneider 2 cells . . . . . . . . . . . . . . 80
10.3 Strategy for preparation of expression strains . . . . . . . . . . . . . 80
10.3.1 Design of constructs . . . . . . . . . . . . . . . . . . . . . . 81
10.3.2 Construction of the huTPH2-pMT/V5-His A vector . . . . . 81
10.3.3 Construction of the DβH-pMT/V5-His A vector . . . . . . . 81
10.3.4 Construction of expression vectors for TPH2 and DβH with
BiP secretion signal . . . . . . . . . . . . . . . . . . . . . . . 85
10.3.5 Calcium phosphate transfection . . . . . . . . . . . . . . . . 85
10.3.6 Selection with blasticidin . . . . . . . . . . . . . . . . . . . . 85
11 Experimental work with Drosophila Melanogaster cells 89
11.1 Preparation of DNA for transfection . . . . . . . . . . . . . . . . . 89
11.1.1 Polymerase chain reaction . . . . . . . . . . . . . . . . . . . 90
11.1.2 Agarose gel electrophoresis . . . . . . . . . . . . . . . . . . . 91
11.1.3 Extraction of DNA fragment from gel material . . . . . . . . 92
11.1.4 Ligation in PCR vector . . . . . . . . . . . . . . . . . . . . . 92
11.1.5 Transformation of constructs . . . . . . . . . . . . . . . . . . 92
11.1.6 Overnight cultures . . . . . . . . . . . . . . . . . . . . . . . 93
11.1.7 Preparation of bacterial stocks . . . . . . . . . . . . . . . . . 93
11.1.8 Purification of DNA from bacteria . . . . . . . . . . . . . . . 93
11.1.9 Preparation of DNA for sequencing . . . . . . . . . . . . . . 93
11.1.10 Digestion with restriction enzymes . . . . . . . . . . . . . . 94
11.1.11 Ligation of insert and vector DNA . . . . . . . . . . . . . . 95
11.2 General maintenance of Drosophila Melanogaster Schneider 2 cells . 95
11.2.1 Culturing of S2 cells . . . . . . . . . . . . . . . . . . . . . . 95
11.2.2 Thawing cells from frozen stock . . . . . . . . . . . . . . . . 95
11.2.3 Subculturing of cells . . . . . . . . . . . . . . . . . . . . . . 96
11.2.4 Freezing S2 cells for stock . . . . . . . . . . . . . . . . . . . 96
11.3 Experiments with S2 cells . . . . . . . . . . . . . . . . . . . . . . . 96
XIII
11.3.1 Transient transfection of S2 cells . . . . . . . . . . . . . . . 96
11.3.2 Stable transfection of S2 cells . . . . . . . . . . . . . . . . . 97
11.3.3 Testing blasticidin effect . . . . . . . . . . . . . . . . . . . . 98
11.3.4 Adaption of cells to serum free medium . . . . . . . . . . . . 98
11.4 Detection of protein expression . . . . . . . . . . . . . . . . . . . . 98
11.4.1 Western blotting . . . . . . . . . . . . . . . . . . . . . . . . 98
12 Construction of eukaryotic expression strains 101
12.1 Creation of TPH2 vector for expression in S2 cells . . . . . . . . . . 101
12.2 Construction of DβH vector for expression in S2 cells . . . . . . . . 102
12.3 Construction of BiP-TPH2 and BiP-DβH vectors for transfection of
S2 cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104
12.4 Overview of prepared E. coli strains . . . . . . . . . . . . . . . . . . 105
12.5 Transient transfection results . . . . . . . . . . . . . . . . . . . . . 106
12.6 Stable transfected cell lines . . . . . . . . . . . . . . . . . . . . . . . 108
12.7 Conclusion of transfections . . . . . . . . . . . . . . . . . . . . . . . 108
13 Eukaryotic production of TPH2 and DβH - experimental 111
13.1 Transfected S2 cells in spinner cultures . . . . . . . . . . . . . . . . 111
13.2 Detection of proteins . . . . . . . . . . . . . . . . . . . . . . . . . . 112
13.2.1 Sodium dodecyl sulfate polyacrylamide gel electrophoresis . 112
14 Eukaryotic production of TPH2 and DβH 115
14.1 TPH2 production in S2 cells . . . . . . . . . . . . . . . . . . . . . . 115
14.2 DβH production in S2 cells . . . . . . . . . . . . . . . . . . . . . . . 117
14.3 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118
15 Protocols for purification and characterisation of eukaryotic pro-
duced DβH 121
15.1 Strategy for purification of DβH produced in S2 cells . . . . . . . . 121
15.2 Purification of glycosylated DβH . . . . . . . . . . . . . . . . . . . 122
15.3 Deglycosylation of DβH . . . . . . . . . . . . . . . . . . . . . . . . 123
15.4 Separation of DβH from deglycosylation enzyme . . . . . . . . . . . 124
15.5 Crystallization screens . . . . . . . . . . . . . . . . . . . . . . . . . 124
15.6 Mass spectrometry . . . . . . . . . . . . . . . . . . . . . . . . . . . 124
16 Purification and characterisation of eukaryotic expressed DβH 129
16.1 Preliminary purification of DβH . . . . . . . . . . . . . . . . . . . . 129
16.2 Changed column and gradient in DβH purification . . . . . . . . . . 132
16.3 Small scale deglycosylation of DβH . . . . . . . . . . . . . . . . . . 133
16.4 Final purification procedure for deglycosylated DβH . . . . . . . . . 135
16.5 Crystallization of deglycosylated DβH . . . . . . . . . . . . . . . . 138
16.6 Mass spectrometric analysis of DβH . . . . . . . . . . . . . . . . . . 138
16.7 Overall discussion of the purification and characterisation of DβH . 139
17 Concluding remarks of part III 141
18 Future perspectives 143
XIV
References 145
Appendix 159
XV
XVI
Part I:
Metal-containing
monooxygenases
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2
Introduction to part I
Tryptophan hydroxylase (TPH) and dopamine β-hydroxylase (DβH) are two
metal-containing monooxygenases which function e.g. in the brain. They are both
involved in the synthesis of neurotransmitters, TPH is the rate-limiting enzyme
in the biosynthesis of serotonin and DβH convert dopamine into norepinephrine
thereby controlling the levels of both these neurotransmitters.
Since both enzymes are involved in regulating the levels of neurotransmitters
they are also possible targets for medicine against the disorders related to inappro-
priate levels of the neurotransmitters. These diseases include e.g. depression, anxi-
ety disorders, obsessive-compulsive disorder (OCD), Parkinson’s disease, attention
deficit-hyperactivity disorder (ADHD) and schizophrenia (Cubells and Zabetian,
2004; Gray et al., 2006; Lucki, 1998; Walther and Bader, 2003). Common for these
diseases are their profound human and economic costs and therefore investigations
in TPH and DβH are very important.
Part I of this dissertation include a general description of monooxygenases
and the biogenic amines. The next chapters are a survey of TPH including its
function, protein family, sequence and structure, the neurotransmitter serotonin
and the disorders related to TPH and serotonin. Afterwards DβH and its function,
sequence and protein family will be described, moreover the structure of the related
enzyme peptidyl-glycine alpha-amidating monooxygenase and disorders related to
DβH, dopamine and norepinephrine will be outlined.
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1 Metal-containing
monooxygenases
Oxygenases are enzymes that catalyse the incorporation of oxygen into a substrate.
Many oxygenases play a crucial role in the metabolism and synthesis of a variety
of biological substances (Hayaishi and Nozaki, 1969; Sugimoto et al., 2006). The
oxygenases can be divided into two subclasses, monooxygenases or mixed function
oxygenases are responsible for the incorporation of a single atom of oxygen into
the substrate, whereas dioxygenases catalyse the incorporation of both atoms from
molecular oxygen into a substrate molecule (Hayaishi and Nozaki, 1969; Sugimoto
et al., 2006). The generalized reaction scheme for the monooxygenases can be
written as:
Substrate + 1
2
02 → Substrate-0
The reaction scheme for dioxygenases is written as:
Substrate + 02 → Substrate-02
Dioxygenases often cleave an aromatic double bond between two hydroxy-
lated carbon atoms, adjacent to a hydroxylated carbon atom or in an indole ring.
Monooxygenases are, on the other hand, involved in hydroxylation of aromatic or
aliphatic compounds. Moreover monooxygenases can catalyse among others epox-
ide formations, dealkylations, decarboxylations, deaminations and N- or S-oxide
formations, all reactions initiated by the incorporation of one oxygen atom into
the substrate (Hayaishi and Nozaki, 1969).
The amino acid tryptophan is the substrate for both a monooxygenase, namely
tryptophan hydroxylase, and a dioxygenase, tryptophan-2,3-dioxygenase also
known as tryptophan pyrrolase. These two reactions (shown in figure 1.1) are
the first step in respectively the biosynthesis of the neurotransmitter serotonin
and the biosynthesis of nicotinamide-adenine dinucleotide (NAD+), a coenzyme
found in all living cells (Hayaishi and Nozaki, 1969).
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Tryptophan 
2,3-dioxygenase
Figure 1.1: Tryptophan is a substrate of both a monooxygenase and a dioxygenase. Tryptophan
hydroxylase is the monooxygenase hydroxylating tryptophan as the first step in the biosynthesis of the neuro-
transmitter serotonin, whereas the diooxygenase tryptophan-2,3-dioxygenase catalyse the incorporation of two
oxygen atoms into tryptophan forming formylkynurenine as the first step in the biosynthesis of the coenzyme
NAD+. Modified from Hayaishi and Nozaki (1969).
The present dissertation concerns the two metal-containing monooxygenases
tryptophan hydroxylase (TPH) and dopamine β-hydroxylase (DβH), both func-
tioning e.g. in the brain, where they hydroxylate their respective substrates in
the process of producing neurotransmitters. As already mentioned tryptophan
hydroxylase convert tryptophan into 5-hydroxytryptophan in the biosynthesis of
serotonin (Grahame-Smith, 1967; Hosoda and Glick, 1966; Kaufman, 1983), and
dopamine β-hydroxylase catalyse the conversion of dopamine into norepinephrine
in the biosynthesis of the catecholamine neurotransmitters (Goldstein et al., 1965;
Levin et al., 1960).
Since tryptophan hydroxylase and dopamine β-hydroxylase are involved in the
biosynthesis of neurotransmitters they are also possible targets for medicine against
neurological diseases caused by irregular levels of the neurotransmitters. Therefore
investigation of these enzymes is very important in order to improve the conditions
for people suffering from these disorders.
1.1 The biogenic amines
Since both tryptophan hydroxylase and dopamine β-hydroxylase are involved in
the synthesis of the biogenic amine neurotransmitters these will be very briefly
described. A more detailed description of the relevant neurotransmitters is given
in sections 2.7 and 3.1.
The biogenic amines are considered small-molecule neurotransmitters, they
include the three catecholamines, dopamine, norepinephrine/noradrenaline, and
epinephrine/adrenaline, as well as serotonin (an indoleamine) and histamine (im-
idazolamine). Overall the biogenic amines are implicated in a wide range of roles
including both central homeostatic functions and cognitive functions, as for ex-
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Figure 1.2: Distribution of brain neurons containing biogenic amines. The arrows show how dopamin-
ergic (A), norepinephrinergic (B), histaminergic (C) and serotonergic (D) neurons are distributed in the human
brain. Epinephrine is present in much lower levels than especially the other catecholamines and the distribution
of these neurons is not shown (Purves et al., 2001). Reprinted with permission from Sinauer Associates.
ample attention, and they act on different regions of the central nervous system
(CNS, figure 1.2), and norepinephrine and serotonin also in the peripheral nervous
system (Purves et al., 2001; Warberg, 1998).
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2 Tryptophan hydroxylase
Tryptophan hydroxylase (TPH, tryptophan 5-monooxygenase, EC 1.14.16.4) is
a member of the aromatic amino acid hydroxylases (AAAH). The enzyme exist
in two isoforms, isoform 1 (TPH1) and isoform 2 (TPH2) expressed in different
tissues. The present chapter is an introduction to TPH and its properties, and
also the neurotransmitter serotonin and its function as well as related disorders
will be introduced.
2.1 Biosynthesis of serotonin
Tryptophan hydroxylase catalyses the first and rate-limiting step in the biosynthe-
sis of the neurotransmitter and hormone serotonin (5-hydroxytryptamine), namely
the conversion of tryptophan into 5-hydroxytryptophan. As shown in figure 2.1
TPH uses 5,6,7,8-tetrahydrobiopterin (BH4) and O2 as co-substrates and together
with 5-hydroxytryptophan 4a-hydroxy-tetrahydrobiopterin (4a-tetrahydro-BH4/
4-OH-BH4) is produced (Grahame-Smith, 1967; Hosoda and Glick, 1966; Kaufman,
1983).
N
H
NH2
COOH
N
H
NH2
COOH
OH
N
H
NH2
OH
Fe
2+
O2 OH2BH4 H4
CO2O
  Tryptophan                                          5-hydroxytryptophan                                             Serotonin 
                                                                                                                                  (5-hydroxytryptamine/5-HT)
Tryptophan
hydroxylase
Aromatic L-amino
acid decarboxylase
4-OH-B
Figure 2.1: Biosynthesis of serotonin. Tryptophan hydroxylase catalyses the hydroxylation of tryptophan
into 5-hydroxytryptophan, which is the first and rate-limiting step in the biosynthesis of serotonin. 5,6,7,8-tetra-
hydrobiopterin (BH4) and O2 are co-substrates in the reaction and 4a-hydroxy-tetrahydrobiopterin (4-OH-BH4)
is formed from BH4 as a side-product (Grahame-Smith, 1967; Hosoda and Glick, 1966; Kaufman, 1983).
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2.2 The aromatic amino acid hydroxylases
Together with phenylalanine hydroxylase (PAH, EC 1.14.16.1) and tyrosine hy-
droxylase (TH, EC 1.14.16.2) TPH constitutes the family of aromatic amino acid
hydroxylases (Moran et al., 1998; Walther and Bader, 2003). These enzymes
all contain iron as a co-factor and use BH4 (tetrahydrobiopterin) and O2 as co-
substrates in the hydroxylation of their respective aromatic amino acid substrates
(Fisher et al., 1972; Hoeldtke and Kaufman, 1977; Moran et al., 1998; Teigen et al.,
2007).The overall structure of the mammalian AAAH’s are also alike as they all
form homotetramers and the monomers consist of three domains. These domains
are the N-terminal regulatory domains (100-150 residues), the catalytic domain
(approximately 315 residues) and the C-terminal tetramerisation domain (approx-
imately 30-40 residues) (Fitzpatrick, 1999; Fusetti et al., 1998; Moran et al., 1998).
Sequences from the three aromatic amino acid hydroxylases are shown and com-
pared in section 2.3, figure 2.3.
2.2.1 Phenylalanine hydroxylase
PAH is found mainly in the liver, it catalyses the rate-limiting step in the break-
down of phenylalanine to CO2 and water, namely the hydroxylation of pheny-
lalanine forming tyrosine (Kaufman, 1957; Udenfriend and Cooper, 1952). PAH
activity is tightly regulated since Phe is an essential amino acid and insufficient
levels of it interfere with protein synthesis. On the other hand mutations in PAH
leaving it dysfunctional are associated with phenylketonuria (PKU), a inborn dis-
ease characterized by accumulation of Phe and its metabolites resulting in impaired
brain function and development (Hufton et al., 1995; Teigen et al., 2007).
2.2.2 Tyrosine hydroxylase
TH is found both the central nervous system (CNS), the peripheral sympathetic
neurons and the adrenal medulla (Hufton et al., 1995; Teigen et al., 2007). TH
catalyse the conversion of tyrosine into dihydroxyphenylalanine, the rate-limiting
step of the biosynthesis of the catecholamines, dopamine, norepinephrine and
epinephrine (Nagatsu et al., 1964). Dysfunction of tyrosine hydroxylase is as-
sociated with Parkinson’s disease and cardiovascular diseases (Fitzpatrick, 1999;
Teigen et al., 2007).
At least four different isoforms of human TH exist. These differ in the regula-
tory domain and are generated from alternative splice variants of the same gene
for TH (Fitzpatrick, 1999; Teigen et al., 2007).
2.3 The two isoforms of tryptophan hydroxylase
TPH exist in two isoforms, TPH1 and TPH2, which are expressed in different
tissues. Until the early eighties only one isoform was known, but purification and
characterisation of TPH from different tissues revealed the existence of two differ-
ent isoforms (Cash et al., 1985; Nakata and Fujisawa, 1982a,b). TPH2 which is
also called neuronal TPH is expressed mainly in the serotonergic neurons of the
brain and gut (Coates et al., 2004; Gershon et al., 1977; Patel et al., 2004; Walther
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et al., 2003; Zhang et al., 2004) whereas TPH1 is expressed in peripheral organs
such as the pineal gland (Patel et al., 2004), skin cells (Slominski et al., 2003), mast
cells (Levine et al., 1964), intestinal mucosa and enterochromaffin cells (Hasegawa
et al., 1987) and in cancer cells (Grahame-Smith, 1964; Hosoda et al., 1977). The
genes for the two TPH isoforms are located on different chromosomes, the human
tph1 gene is thus situated on chromosome 11 (Boularand et al., 1990) whereas
the human tph2 gene is located on chromosome 12 (Walther et al., 2003). The
different expression patterns for TPH1 and TPH2 result in unlike functions of
the two isoforms. TPH1 is thus involved in regulation of e.g. haemostasis, mela-
tonin synthesis, vasoconstriction and T-cell mediated immune responses, whereas
TPH2 is implicated in regulation of sleep, aggression, major depression, anxi-
ety, obsessive-compulsory-disorder (OCD) and schizophrenia (Walther and Bader,
2003). Figure 2.2 shows the different functions of the two TPH isoforms.
Figure 2.2: Different functions of the two TPH isoforms. Due to their different expression patterns,
TPH1 in the peripheral nervous system and TPH2 in the central nervous system, the serotonin produced by the
two TPH isoforms are involved in different processes (Walther and Bader, 2003). Reprinted with permission.
Beside the differences in expression the kinetic properties of TPH1 and TPH2
are also different. Substrate inhibition by tryptophan is observed for TPH1 but
not for TPH2, and the Km values for BH4 also differ by a factor 10 (Windahl et al.,
2009).
Human TPH1 (huTPH1) and human TPH2 (huTPH2) share 70% overall iden-
tity and the major difference between the two isoforms is that the N-terminal
of huTPH2 is extended by 46 amino acids compared to huTPH1 (Walther and
Bader, 2003). A sequence alignment of chicken ggTPH1 (Florez et al., 1996),
huTPH1 (Boularand et al., 1990), huTPH2 (Walther et al., 2003), human PAH
(huPAH) (Kwok et al., 1985) and human TH isoform 3 (huTH3) (Kaneda et al.,
1987) is shown in figure 2.3.
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Figure 2.3: Alignment of the aromatic amino acid hydroxylases. Chicken ggTPH1 (GenBank ID P70080),
huTPH1 (GenBank ID P17752), huTPH2 (GenBank ID Q8IWU9), human PAH (GenBank ID P00439) and human
TH isoform 3 (GenBank ID P07101) are aligned using AlignX R©, part of Vector NTI AdvanceTM 10.3.0 (Invitrogen
Life Sciences, 2006). Identical residues are marked with red text/yellow background, conservative substitutions
with blue text/light blue background, similar residues with light green background and weakly similar residues
are written in green. Arrows indicate the domain boundaries between the regulatory and catalytic domains and
the catalytic and tetramerisation domains respectively. The residues coordinating to iron are marked with black
boxes.
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2.4 The TPH sequence
The human TPH1 sequence consist of 444 amino acids (Boularand et al., 1990).
The approximate domain boundaries are the following: the regulatory domain
consist of residues 1-99, the catalytic domain of residues 100-414 and residues
415-444 comprise the tetramerisation domain (Nielsen, 2007).
The human TPH2 sequence is extended with 46 amino acids compared to hu-
man TPH1, the sequence consist of 490 amino acids in total (Walther and Bader,
2003). The approximate domain boundaries for TPH2 are: residues 1-145 comprise
the regulatory domain, the catalytic domain encompass residues 146-459 and the
last thirty residues 460-490 comprise the tetramerisation domain (Nielsen, 2007).
Human TPH1 contains one potential N-glycosylation site at Asp94, whereas
no N-glycosylation sites is predicted for human TPH2 (Gupta et al., 2007). Hu-
man TPH1 is known to be phosphorylated at Ser58 and Ser260 whereas human
TPH2 has a phosphorylation site at Ser19 (Jiang et al., 2000; Kuhn et al., 2007;
Winge et al., 2008). Human TPH2 also has a phosphorylation site at Ser104, but
phosphorylation of Ser19 is more important for activation and binding of 14-3-3
protein (Winge et al., 2008).
TPH coordinates an iron atom in each subunit, in human TPH1 iron is co-
ordinated to His272, His277 and Glu317 (Wang et al., 2002; Windahl et al.,
2008), whereas the ligand residues in human TPH2 are His318, His323 and Glu363
(Walther and Bader, 2003).
2.5 Three-dimensional structure of TPH
No crystal structure of full length TPH exist, only the catalytic domain of TPH1
(cTPH1) has been crystallized. The first structure reported was human cTPH1
with bound 7,8-dihydrobiopterin (BH2, PDB: 1MLW, Wang et al. (2002)), later
also structures of chicken cTPH1 with bound tryptophan (PDB: 3E2T, Windahl
et al. (2008)) and human cTPH1 with an inhibitor bound (PDB: 3HF6, Jin et al.
(2009)) have been published.
The overall structure of human cTPH1 is shown in figure 2.4 and the structure
of chicken cTPH1 with bound substrate is shown in figure 2.5.
In the resting state the iron atom in cTPH1 is octahedrally coordinated to
two histidines (His272 and His277), one glutamate (Glu317) and three water
molecules (Wang et al., 2002; Windahl et al., 2008).
The active site of human cTPH1 consist of an approximately 9 A˚ deep and 10 A˚
wide cavity where the iron is bound. The active site is accessible for substrates
through a 12 A˚ long and 7 A˚ wide channel (Wang et al., 2002). Upon binding of
tryptophan the conformation of cTPH1 changes, and the chicken cTPH1 structure
is therefore more closed and compact compared to the human cTPH1 structure
with two loops closing the active site (Windahl et al., 2008). Upon Trp binding
the distance between the Cα atoms of Leu129 and Thr367 (numbering according
to human cTPH1) is reduced from 17.3 A˚ in human cTPH1 to 7.1 A˚ in chicken
cTPH1. Closing of the active site upon substrate binding is illustrated in figure 2.6.
The structures of cTPH1 are very similar to the catalytic domains of PAH
and TH. The root-mean-square for the deviations of Cα atoms of human cTPH1
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Glu317
His272
His277
Figure 2.4: Overall structure of human cTPH1.
Human cTPH1 with bound BH2 and iron (PDB:
1MLW, Wang et al. (2002)). The active site amino
acids are colored by element (carbon is gray, nitrogen
is blue and sulfur is yellow), the carbons of BH2 are
colored orange and iron is brown. Iron coordination are
represented by dotted lines. The figure was made with
the program Pymol (DeLano Scientific LLC., 2006).
His273
His278
Glu318
Figure 2.5: Overall structure of chicken cTPH1.
Chicken cTPH1 with bound Trp substrate and iron
(PDB: 3E2T, Windahl et al. (2008)). The active site
amino acids are colored by element (carbon is gray,
nitrogen is blue and sulfur is yellow), the carbons of
tryptophan are colored yellow and iron is brown. Iron
coordination are represented by dotted lines. The fig-
ure was made with the program Pymol (DeLano Sci-
entific LLC., 2006).
(PDB: 1MLW) and human cPAH (PDB: 1PAH) are 1.0 A˚ whereas the correspond-
ing deviations human cTPH1 (PDB: 1MLW) and human cTH (PDB: 1TOH) are
0.9 A˚ (Wang et al., 2002).
Since only the catalytic domain of TPH has been crystallized most informa-
tion of the remaining structure come from comparisons with the other aromatic
Leu129
Thr367
Figure 2.6: Structural alignment of the active site of human cTPH1 and chicken cTPH1. Human
cTPH1 is shown in purple and chicken cTPH1 is green. Leu129 and Thr367 (numbering according to human
cTPH1) of the loops moving upon substrate binding are shown with yellow carbons and red oxygens. The Cα
carbons of these residues are 10.2 A˚ closer in the chicken cTPH1 with bound substrate (Windahl et al., 2008).
The figure was made with the program Pymol (DeLano Scientific LLC., 2006).
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Figure 2.7: Structure of tetrameric human PAH.
Tetrameric representation of PAH monomers consisting of the
catalytic and tetrameric domains (PDB: 2PAH, Fusetti et al.
(1998)). Each monomer is colored differently with iron shown
as brown spheres. The figure was made with the program Py-
mol (DeLano Scientific LLC., 2006).Tetrameric representation of
PAH monomers consisting the catalytic and te tra me ric do mains
(PDB: 2PAH, Fusetti et al. (1998)). Each monomer is colored dif-
ferently with iron shown as brown spheres. The figure was made
with the program Pymol. Each monomer is colored differently
with iron shown as brown spheres. The figure was made with the
program Pymol
Figure 2.8: Structure of the regu-
latory and catalytic domains of rat
PAH. The structure of the regulatory and
catalytic domains of PAH (PDB: 1PHZ,
Kobe et al. (1999)) is shown with the cat-
alytic domain oriented as the green mono-
mer of the tetrameric PAH (figure 2.7). The
regulatory domain is colored purple and
the catalytic domain is green with the iron
shown as a brown sphere. The figure was
made with the program Pymol (DeLano
Scientific LLC., 2006).
amino acid hydroxylases. The structure of tetrameric phenylalanine hydroxylase
(PDB: 2PAH) is shown in figure 2.7, the structure contains a truncated version
of PAH only consisting of the catalytic domain and the tetramerisation domain of
the four monomers. Figure 2.8 illustrates the crystal structure of the regulatory
and catalytic domains of PAH (PDB: 1PHZ), the catalytic domain is oriented as
the green monomer of the tetrameric PAH in figure 2.7.
2.6 Reaction mechanism for TPH
It is generally believed that the three aromatic amino acid hydroxylases share a
common reaction mechanism (Bassan et al., 2003; Fitzpatrick, 2003). The catalytic
mechanism can be divided into two partial reactions, the first one is formation of
the hydroxylating intermediate and the second is oxygen transfer to the amino acid
substrate. For TH the hydroxylating intermediate has been trapped (Eser et al.,
2007), but no intermediates have been trapped for the two other AAAH’s (Eser
et al., 2007; Fitzpatrick, 2003).
All three enzymes require ferrous iron for activity, and BH4 is believed to be
the physiological reductant of ferric iron to ferrous iron (Fitzpatrick, 2003; Moran
et al., 1998). It has also been shown that the oxygen atom incorporated into the
amino acid substrate comes from molecular oxygen, and the other oxygen atom is
found in the pterin product (Fitzpatrick, 2003).
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Different possibilities have been suggested for the hydroxylating intermediate
for TPH, these include a pterin peroxide, a high valence iron oxo species and a
peroxypterin iron intermediate (Moran and Fitzpatrick, 1999). The most likely of
these candidates is the high valence iron oxo species Fe(IV)=O which can carry
out the subsequent hydroxylation (Bassan et al., 2003; Fitzpatrick, 2003; Moran
and Fitzpatrick, 1999). This is supported by the recent trapping of a high-spin
Fe(IV) intermediate for tyrosine hydroxylase, which is probably Fe(IV)=O (Eser
et al., 2007) and also density functional theory calculations on TPH support these
findings (Haahr et al., 2010).
Prior to the reaction two water molecules coordinating the iron atom are lost
and the bond between glutamate and iron becomes bidentate, which leaves a free
coordination site on the iron atom (Andersen et al., 2002; Haahr et al., 2010).
4a-hydroxy-tetrahydrobiopterin and the high-valent iron oxo species Fe(IV)=O
are formed with one of the oxygen atoms in the pterin product and the other in
the Fe(IV)=O species (Bassan et al., 2003). Figure 2.9 shows the activation of
molecular oxygen forming Fe(IV)=O.
NH
N
N
H
N
H
OH
OH
NH2
O
O2
Fe(II)
N
N
N
H
N
H
OH
OH
NH2
OH
O
Fe(IV)=O
Figure 2.9: Formation of hydroxylation intermediate. The hydroxylation intermediate Fe(IV)=O is formed
while BH4 is converted to 4a-hydroxy-tetrahydrobiopterin (Fitzpatrick, 2003; Haahr et al., 2010).
Also for the hydroxylation reaction more possibilities are proposed, with either
an arenium cation intermediate or an arene oxide (Fitzpatrick, 2003; Moran and
Fitzpatrick, 1999). The arenium cation is though the most likely of these inter-
mediates (Fitzpatrick, 2003; Moran and Fitzpatrick, 1999). This step involves an
electrophilic attack from the Fe(IV)=O on tryptophan which create the arenium
cation intermediate, the cation subsequently undergoes a NIH shift (rearrange-
ment of the H atom from carbon 5 to carbon 4 as shown by tritium migration)
followed by re-aromatisation generating 5-hydroxytryptophan (Fitzpatrick, 2003;
Moran and Fitzpatrick, 1999). The second part of the reaction mechanism is shown
in figure 2.10.
N
H
COO-
NH3+
Fe(IV)=O
N
H
COO-
NH3+
H
HO
Fe
N
H
COO-
NH3+
OH
Fe(II)
+
Figure 2.10: Hydroxylation of tryptophan. The Fe(IV)=O intermediate attacks the aromatic C atom
making an arenium cation intermediate, which is then converted into 5-OH-Trp. Modified from (Fitzpatrick,
2003).
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2.7 The neurotransmitter serotonin
Serotonin is a neurotransmitter in both the peripheral and central nervous system.
Most serotonin (produced by TPH1) is involved in the peristaltic movements in the
mammalian enteric system (Gershon, 2003, 2004; Sakowski et al., 2006), whereas
serotonin in the CNS (produced by TPH2) mediates many physiological processes
including cardiovascular regulation, sleep, food intake and sexual behavior (Lucki,
1998; Sakowski et al., 2006). In the pineal gland in the center of the brain (see
figure 1.2 in section 1.1) serotonin serves as a precursor for production of melatonin,
which is a hormone involved in sleep and temperature regulation, circadian and
seasonal rhythmicity, and reproductive physiology (Macchi and Bruce, 2004).
2.8 Disorders related to TPH and serotonin
Due to its many actions serotonin has been linked to disorders both in peripheral
parts of the body as well as in the central nervous system. Disturbances of sero-
tonin level in the gut is associated with irritable bowel syndrome (Gershon, 2004)
and regulation of its function in the brain influence a whole range of traditional
psychiatric disorders (Lucki, 1998). These psychiatric disorders include depression,
anxiety disorder, panic disorder, obsessive-compulsive disorder (OCD), social pho-
bia, schizophrenia and anorexia nervosa (Lucki, 1998; Walther and Bader, 2003).
Moreover low levels of serotonin in the brain may be the cause of sudden infant
death syndrome (Audero et al., 2008; Paterson et al., 2006). On the other hand ex-
tremely high levels of serotonin can have toxic and potentially fatal effects, causing
a condition known as serotonin syndrome. Serotonin toxicity is characterised by
increased heart rate, clonus (cramps), hyperthermia, excessive sweating, anxiety,
agitation and confusion (Isbister et al., 2007). Severe serotonin toxicity however
only occurs as the result of different drugs acting at different sites, most commonly
a monoamine oxidase inhibitor preventing breakdown of serotonin and a serotonin
reuptake inhibitor (Isbister et al., 2007).
Many people suffer from disorders related to serotonin and tryptophan hydrox-
ylase. For example most people exhibit symptoms of irritable bowel syndrome
in shorter or longer periods of their life. Every year approximately 10-15 % of
all adults have these symptoms, younger people is more frequently affected com-
pared to older people, and women more often than men (Peter Matzen, Danmarks
Apotekerforening, 2008). In Denmark the most frequently occurring diseases are
depression, anxiety and abuse. At present about 200,000 danish people have a de-
pression, and 15 % of the danish population are going to experience a depression
at a point of their life. Another 15 % suffer from anxiety diseases including OCD
and social phobia (Psykiatrifonden, 2009).
Mostly younger women suffer from eating disorders, altogether anorexia nervosa
and bulimia affect 1-3 % of 15-24 year olds but more than 25 % in this age group
have the risk of developing an eating disorder (Psykiatrifonden, 2009). In total
psychic disorders are the most costfull in the danish society, accounting for social
expenses of 30 billions DKK every year (Psykiatrifonden, 2009).
Sudden infant death syndrome fortunately only occur in rare instances. In
Denmark 0.3 per 1000 live born babies suffer from this disease, which correspond
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to approximately 20 babies a year (Hillerød Kommune, 2009).
Since serotonin and tryptophan hydroxylase related disorders have these pro-
found human and economic costs is it crucial to increase the knowledge of tryp-
tophan hydroxylase in order to hopefully being able to help these patients in the
future.
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Dopamine β-hydroxylase (DβH, EC 1.14.17.1), also called dopamine β-monooxy-
genase, is a copper-containing, ascorbate dependent monooxygenase which cata-
lyse the third step in the catecholamine biosynthesis, namely the conversion of
dopamine into norepinephrine as shown in figure 3.1 (Goldstein et al., 1965; Levin
et al., 1960). By catalysing this reaction DβH plays a very important role in
controlling the levels of both of these neurotransmitters.
DβH exist in both soluble and membrane bound forms in substantia nigra in the
ventral tegmental area of the brain (see figure 1.2 in section 1.1), in the chromaffin
vesicles of the adrenal gland and in the synaptic vesicles of norepinephrinergic and
NH3+
COO-
OH NH3+
COO-
OH
OH
NH3+OH
OH
NH3+OH
OH
OH
OH
OH
NH2+
O2 CO2
O2 RRCH3
Tyrosine
hydroxylase
DOPA 
decarboxylase
Dopamine-β-
hydroxylase
Phenylethanolamine-
N-methyltransferase
   Tyrosine                                        Dihydroxyphenylalanine (DOPA)                                                                                   
 Dopamine                                                  Norepinephrine                                                                                
Epinephrine
Figure 3.1: The catecholamine biosynthesis. Dopamine β-hydroxylase catalyses the third step of the
catecholamine biosynthesis which is the hydroxylation of the β-carbon of dopamine to convert it into nore-
pinephrine (Blaschko, 1973; Hanna, 1965).
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epinephrinergic neurons in the sympathetic nervous system (Klinman, 2006; Lewis
and Asnani, 1992; Purves et al., 2001).
Very little is known about dopamine β-hydroxylase and most of the information
comes from related proteins especially peptidyl α-hydroxylating monooxygenase
(PHM).
3.1 The catecholamine neurotransmitters
The catecholamines are part of the biogenic amine neurotransmitters (section 1.1),
they share a catechol moiety (i.e. hydroxylated benzene ring) and they are all de-
rived from a common precursor, the amino acid tyrosine (see figure 3.1). The
conversion from tyrosine to dihydroxyphenylalanine is catalysed by tyrosine hy-
droxylase (described in section 2.2) and is the rate-limiting step of the cate-
cholamine synthesis (Purves et al., 2001). Dopamine is produced in dopamin-
ergic neurons by DOPA decarboxylase and can then be transported by vesicles
to epinephrinergic neurons where dopamine β-hydroxylase convert it into nore-
pinephrine. Epinephrine, produced from norepinephrine by phenylethanolamine-
N-methyltransferase is only present in epinephrine-secreting neurons (Purves et al.,
2001).
3.2 The DβH sequence
The human DβH enzyme consist of 603 amino acids. The sequence include the
mature polypeptide chain of 578 residues as well as a N-terminal signal peptide of
25 amino acids (Lamouroux et al., 1987; Li et al., 1996). Two functional variants of
DβH exist, these differ by a single amino acid at position 304, which can be either
alanine (most often) or serine (Li et al., 1996; Williams et al., 1999). The sequences
used in this project have Ala in position 304 (see figure 3.2 and section 10.3.4,
figure 10.3).
DβH contains four potential N-glycosylation sites and 15 cysteine residues
(Gupta et al., 2007; Li et al., 1996). 12 of the cysteines are involved in six in-
tramolecular disulfide bridges and two are responsible for dimerisation by mak-
ing intermolecular disulfide bridges. Based on similarity with bovine dopamine
β-hydroxylase the disulfide bridges in human DβH are between Cys140-Cys582,
Cys218-Cys269, Cys255-Cys281, Cys376-Cys489, Cys380-Cys551 and Cys452-
Cys474. Cys514 of one monomer is bound to Cys514 in another monomer and
Cys516 from each monomer are making up another disulfide bridge holding dimers
together (Robertson et al., 1994). The DβH sequence is shown in figure 3.2 and
the disulfide bonds and possible N-glycosylation sites are depicted in figure 3.3.
Dopamine β-hydroxylase contains two copper ions, CuH coordinates three
histidine ligands His248, His249 and His319 whereas CuM coordinates two his-
tidines and a mehtionine His398, His400 and Met473 (numbering by similarity to
PHM (Klinman, 2006)). The copper ions in the active site will be further described
in sections 3.3.1 and 3.5.2.
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MREAAFMYST AVAIFLVILV AALQGSAPRE SPLPYHIPLD PEGSLELSWN 
VSYTQEAIHF QLLVRRLKAG VLFGMSDRGE LENADLVVLW TDGDTAYFAD 
AWSDQKGQIH LDPQQDYQLL QVQRTPEGLT LLFKRPFGTC DPKDYLIEDG 
TVHLVYGILE EPFRSLEAIN GSGLQMGLQR VQLLKPNIPE PELPSDACTM 
EVQAPNIQIP SQETTYWCYI KELPKGFSRH HIIKYEPIVT KGNEALVHHM 
EVFQCAPEMD SVPHFSGPCD SKMKPDRLNY CRHVLAAWAL GAKAFYYPEE 
AGLAFGGPGS SRYLRLEVHY HNPLVIEGRN DSSGIRLYYT AKLRRFNAGI 
MELGLVYTPV MAIPPRETAF ILTGYCTDKC TQLALPPSGI HIFASQLHTH 
LTGRKVVTVL VRDGREWEIV NQDNHYSPHF QEIRMLKKVV SVHPGDVLIT 
SCTYNTEDRE LATVGGFGIL EEMCVNYVHY YPQTQLELCK SAVDAGFLQK 
YFHLINRFNN EDVCTCPQAS VSQQFTSVPW NSFNRDVLKA LYSFAPISMH 
CNKSSAVRFQ GEWNLQPLPK VISTLEEPTP QCPTSQGRSP AGPTVVSIGG 
GKG 
Figure 3.2: Human dopamine β-hydroxylase sequence (Genbank ID P09172). The first 25 amino acids is
the signal peptide followed by the sequence of the mature protein. The Cu-ligands are marked in cyan: His248,
His249 and His319 coordinate CuH and CuM is bound to His398, His400 and Met473. Possible N-glycosylation
sites are marked with magenta (Gupta et al., 2007; Klinman, 2006). The figure was made with Vector NTI
AdvanceTM 10.3.0 (Invitrogen Life Sciences, 2006)
Signal peptide
Mature dopamine β-hydroxylase chain
Possible N-glycosylation site (N50)
Possible N-glycosylation site (N170)
Possible N-glycosylation site (N330)
Possible N-glycosylation site (N552)
S-S bond (C140-C582)
S-S bond (C218-C269)
S-S bond (C255-C281) S-S bond (C376-C489)
S-S bond (C380-C551)
S-S bond (C452-C474)
Intermolecular S-S bond (C514-C514)
Intermolecular S-S bond (C516-C516)
Free cysteine (C198) CuH binding
H248
H249
H319
CuM binding
H398
H400
M473
Figure 3.3: Graphic illustration of DβH with disulfide bonds, copper ligands and possible N-
glycosylation sites. The six intramolecular disulfide bonds and the two intermolecular ones are depicted on
the DβH sequence (orange). Copper ligands and possible N-glycosylation sites are also marked (cyan and violet
arrowheads respectively) (Gupta et al., 2007; Klinman, 2006; Robertson et al., 1994). The picture was made with
Vector NTI AdvanceTM 10.3.0 (Invitrogen Life Sciences, 2006)
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3.3 Ascorbate dependent type II Cu monooxygenases
Dopamine β-hydroxylase belongs to the family of type II copper ascorbate-depen-
dent monooxygenases found exclusively in higher eukaryotes (Klinman, 2006).
Two other enzymes belong to this family, namely peptidylglycine α-hydroxylating
monooxygenase (PHM) and monooxygenase X (MOX). Common for these enzymes
are their type II copper centres (see also section 3.3.1) and that they use molecular
oxygen and ascorbate to catalyse the hydroxylation of their substrates (Xin et al.,
2004).
PHM is the N-terminal part of the bifunctional enzyme peptidylglycine α-
amidating monooxygenase (PAM) which also contains peptidyl-α-hydroxyglycine
α-amidating lyase (PAL). In some organisms these two enzymes are expressed
independently but in higher eukaryotes they are expressed as one polypeptide
chain (Han, 1996; Prigge et al., 2000). Many peptide hormones require amida-
tion of their carboxy terminus to achieve full biological activity, this amidation is
catalysed by PAM in two sequential reactions. PHM catalyse a stereospecific hy-
droxylation of the glycine α-carbon of the peptidylglycine substrates and hereafter
PAL catalyse the second step where an α-amidated peptide product and glyoxylate
are produced (Prigge et al., 1997, 2000).
The catalytic cores of PHM and DβH are 26% identical and 40% similar (a
region of 250 residues). In this region six copper ligands and eight of ten Cys
residues of PHM are conserved in DβH, and disulfide bonds occur in homologous
locations. Moreover the evolutionary relationship between these two proteins are
confirmed by conservation of the exon/intron junctions in their genes (Gray et al.,
2006; Prigge et al., 2000). Since most of the information about the structure
and mechanism for DβH comes from extensions of PHM experimental results this
enzyme will be further described in sections 3.5 and 3.6.
The third member of the type II copper ascorbate-dependent monooxygenase
family is monooxygenase X. This enzyme was recently identified by sequence com-
parisons, it is called MOX because its substrate is unknown. MOX contain all of
the residues expected to be critical for copper binding, and its cysteine residues
can yield the intramolecular disulfide bond pattern observed in DβH (Chambers
et al., 1998; Xin et al., 2004).
Figure 3.4 shows an of alignment the mature chains (no signal peptides) of
human dopamine β-hydroxylase, human peptidyl α-hydroxylating monooxygenase
and human monooxygenase X. Overall the three proteins are 46.1% homologous.
The insect analog of DβH is tyramine β-monooxygenase (TβM) found in the
fruit fly Drosophila melanogaster. TβM catalyse the hydroxylation of tyramine
into octopamine, an insect neurotransmitter involved in control of the heart, vis-
ceral muscle contractions, pheromone biosynthesis, perception and regulation of
hormone release. TβM and DβH are similar enzymes which share substrate speci-
ficities. In vitro DβH can hydroxylate tyramine to form octopamine just like
TβM is able to catalyse the conversion of dopamine into norepinephrine. More-
over the similarities of these two enzymes cover the entire sequence in contrast to
DβH/PHM which are only similar in regions. TβM and DβH are 39% identical
and 55% similar over more than 600 residues (Gray et al., 2006).
22
3.3 Ascorbate dependent type II Cu monooxygenases
         
1 7010 20 30 40 50 60    
-----------------SAPRESPLPYHIPLDPEGSLELSWNVSYTQEAIHFQLLVRRLKAGVLFGMSDR      
----------------------------------------------------------------------       
MCCWPLLLLWGLLPGTAAGGSGRTYPHRTLLDSEGKYWLGWSQRGSQIAFRLQV--R-TAGYVGFGFSPT       
                 AA      PH   LD EG   L W    SQ A   QL  R   A V FG S              
         
71 14080 90 100 110 120 130     
GELENADLVVLWTDGDTAYFADAWSDQKGQIHLDPQQDYQLLQVQRTPEGLTLLFKRPFGTCDPKDYLIE       
----------------------------------------------------------------------       
GAMASADIVVGGVAHGRPYLQDYFTNANRELKKDAQQDYHLEYAMENSTHTIIEFTRELHTCDINDKSIT        
G L  ADIVV        Y  D FS     I  D QQDY L           I F R   TCD  D  I              
         
141 210150 160 170 180 190 200      
DGTVHLVYGILEEPFRSLEAINGSGLQMGLQRVQLLKPNIPEPELPSDACTMEVQAPNIQIPSQETTYWC        
-------------------------------------------------------FKETTRPFSNECLGT       
DSTVRVIWAYHHED--AGEAGPKYHDSNRGTKSLRLLNPEKTSVLSTALPYFDLVNQDVPIPNKDTTYWC         
D TV LIWA   E   A EA           K   L        L S     DL   DI IP  DTTYWC              
         
211 280220 230 240 250 260 270      
YIKELPKGFSRHHIIKYEPIVTK---------------------------GNEALVHHMEVFQCAPE-MD        
TRPVVPIDSSDFALDIRMPGVTPKQSDTYFCMSMRIPVDEEAFVIDFKPRASMDTVHHMLLFGCN---MP        
QMFKIPVFQEKHHVIKVEPVIQR---------------------------GHESLVHHILLYQCSNNFND         
 I  IPI  SKHHIIK EPIVTK                           G EALVHHMLLFQCA   MD              
        
281 350290 300 310 320 330 340      
SVPHFSGPCDSKMKPDRLNYCRHVLAAWALGAKAFYYPEEAGLAFGGPGSSRYLRLEVHYHNPLVIEGRN        
SSTGSYWFCDEGTCTDKAN----ILYAWARNAPPTRLPKGVGFRVGGETGSKYFVLQVHYGDISAFRDNN        
SVLESGHECYHPNMPDAFLTCETVIFAWAIGGEGFSYPPHVGLSLGTPLDPHYVLLEVHYDNPTYEEGLI         
SV  S   CD    PDK N C  VLFAWAIGA AF YP  VGLALGGP  SKYLLLEVHY NPS  EG N              
         
351 420360 370 380 390 400 410      
-DSSGIRLYYTAKLRRFNAGIMELGLVYTPVMAIPPRETAFILTGYCTDKCTQLALP---PSGIHIFASQ        
KDCSGVSLHLTRLPQPLIAGMYLMMSVDTVIPAGEKVVNSDISCHYKN-------------YPMHVFAYR         
-DNSGLRLFYTMDIRKYDAGVIEAGLWVSLFHTIPPGMPEFQSEGHCTLECLEEALEAEKPSGIHVFAVL         
 D SGIRLHYT  IRKF AGIIELGLV TLI AIPP M AFIS GYCT  C   AL    PSGIHVFA                
        
421 490430 440 450 460 470 480      
LHTHLTGRKVVTVLVRDGREWEIVNQDNHYSPHFQEIRMLKKVVSVHPGDVLITSCTYNTEDRELATVGG        
VHTHHLGKVVSGYRVRNG-QWTLIGRQSPQLP--QAFYPVGHPVDVSFGDLLAARCVFTGEGRTEATHIG         
LHAHLAGRGIRLRHFRKGKEMKLLAYDDDFDFNFQEFQYLKEEQTILPGDNLITECRYNTKDRAEMTWGG         
LHTHL GR V    VR GKEW LIA D  F P FQEF  LK  VSV PGDLLIT C YNTEDR EAT GG              
         
491 560500 510 520 530 540 550      
FGILEEMCVNYVHYYPQTQLELCKSAVDAGFLQKYFHLIN--------RFNNEDVCTCPQASVSQQFTSV        
GTSSDEMCNLYIMYYMEAKHAVSFMTCTQNVAPDMFRTIP--------PEANIPIPVKSDMVMMHEHHKE         
LSTRSEMCLSYLLYYPRINLTRCASIPDIMEQLQFIGVKEIYRPVTTWPFIIKSPKQYKNLSFMDAMNKF         
 SS DEMCL YILYYP  NL LC S  D      FF LI         PF N  I    NLSMM    K               
         
561 630570 580 590 600 610 620      
PWNSFNRDVLKALYSFAPISMHCNKSSAVRFQGEWNLQPLPKVISTLEEPTPQCPTSQGRSPAGPTVVSI        
TEYKDKIPLLQQPKREEEEVLDQGDFYSLLSKLLGEREDVVHVHKYNPTEKAESESDLVAEIANVVQKKD         
KWTKKEGLSFNKLVLSLPVNVRCSKTDNAEWSIQGMTALPPDIERPYKAEPLVCGTSSSSSLHRDFSINL         
 W K    LLN L    PI L C KS AL F I G    LP V K    E   C TS  ASIA    I I              
          
631 690640 650 660 670 680      
GGGKG-------------------------------------------------------        
LGRSDAREGAEHERGNAILVRDRIHKFHRLVSTLRPPESRVFSLQQPPPGEGTWEPEHTG         
LVCLLLLSCTLSTKSL--------------------------------------------         
LG           K                                                            
 (1)
DβH   (1)
PHM    (1)
MOX    (1)
 Consensus        (1)
 (71)  
DβH   (54) 
PHM      (1) 
MOX    (68) 
 Consensus        (71)  
 (141)   
DβH   (124)  
PHM        (1)  
MOX    (138)  
 Consensus        (141)   
 (211)   
DβH   (194)  
PHM      (16)   
MOX    (206)  
 Consensus        (211)   
 (281)   
DβH   (236)   
PHM    (83)   
MOX   (249)   
 Consensus        (281)   
 (351)   
DβH   (306)   
PHM    (149)   
MOX   (319)   
 Consensus        (351)   
 (421)   
DβH   (372)   
PHM    (206)   
MOX   (388)   
 Consensus        (421)   
 (491)   
DβH   (442)   
PHM    (273) 
MOX   (458)   
 Consensus        (491)   
 (561)   
DβH   (504)   
PHM    (335)   
MOX   (528)   
 Consensus        (561)   
 (631)   
DβH   (574)   
PHM    (405)  
MOX   (598)   
 Consensus        (631)   
CuH
CuH
CuM
CuM
Figure 3.4: Type II copper ascorbate-dependent monooxygenases. Alignment of human DβH (Gen-
bank ID P09172), human PHM (N-terminal part of PAM, Genbank ID P19021) and human MOX (Genbank ID
Q6UVY6), the first two without signal sequences. Identical residues are marked with red text/yellow background,
conservative substitutions with blue text/light blue background, similar residues with light green background and
weakly similar residues are written in green. The copper binding residues are marked with black boxes. The
alignment was made using AlignX R© from Vector NTI AdvanceTM 10.3.0 (Invitrogen Life Sciences, 2006)
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3.3.1 Copper centres in proteins
Copper has many biological roles including electron transfer, oxidation of organic
substrates and metal ions, dismutation of superoxide, monooxygenation, transport
of dioxygen and iron, and reduction of various substrates (Sakurai and Kataoka,
2007). Copper centres in proteins can be mononuclear (type I or II), dinuclear
(type III) or trinuclear (type II and type III), with no direct correlation between
nuclearity and reactivity. The type I, II or III classification of copper sites are
based on their optical and electron paramagnetic resonance (EPR) spectroscopic
properties (Holm et al., 1996; Rosenzweig and Sazinsky, 2006; Solomon et al.,
1996).
Type I copper centres are involved in electron transfer, they are characterized by
a single copper atom coordinated by two histidine residues and a cysteine residue
in a trigonal planar structure with a variable axial ligand. Proteins containing
type I copper is often referred to as blue copper proteins due to their strong
absorption near 600 nm. These copper centres give rise to an EPR signal different
from common copper coordination compounds (Holm et al., 1996; Rosenzweig and
Sazinsky, 2006; Solomon et al., 1996).
Type II coppers are coordinated in a square planar structure by N or N/O
ligands, their EPR signals are similar to those of common copper coordination
compounds and their optical spectra have no distinctive features. The dinuclear
type III copper centres consist of two copper ions each coordinated by three his-
tidine residues. These proteins exhibit no EPR signal due to spin pairing (Holm
et al., 1996; Solomon et al., 1996).
Dopamine β-hydroxylase and peptidyl α-hydroxylating monooxygenase both
contain two non coupled mononuclear copper type II centres (Holm et al., 1996;
Rosenzweig and Sazinsky, 2006; Solomon et al., 1996).
3.4 The catalytic activity of DβH
Dopamine β-hydroxylase catalyses the hydroxylation of the β-carbon in dopamine
in the presence of dioxygen and ascorbate as the physiological electron donor as
shown in figure 3.5 (Terland and Flatmark, 2003).
NH3OH
OH
NH3OH
OH
OH
 Dopamine                                                   Norepinephrine                                                                                
+ +
Dopamine 
β-hydroxylase
2 ascorbate     2 semihydroascorbate
    + O                   + H O2 2
Figure 3.5: Dopamine is converted into norepinephrine in the presence of dioxygen. The reaction is catal-
ysed by dopamine β-hydroxylase which undergo reduction by two successive one-electron oxidations of ascorbate,
the physiological electron donor (Goldstein et al., 1965; Levin et al., 1960).
DβH and PHM are believed to have similar active sites and to follow the same
mechanism even though they have different substrate specificities (PHM reaction
is shown in figure 3.6). Both enzymes are localized in subcellular compartments,
DβH in the chromaffin vesicles of the adrenal gland and the synaptic vesicles of
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the sympathetic nervous system and PHM in and the secretory vesicles of the
pituitary gland (see figure 1.2), and they both exist in soluble and membrane-
bound forms (Klinman, 2006).
Both of the enzymes do have very broad, but as previously mentioned also very
different, substrate specificities (Dharmasena et al., 2002; Klinman, 2006; Terland
and Flatmark, 2003).
N COO-
O
R R N COO-
O OH
Peptidylglycine                                          Peptidyl α-hydroxyglycine                                                                               
Peptidyl α-hydroxylating 
monooxygenase
2 2
2 ascorbate     2 semihydroascorbate
    + O                   + H O
Figure 3.6: Peptidyl α-hydroxylating monooxygenase (PHM) convert peptidylglycine into peptidyl
α-hydroxyglycine in the presence of dioxygen. As with DβH ascorbate is the physiological electron donor and is
converted into semihydroascorbate (Eipper et al., 1983).
3.4.1 Regulation of DβH activity
Dopamine β-hydroxylase exist as a homodimer and as a tetramer. The dimers
are linked by intermolecular disulfide bonds whereas tetramers are hold together
by non-covalent forces between dimers (Li et al., 1996; Terland and Flatmark,
2003). For the bovine enzyme it has been shown that a reversible dimer-tetramer
conversion occur at pH 5.7. This conversion is furthermore correlated to the pH
dependency of the enzyme activity (Saxena et al., 1985). In contrast to the bovine
enzyme, human DβH dimers and tetramers are not rapidly interconverted (Li et al.,
1996; Rosenberg and Lovenberg, 1977).
The catalytic activity of dopamine β-hydroxylase do not only depend on pH,
but also anions regulate the activity. At low pH around 5.1-5.3 enzyme activity
depend on the presence of anion whereas activity is high at pH 6.0 even without
anions present (Terland and Flatmark, 2003). The effect of anions could be related
to an anion-induced conformational change of DβH at pH 5.1-5.3 which facilitate
access of the substrate to the active site. Moreover Cl− is the physiological anion
of the catecholamine storage granules where DβH operate (Terland and Flatmark,
2003).
3.5 The structure of dopamine β-hydroxylase
There has never been established a high-level expression system for dopamine β-
hydroxylase which gave rise to an x-ray structure (Klinman, 2006). This fact
elucidate the necessity for more research on DβH to solve the protein struc-
ture and mechanism. Meanwhile structural and mechanistic results from peptidyl
α-hydroxylating monooxygenase are extended to DβH.
3.5.1 3D structure of PHM
Only the catalytic core of PHM have been crystallized. The structure of the cat-
alytic core (ccPHM, residues 42 to 356, PDB: 1PHM) of rat PHM shows that
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ccPHM is composed of two nine-stranded β-sandwich domains as shown in fig-
ure 3.7 (Prigge et al., 1997). Each of these domains of about 150 residues binds
one Cu-atom. CuH (or CuA) is coordinated to three histidine residues in domain I,
whereas the second copper, CuM (or CuB) bind two histidines and a methionine in
domain II. The two coppers are located 11 A˚ apart facing the interdomain space.
Between the coppers is a cleft fully accessible to solvent.
The interior of both domains are highly hydrophobic and lack any charged
residues. Both domains consist primary of β-sheets, in the C-terminal domain
these are linked by disulfide bridges whereas the disulfide bridges in the N-terminal
domain anchor loops without connecting the β-sheets (Prigge et al., 1997, 2000).
11Å
CuM
CuH
Met314
His242
His244
His172
His107
His108
Figure 3.7: The ccPHM structure. The catalytic core of PHM (PDB: 1PHM) is shown with yellow β-sheets,
red α-helices and green backbone. The coppers are represented by brown spheres and the ligand sidechains are
colored by atom (carbon is gray, nitrogen is blue and sulfur is yellow). Disulfide bridges are shown in orange.
Domain I coordinating CuH is shown to the right and domain II with CuM is to the left. The figure was made
with the program Pymol (DeLano Scientific LLC., 2006).
3.5.2 The active site coppers
The copper located in domain I is designated CuH and is believed to be the site
of electron storage/transfer. This copper is coordinated to His106, His107 and
His172 in an unusual fashion which can be described as square pyramidal with two
unoccupied positions or as “T-shaped” (Klinman, 2006; Prigge et al., 1997, 2000).
The second copper, CuM , is the site of substrate hydroxylation. This copper is
coordinated in domain II to two histidines, His242 and His244, and one methionine,
Met314. Moreover, a solvent molecule (probably water) bind to CuM forming a
tetrahedral geometry. During catalysis the water ligand is replaced by O2 (Prigge
et al., 1997, 2000).
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Even though no x-ray structure exist for dopamine β-hydroxylase, the ligand
environment of the coppers has been characterized by extended x-ray absorption
fine structure spectroscopy (EXAFS). These experiments confirm that the ligands
for both coppers is conserved between the two enzymes (Blackburn et al., 1991;
Evans et al., 2003; Scott et al., 1988). By comparison with PHM it is found that
in DβH is CuH coordinated to His262, His263 and His333 and CuM is coordinated
to His412, His414 and Met487 (see figure 3.4).
3.6 Proposed mechanisms for the DβH reaction
Despite their very different substrate specificities the reaction mechanisms for
dopamine β-hydroxylase and peptidyl α-hydroxylating monooxygenase are sim-
ilar (Klinman, 2006; Prigge et al., 2000).
It has been shown that both enzymes undergo a cyclical reduction of their cop-
pers by ascorbic acid. The reduced Cu(I) sites are returned to Cu(II) by reaction
with substrate and O2 (Bauman et al., 2006; Klinman, 2006).
Several mechanisms for the hydroxylation reaction have been proposed (Klin-
man, 2006; Prigge et al., 2000). The differences arise because is it not known
how controlled electron transfer between the two coppers are conducted. There
is no bridging ligand between the coppers, there is no hinge region allowing the
coppers to move closer to each other (the distance between the coppers are almost
identical in structures of reduced and oxidized ccPHM with and without bound
substrate (Prigge et al., 1999)) and both coppers are fully exposed to solvent (Klin-
man, 2006). Another question is the nature of the reactive intermediate of the
reaction. The suggestions for this copper-oxygen intermediate include copper-
superoxo, copper-peroxo, copper-hydroperoxo and Cu(III)-oxo species (Gherman
et al., 2006; Klinman, 2006; Prigge et al., 2000; Yoshizawa et al., 2006).
Comparison of various data for these copper-oxygen species provide support for
the formation of a copper-superoxo species in the first part of the catalytic cycle,
the reductive phase (Bauman et al., 2006; Evans et al., 2003; Gherman et al.,
2006; Yoshizawa et al., 2006). This part of the reaction mechanism is illustrated
in figure 3.8.
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Figure 3.8: Proposed mechanism for the reductive phase of DβH and PHM. The resting enzyme
with two Cu(II) is reduced by 2 ascorbates to two Cu(I) under formation of 2 semihydroascorbates. Substrate
and molecular oxygen are bound in a reversible reaction triggering O2-activation by transfer of an electron from
CuM (I) to O2 forming the copper-superoxo complex (Evans et al., 2003; Prigge et al., 2000; Yoshizawa et al.,
2006).
From the resting form of the enzyme where both coppers are oxidized, two
ascorbate molecules donate two electrons to reduce each of the coppers to Cu(I)
while two semihydroascorbates are formed. The reduced enzyme is then catalyt-
ically competent and reversible binding of substrate and molecular oxygen occur.
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This triggers activation of O2 by electron transfer from CuM(I) to form the copper-
superoxo intermediate (Bauman et al., 2006; Evans et al., 2003; Klinman, 2006;
Prigge et al., 2000).
From this point there are different opinions on how the catalytic cycle continues.
Some researchers support a mechanism where the hydrogen-transfer that produce
the substrate-derived radical occur before an electron is transferred from CuH to
CuM (figure 3.9). Other researchers propose mechanisms where these two incidents
occur in the opposite order (figure 3.10).
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Figure 3.9: Possible mechanism for the oxidative phase of the DβH/PHM reaction. According to
Evans et al. a hydrogen is abstracted from the substrate prior to electron transfer between the copper centres.
Three ordered water molecules make up the electron transfer pathway (Evans et al., 2003; Klinman, 2006).
According to Evans et al. who proposed the mechanism shown in figure 3.9,
the next step is an irreversible hydrogen-transfer to form a substrate-derived free
radical and a hydroperoxo specie, Cu(II)-OOH. From this highly reactive state one
electron is driven from the reduced CuH to the terminal oxygen of the CuM(II)-
OOH via a network of three oriented water molecules. The CuM(II)-OOH is then
cleaved to produce water and a CuM(II)-oxo radical which rapidly react with the
substrate-derived radical to give the hydroxylated prod ct, which dissociates from
the protein active site (Evans et al., 2003; Klinman, 2006).
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Figure 3.10: Proposed oxidative phase mechanism for DβH and PHM reaction. This mechanism
involve electron transfer before hydrogen abstraction via a Cu(III)-oxo specie. The electron transfer pathway is
not included in this model (Yoshizawa et al., 2006).
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Yoshizawa and coworkers support a mechanism with electron transfer before
hydrogen abstraction. This mechanism is illustrated in figure 3.10. After formation
of the copper(II)-superoxo complex in the reductive phase an electron is transferred
from CuH to CuM resulting in a CuM(I)-superoxo specie, which is then protonated
to form a CuM(II)-hydroperoxo specie. The CuM(II)-OOH abstracts a hydro-
gen from a nearby tyrosine residue to produce a Cu(III)-oxo complex which can
abstract the hydrogen from the bound substrate creating a radical intermediate.
Rebinding of the substrate radical to CuM allows formation of the hydroxylated
product and leaves the protein in the resting oxidized state (Yoshizawa et al., 2006).
As opposed to the mechanism with hydrogen transfer before electron transfer this
mechanism does not suggest how the electron transfer occurs.
Since the mechanisms described above have never been confirmed more investi-
gation needs to be done on dopamine β-hydroxylase, its structure and function. An
x-ray structure could give information about how the reaction occur and both the
structure and the reaction mechanism would be useful information for discovery
of medicine targeted at DβH.
3.7 Disorders related to dopamine β-hydroxylase
Due to its action in the catecholamine synthesis dopamine β-hydroxylase is in-
volved in controlling the levels of both dopamine and norepinephrine. Abnormal-
ities in the levels of these neurotransmitters have been linked to many disorders
mentioned below (Gray et al., 2006).
Dopamine is mainly present in the corpus striatum (indicated with arrows in
figure 1.2, section 1.1), a brain area that plays an essential role in the coordination
of body movements. Moreover dopamine is involved in behavior and cognition,
motivation and reward, inhibition of prolactin production (involved in lactation),
sleep, mood, attention and learning. Appropriate levels of dopamine is impor-
tant to conduct these functions. For example the motoric dysfunction seen in
Parkinson’s disease is caused by degeneration of dopaminergic neurons resulting
in lowered dopamine levels (Gray et al., 2006; Purves et al., 2001).
In the central nervous system, norepinephrine is the transmitter used by the
locus coeruleus (see figure 1.2 in section 1.1), a brainstem nucleus that projects
diffusely to a variety of forebrain targets, where it influences sleep and wakefulness,
attention, and feeding behavior (Cubells and Zabetian, 2004; Purves et al., 2001).
Norepinephrine is also known as a stress hormone as it is functioning in the sym-
phatic nervous system (part of the peripheral nervous system), where it is involved
in controlling attention and responding actions. These include increase of heart
rate, release of glucose from energy stores and increasing blood flow to the skeletal
muscles making the person ready to fight (Cubells and Zabetian, 2004).When the
sympathetic nervous system is overactivated on the other hand, the elevated nore-
pinephrine levels has been shown to be involved in hypertension and congestive
heart failure (Gray et al., 2006; Li et al., 1996).
Moreover norepinephrine is involved in neurological disorders such as sleep
disorders, migraine, depression, attention deficit-hyperactivity disorder (ADHD),
schizophrenia, cocaine-induced paranoia and anxiety disorders (Cubells and Za-
betian, 2004).
29
3 Dopamine β-hydroxylase
Human DβH deficiency is a very rare disorder involving elevated dopamine
levels and lack of norepinephrine. Patients suffering from this disease exhibit hy-
potension (lowered blood pressure) and other signs of failure in the sympathetic
nervous system (Cubells and Zabetian, 2004).
The disorders associated with dopamine β-hydroxylase and the levels of dopa-
mine and norepinephrine affect many people and are very costly. In Denmark at
least 200,000 people are suffering from depression, another 200,000 from anxiety
disorders, 6-8,000 are affected by Parkinson’s disease and 2-6% of children have
ADHD (ADHD foreningen, 2008; Parkinsonforeningen, 2009; Psykiatrifonden,
2009). The social expensis associated with psychic disorders in Denmark are 30
billions DKK per year, which is more than any other disease (Psykiatrifonden,
2009).
Because of these profound human and economic costs it is very important to
gain more knowledge of dopamine β-hydroxylase. Such knowledge will hopefully
lead to a cure or at least a better treatment for the patients suffering from these
disorders.
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Introduction to part II
Tryptophan hydroxylase is known as a very difficult protein with respect to stabil-
ity and solubility (McKinney et al., 2005; McKinney et al., 2004; Windahl et al.,
2009). Part II of this dissertation is an attempt to solve this problem by designing
stability and solubility optimized variants of TPH2.
Two variants with 9 or 12 mutations were designed according to the recom-
mendations of Guruprasad et al. (1990) and Davis et al. (1999), who introduced
methods for calculation of protein stability and solubility, respectively. These
methods are introduced and the TPH2 variants described. Afterwards the exper-
imental work with creation of E. coli expression strains for huTPH2 and the two
variants are described and the results presented. At the end is a description of the
protocols for expression and purification of the TPH2 variants and the results of
these experiments.
E. coli expression strains for both huTPH2 and the two mutated variants were
successfully created. Unfortunately more soluble or stable protein was not ob-
tained.
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4 Stability and solubility
optimized variants of
tryptophan hydroxylase
Tryptophan hydroxylase is notoriously known as an unstable protein, and it is
very difficult to produce recombinant soluble and active TPH (McKinney et al.,
2005; McKinney et al., 2004; Windahl et al., 2009). To overcome this problem
a mutated form of TPH2 was designed on the basis of instability index calcula-
tions (Guruprasad et al., 1990) and solubility calculations (Davis et al., 1999).
In order to avoid influence of the mutations on the catalytic activity, the muta-
tions were made in the regulatory domain (9 mutations) and the tetramerisation
domain (2 mutations), whereas only one conservative mutation was introduced in
the catalytic domain. The mutated sequence was designed in the Metalloprotein
Chemistry and Engineering Group by Ph.D. Michael S. Windahl and due to a two
step procedure for introducing the 12 mutations in the sequence (see section 4.3)
two constructs were made: m9TPH2 containing the 9 mutations in the regulatory
domain and m12TPH2 containing all 12 mutations.
4.1 Instability index and solubility
Instability index (II) was introduced by Guruprasad et al. (1990), who compared
the occurrence of dipeptides in a group of unstable proteins (in vivo half-life <5 hr),
a group of stable proteins (in vivo half-life >16 hr) and the proteins in a protein
sequence database (Georgetown University Medical Center, 2009) which is now
part of the UniProt database (The UniProt Consortium, 2009). Based on these
comparisons a dipeptide instability weight value (DIWV) was given to each possible
dipeptide as shown in figure 4.1. The higher positive DIWV a given dipeptide has
the more unstable is it. 81 out of the 400 possible dipeptides have DIWV > 1 and
may be involved in the instability of a given protein, whereas 72 dipeptides have
DIWV < 1 and are contributing to protein stability (Guruprasad et al., 1990).
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DIWV 
2. amino acid of dipeptide (y) 
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e 
(x
) 
W 1 1 24.68 24.68 1 1 1 13.34 1 1 1 1 -14.03 1 1 -7.49 1 -9.37 -14.03 13.34 
C 24.68 1 33.6 33.6 1 1 -6.54 1 1 1 20.26 20.26 33.6 1 1 -6.54 1 1 1 20.26 
M 1 1 -1.88 58.28 24.68 1 -6.54 1 1 -6.54 1 44.94 -1.88 1 1 1 44.94 1 13.34 1 
H -1.88 1 1 1 44.94 -9.37 1 24.68 44.94 1 1 -1.88 -6.54 24.68 1 1 1 -9.37 1 1 
Y -9.37 1 44.94 13.34 13.34 1 1 1 1 -15.91 24.68 13.34 -7.49 1 -6.54 1 1 -7.49 24.68 1 
F 1 1 1 1 33.6 1 1 1 1 1 13.34 20.26 1 -14.03 1 1 1 1 1 1 
Q 1 -6.54 1 1 -6.54 -6.54 20.26 1 1 1 20.26 20.26 1 1 20.26 -6.54 44.94 1 1 1 
N -9.37 -1.88 1 1 1 -14.03 -6.54 1 44.94 1 1 -1.88 -7.49 24.68 1 1 1 -14.03 1 1 
I 1 1 1 13.34 1 1 1 1 1 .10 1 -1.88 1 -7.49 44.94 -7.49 1 1 1 20.26 
R 58.28 1 1 20.26 -6.54 1 20.26 13.34 1 58.28 1 20.26 1 1 1 1 44.94 -7.49 1 1 
D 1 1 1 1 1 -6.54 1 1 1 -6.54 1 1 -14.03 -7.49 1 1 20.26 1 1 1 
P -1.88 -6.54 -6.54 1 1 20.26 20.26 1 1 -6.54 -6.54 20.26 1 1 18.38 20.26 20.26 1 20.26 1 
T -14.03 1 1 1 1 13.34 -6.54 -14.03 1 1 1 1 1 1 20.26 1 1 -7.49 1 1 
K 1 1 33.6 1 1 1 24.68 1 -7.49 33.6 1 -6.54 1 1 1 -7.49 1 -7.49 1 -7.49 
E -14.03 44.94 1 -6.54 1 1 20.26 1 20.26 1 20.26 20.26 1 1 33.6 1 20.26 1 1 1 
V 1 1 1 1 -6.54 1 1 1 1 1 -14.03 20.26 -7.49 -1.88 1 1 1 -7.49 1 1 
S 1 33.6 1 1 1 1 20.26 1 1 20.26 1 44.94 1 1 20.26 1 20.26 1 1 1 
G 13.34 1 1 1 -7..49 1 1 -7.49 -7.49 1 1 1 -7.49 -7.49 -6.54 1 1 13.34 -7.49 1 
A 1 44.94 1 -7.49 1 1 1 1 1 1 -7.49 20.26 1 1 1 1 1 1 1 1 
L 24.68 1 1 1 1 1 33.6 1 1 20.26 1 20.26 1 -7.49 1 1 1 1 1 1 
Figure 4.1: Dipeptide instability weight values (DIWV) based on comparisons of a group of unstable
proteins, a group of stable proteins and the proteins from a protein sequence database. The higher positive DIWV
value a dipeptide has the more it contributes to the instability of a given protein (Guruprasad et al., 1990). All
DIWV values contributing to instability are written in red, whereas the highest values (33.6-58.28) are further
highlighted with yellow background. Reprinted with permission.
The instability index for a protein is calculated based on the dipeptide insta-
bility weight values:
II = (10/L)
L−1∑
i=1
DIWV (xiyi+1)
where (xiyi+1) is a dipeptide, L is the length of the sequence and 10 is a sca-
ling factor. Stable proteins have an II < 40 whereas unstable proteins have an
II > 40 (Guruprasad et al., 1990). The Instability Index is implemented in the
ProtParam tool of the ExPASy Proteomics Server (Gasteiger et al., 2003).
A model for predicting the solubility of proteins expressed in E. coli was devel-
oped by Wilkinson and Harrison (1991). The original model was later simplified
since it was discovered that only two of the original five parameters were critical
in distinguishing between soluble and insoluble protein expression (Davis et al.,
1999). The two-parameter version of the Wilkinson-Harrison solubility model in-
volves calculating a canonical variable (cv):
cv = 15.43
(
N + G + P + S
n
)
− 29.56
∣∣∣∣∣(R + K) - (D + E)n − 0.03
∣∣∣∣∣
where N, G, P, S, R, K, D and E refer to the number of the respective amino
acids in the protein and n is the total number of residues in the protein. The
difference between Arg plus Lys residues vs. Asp plus Glu residues accounts for
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the approximate charge of the protein whereas Asn, Gly, Pro and Ser are the turn-
forming residues. When cv < 1.71 the protein is predicted to be soluble, which
means that for a protein to be soluble it should contain few turn-forming residues
and be highly charged, preferably negatively charged (Davis et al., 1999).
When cv is known, the probability of solubility or insolubility can be calculated
from following equation:
probability = 0.4934 + 0.276|cv − 1.71| − 0.0392(cv − 1.71)2
cv < 1.71: soluble protein
cv > 1.71: insoluble protein
Recombinant protein solubility predictions based on protein sequences can be
calculated on www.biotech.ou.edu (Harrison, 2000).
4.1.1 Design of the mutated TPH2 sequence
The Instability Index of the human TPH2 sequence is computed to be 51.15 which
classifies the protein as unstable (Gasteiger et al., 2003; Guruprasad et al., 1990).
Table 4.1: Residues which were not mutated in the designed sequence. It was avoided to mutate the
residues mentioned here in order not to disturb the activity or folding of the resulting protein.
Residue Reason
Ser52 S52 might be involved in hydrogenbonding to BH4. The equiv-
alent S23 in phenylalanine hydroxylase (PAH) binds BH4 (Sol-
stad et al., 2003).
Phe68 F68 is involved in the hydrophobic core. Equivalent F39 muta-
tion in PAH destabilizes the enzyme (Wang et al., 2007).
Arg97 R97 is possibly making a hydrogen bond to the catalytic do-
main, in PAH the equivalent R68 hydrogen bonds to C237
(corresponding amino acid in TPH2 is an arginine) (Tho´ro´lf-
sson et al., 2003).
Arg100 R100 is probably in a loop making hydrogenbonding to the
catalytic domain. PAH equivalent R71 is involved in a H-bond
to R297 in the catalytic domain (Tho´ro´lfsson et al., 2003).
Arg441 R441H might be involved in major depression (Zhang et al.,
2005), mutation of the equivalent residue (R408W) in PAH
gives phenylketonuria (Gersting et al., 2008).
Thr460 T460 is probably important in the tetramerisation hinge re-
gion. Equivalent T427 in PAH hinge region is important for
tetramerisation (Bjørgo et al., 2001).
Ile463-Val477 I463-V477 is probably part of a leucine zipper important for
tetramerisation. In PAH the leucine zipper comprises amino
acids L430-L448 (Knappskog et al., 1996) which correspond to
I463-V477 in TPH2.
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The two-parameter version of the Wilkinson-Harrison solubility model predict this
sequence to have 57.7 % chance of insolubility (Davis et al., 1999; Harrison, 2000).
These data agree with the experimental experience that tryptophan hydroxylase
is an unstable protein, and it is very diffucult to produce recombinant soluble and
active TPH (McKinney et al., 2005; McKinney et al., 2004; Windahl et al., 2009).
Based on these calculations Ph.D. Michael S. Windahl designed a mutated
TPH2 sequence which theoretically was predicted to give a stable and soluble
protein when over expressed in E. coli.
First of all it was decided to preferably avoid mutations in the catalytic domain
in order to keep the activity of tryptophan hydroxylase 2. Moreover it was chosen
to avoid mutating the residues mentioned in table 4.1.
Mutation of serine 19
Ser19 is believed to be a phosphorylation site in TPH2 (McKinney et al., 2005).
This serine aligns with Ser19 from tyrosine hydroxylase from rat, which is phospho-
rylated at positions 8, 19, 31 and 40. Mutation of Ser19 of rat TH to glutamate
(S19E) results in a more stable protein (Royo et al., 2005) and therefore Ser19
in TPH2 was considered a good candidate for mutation. Mutation of Ser19 to
either aspartate or glutamate would introduce a negative charge, which accord-
ing to Davis et al. (1999) increase the chance of a soluble protein. Unfortunately
mutation into aspartate introduces a dipeptide instability weight value for FD of
13.34 whereas both the original FS and FE has a DIWV of 1.00 (see figure 4.1).
Since Asp is more frequent in stable proteins compared to Glu (Guruprasad et al.,
1990) it was chosen to change Ser19 into Asp (S19D) anyway.
Mutation of S19D results in a slight change in instability index from 51.15 to
51.41, whereas the chance of insolubility decreases from 57.7 % to 55.3 %.
Dipeptides with high penalty
According to instability index calculations the TPH2 sequence contain three dipep-
tides with the highest DIWV 58.28 and 15 dipeptides with penalty 44.94. These
dipeptides are marked in the TPH2 sequence shown in figure 4.2.
Beginning from highest penalty dipeptides it was chosen to mutate Arg16 into
Asp. This mutation eliminates a RR dipeptide and introduces an extra negative
charge to the protein. This could also be achieved by mutation of Arg15, but
this residue is more conserved than Arg16 (alignment with TH, not shown) and
therefore Arg16 was mutated. The R16D mutation alone results in a 54.6 % chance
of insolubility and a II of 50.16. Together with S19E it gives a protein sequence
with 52.2 % chance of insolubility and II of 50.41. This should be compared with
the native sequence having 57.7 % chance of insolubility and II of 51.15.
R101, R102 and S103 cause an RR dipeptide with DIWV = 58.28 and an RS
dipeptide with DIWV = 44.94, therefore both R101 and R102 were mutated to
replace two high penalty dipeptides with more favorable ones. Arg101 was replaced
by Asp introducing negative charge and Arg102 was replaced by Ala. These two
mutations result in a sequence with 53.0 % chance of insolubility and II = 47.92.
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MQPAMMMFSS KYWARRGFSL DSAVPEEHQL LGSSTLNKPN SGKNDDKGNK 
GSSKREAATE SGKTAVVFSL KNEVGGLVKA LRLFQEKRVN MVHIESRKSR
RRSSEVEIFV DCECGKTEFN ELIQLLKFQT TIVTLNPPEN IWTEEEELED 
VPWFPRKISE LDKCSHRVLM YGSELDADHP GFKDNVYRQR RKYFVDVAMG 
YKYGQPIPRV EYTEEETKTW GVVFRELSKL YPTHACREYL KNFPLLTKYC 
GYREDNVPQL EDVSMFLKER SGFTVRPVAG YLSPRDFLAG LAYRVFHCTQ 
YIRHGSDPLY TPEPDTCHEL LGHVPLLADP KFAQFSQEIG LASLGASDED 
VQKLATCYFF TIEFGLCKQE GQLRAYGAGL LSSIGELKHA LSDKACVKAF 
DPKTTCLQEC LITTFQEAYF VSESFEEAKE KMRDFAKSIT RPFSVYFNPY 
TQSIEILKDT RSIENVVQDL RSDLNTVCDA LNKMNQYLGI 
Figure 4.2: Dipeptides contributing to protein instability. Dipeptides with high DIVW are marked in
the TPH2 sequence. Dipeptides with red background have penalty 58.28 whereas dipeptides with penalty 44.94
are marked with yellow background. Residues in the catalytic domain are written in green and other residues
which should not be mutated are written in red. Arrows mark the positions where the DNA coding for TPH2 can
be cut with restriction enzymes.
Together with R16D and S19E the sequence has 51.4 % chance of solubility
and II = 46.92.
The remaining dipeptide with DIWV = 58.28 is located in the catalytic domain
and was therefore not changed.
Mutation of Ile94 eliminates two dipeptides with penalty 44.94, HI and IE.
I94T alone gives 57.7 % chance of insolubility and an instability index of 49.60.
The TPH2 sequence with S19E, R16D, R101D, R102A and I94T mutations result
in a sequence with 51.4 % chance of solubility and II = 45.37.
In order to eliminate another dipeptide with DIWV = 44.94 Ile141 was mutated
into Thr. This mutation alone gives 57.7 % chance of insolubility and II = 49.78.
S19E, R16D, R101D, R102A, I94T and I141T together result in a sequence with
51.4 % chance of solubility and an II of 43.99.
The Arg461, Ser462 dipeptide with DIWV = 44.94 was eliminated by mutat-
ing both residues into Asp at the same time increasing the amount of negatively
charged residues. R461D and S462D alone gives 52.2 % chance of insolubility
and II = 50.26. Together with S19E, R16D, R101D, R102A, I94T and I141T the
resulting sequence has 57.0 % chance of solubility and II = 43.10.
Another 44.94 dipeptide was eliminated while introducing negative charge by
mutating Cys111 to Asp. This mutation alone result in 56.1 % chance of insolu-
bility and II = 50.65. The TPH2 sequence with mutations S19E, R16D, R101D,
R102A, I94T, I141T, R461D, S462D and C111D has 58.5 % chance of solubility
and an II of 42.59.
The above mentioned mutations eliminate all possible high-penalty dipeptides
in the regulatory and tetramerisation domains (see figure 4.2). Since the resulting
protein still has an II above 40 it was chosen to mutate Glu455 in the catalytic
domain into Gln. Gln was chosen since it is present at the corresponding position
in both human and chicken TPH1 (see figure 2.3 in section 2.3). The mutation
eliminates both an IE dipeptide with DIWV = 44.94 and a EI dipeptide with
DIWV = 20.26. The E455Q mutation alone gives 59.2 % chance of insolubility and
an II of 49.86. Together with S19E, R16D, R101D, R102A, I94T, I141T, R461D,
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S462D and C111D mutations the sequence has 57.0 % chance of solubility and
II = 40.96.
As the protein sequence still results in an instability index considered unsta-
ble (Guruprasad et al., 1990), Arg88 was replaced by Asp eliminating a dipeptide
with DIWV = 33.6 and introducing negative charge. R88D alone results in 54.6 %
chance of insolubility and II = 50.49. The TPH2 sequence with S19E, R16D,
R101D, R102A, I94T, I141T, R461D, S462D, C111D, E455Q and R88D mutations
has 60.0 % chance of solubility and an II of 40.64.
Elimination of another unfavorable dipeptide (KR, DIWV = 33.6) was done by
mutating Arg55 into Gly. This mutation also decreases the amount of positively
charged residues. A mutant with only R55G has 56.9 % chance of insolubility and
II = 50.16. Mutation R55G combined with S19E, R16D, R101D, R102A, I94T,
I141T, R461D, S462D, C111D, E455Q and R88D mutations result in a sequence
with 60.7 % chance of solubility and II = 39.65 which classifies the protein
as stable (Guruprasad et al., 1990).
The 12 mutations necessary for making a TPH2 sequence classified as stable
and soluble are shown in figure 4.3. Moreover each mutation and their influence
on solubility and instability index are listed in table 4.2. The protein containing
12 mutations was named m12TPH2.
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GSSKGEAATE SGKTAVVFSL KNEVGGLVKA LRLFQEKDVN MVHTESRKSR
DASSEVEIFV DCEDGKTEFN ELIQLLKFQT TIVTLNPPEN TWTEEEELED 
VPWFPRKISE LDKCSHRVLM YGSELDADHP GFKDNVYRQR RKYFVDVAMG 
YKYGQPIPRV EYTEEETKTW GVVFRELSKL YPTHACREYL KNFPLLTKYC 
GYREDNVPQL EDVSMFLKER SGFTVRPVAG YLSPRDFLAG LAYRVFHCTQ 
YIRHGSDPLY TPEPDTCHEL LGHVPLLADP KFAQFSQEIG LASLGASDED 
VQKLATCYFF TIEFGLCKQE GQLRAYGAGL LSSIGELKHA LSDKACVKAF 
DPKTTCLQEC LITTFQEAYF VSESFEEAKE KMRDFAKSIT RPFSVYFNPY 
TQSIQILKDT DDIENVVQDL RSDLNTVCDA LNKMNQYLGI 
Figure 4.3: Mutated TPH2 sequence. The TPH2 sequence containing the 12 mutations necessary to make a
sequence with 60.7 % chance of solubility and II = 39.65, which classifies the protein as stable (Guruprasad et al.,
1990). Mutated residues are marked with purple background and dipeptides with red background have DIWV
= 58.28 whereas dipeptides with DIWV = 44.94 are marked with yellow background. Residues in the catalytic
domain are written in green and other residues which should not be mutated are written in red. Arrows mark the
positions where the DNA coding for TPH2 can be cut with restriction enzymes.
The intermediary m9TPH2 sequence containing only the 9 mutations in the
regulatory domain has 56.9 % chance of solubility, but an instability index of
42.08, which classifies this protein as unstable (Guruprasad et al., 1990).
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Table 4.2: TPH2 mutations. Each mutation and their influence on solubility and instability index are listed.
All solubility values are given in % chance of solubility. Values corresponding to soluble and/or stable protein are
marked in bold.
Mutation Alone Together with above
mutations
Solubility II Solubility II
none 42.3 % 51.15
S19E 44.7 % 51.41 44.7 % 51.41
R16D 45.4 % 50.16 47.8 % 50.41
R101D and R102A 47.0 % 47.92 51.4 % 46.92
I94T 42.3 % 49.60 51.4 % 45.37
I141T 42.3 % 49.78 51.4 % 43.99
R461D and S462D 47.8 % 50.26 57.0 % 43.10
C111D 43.9 % 50.65 58.0 % 42.59
E455Q 40.8 % 49.86 57.0 % 40.96
R88D 45.4 % 50.49 60.0 % 40.64
R55G 43.1 % 50.16 60.7 % 39.65
4.2 Construction of huTPH2 expression vector
Since the only available TPH2 expression vector contained an upstream ubiqui-
tin tag a new expression vector for TPH2 had to be created. This was done by
replacement of the original N-terminal domain and ubiquitin tag in HC744 (inter-
nal numbering) by a new regulatory domain made by polymerase chain reaction
(PCR). HC744 is a pET26Ub vector (derivative of pET-26b(+) (Novagen, 1998))
containing the gene encoding huTPH2 flanked by SacII/XhoI. The ubiquitin gene,
which is flanked by NdeI/SacII, is placed just upstream of the gene for TPH2 but
the SacII restriction site is placed in a way that it upon digestion will leave some
extra bases on the TPH2 gene, but no start codon (Gohara et al., 1999). The gene
encoding TPH2 furthermore contain an unique DraI restriction site in the begin-
ning of the catalytic domain (between F182 and K183) and a unique HindIII site
in the end of the catalytic domain (cutting between S424 and F425). The primers
used for the PCR reaction creating rTPH2 (TPH2, aa1-182) without ubiquitin tag
Table 4.3: TPH2 primer sequences. Base composition of the primers used for PCR production of rTPH2
without ubiquitin tag. Bases which differ from the template are marked with red.
Gene product Template and primers
rTPH2 without ubiquitin tag Template HC744: TPH2 in pET26Ub vector
(NdeI/DraI) Sense primer HCP599:
5’-AAAA CAT ATG CAG CCG GCG ATG ATG A-3’
Antisense primer HCP600:
5’-TT ATC TTT AAA GCC CGG ATG AT-3’
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is shown in table 4.3.
When the PCR product was made, the template vector HC744 was digested
with NdeI/DraI to removed the regulatory domain and the ubiquitin tag. The
PCR product was also digested with NdeI/DraI and ligated to the vector-part of
digested HC744 (not illustrated). The resulting vector is pET26 (Novagen, 1998)
containing the gene for TPH2 flanked by NdeI/XhoI.
4.3 Construction of m9TPH2 and m12TPH2 expression
vectors
Construction of the m9TH2 and m12TPH2 expression vectors were done in two
steps by replacement of the N-terminal domain and the C-terminal region of TPH2,
respectively, in a pET26Ub vector (derivative of pET-26b(+) (Novagen, 1998), in-
ternal number HC744). First the N-terminal domain was replaced by a N-terminal
domain containing the first nine mutations (m9rTPH2, see table 4.4 and figure 4.4)
resulting in an expression vector for m9PTH2. Next step was the replacement of
the C-terminal region by a new C-terminal region containing the last three muta-
tions (m3tTPH2, shown in table 4.4 and figure 4.4). Replacement of the N-terminal
domain at the same time removed the ubiquitin-tag present in HC744.
To introduce the 12 mutations in TPH2 a DNA sequence with the mutations
was ordered from GenScript. The sequence consist of the mutated N-terminal
domain flanked by the restriction sites for NdeI and DraI followed by the mutated
C-terminal region flanked by HindIII and XhoI. The DNA and protein sequences
of huTPH2 and m12TPH2 are shown in figures 4.5 and 4.6.
Table 4.4: Mutations in m9TPH2 and m12TPH2. The mutations at DNA level and the resulting amino
acid changes. m9TPH2 contain the nine mutations in the regulatory domain and the wild-type tetramerisation
domain, whereas m12TPH2 contain all 12 mutations.
Domain Base numbers Base change Protein mutation
Regulatory 46-48 CGC → GAT Arg16Asp
55-57 AGC → GAT Ser19Asp
163-165 CGT → GGC Arg55Gly
262-264 CGT → GAT Arg88Asp
280-282 ATT → ACC Ile94Thr
301-303 CGC → GAT Arg101Asp
304-306 CGT → GCG Arg102Ala
340-342 TGC → GAT Cys114Asp
421-423 ATT → ACC Ile141Thr
C-terminal 1363-1365 GAA → CAG Glu455Gln
1381-1383 CGT → GAT Arg461Asp
1384-1386 AGC → GAT Ser462Asp
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HC976
6707 bp
m9regTHP2
catTHP2
tetTPH2
DraI (1091)
HindIII (364)
NdeI (1636)
XhoI (159)
m9rTPH2-m3tTPH2/XhoI/NdeI-pUC57
HC970
6935 bp
 
m9rTPH2
m3tTPH2
XhoI (1195)
HindIII (990)
NdeI (185)
DraI (981)
NdeI (434)
HindIII (1240)
DraI (3069)
DraI (2377)
DraI (2358)
m9rTPH2-m3tTPH2
/XhoI/NdeI-pUC57
HC970
3478 bp
Ub
tTPH2
cTPH2
rTPH2
NdeI (1864)
XhoI (159)
SacII (1645)
DraI (1091)
HindIII (364)
huTPH2/SacII/XhoI-pET26Ub
HC744
6935 bp
NdeI (1636)
tTPH2
cTPH2
m9rTPH2
XhoI (159)
DraI (1091)
HindIII (364)
m9TPH2/NdeI/XhoI-pET26
HC989
6707 bp
NdeI (1636)
m3tTPH2
cTPH2
m9rTPH2
XhoI (159)
DraI (1091)
HindIII (364)
m12TPH2/NdeI/XhoI-pET26
HC1012
6707 bp
Enzyme digestion
NdeI/DraI
T4 DNA Ligase
m9rTPH2
m3tTPH2
XhoI (1195)
HindIII (990)
NdeI (185)
DraI (981)
NdeI (434)
HindIII (1240)
DraI (3069)
DraI (2377)
DraI (2358)
m9rTPH2-m3tTPH2
/XhoI/NdeI-pUC57
HC970
3478 bp
Enzyme digestion
HindIII/XhoI
T4 DNA Ligase
Figure 4.4: Overview of the construction of m12TPH2. In the first step the wild-type N-terminal
domain of the gene for TPH2 is replaced by the mutated N-terminal domain (m9rTPH2) resulting in the expres-
sion vector for m9TPH2. The mutated C-terminal region (m3tTPH2) in then inserted instead of the wild-type
C-terminal region to produce the expression vector for m12TPH2. Vector maps were made with Vector NTI
AdvanceTM 10.3.0 (Invitrogen Life Sciences, 2006).
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1 CATATGCAGC CGGCGATGAT GATGTTTAGC AGCAAATATT GGGCGCGTCG CGGCTTTAGC CTGGATAGCG CGGTGCCGGA AGAGCATCAG
GTATACGTCG GCCGCTACTA CTACAAATCG TCGTTTATAA CCCGCGCAGC GCCGAAATCG GACCTATCGC GCCACGGCCT TCTCGTAGTC
NdeI
+1 Met Gln Pro Ala Met Met Met Phe Ser Ser Lys Tyr Trp Ala Arg Arg Gly Phe Ser Leu Asp Ser Ala Val Pro Glu Glu His Gln
91 CTGCTGGGCA GCAGCACCCT GAACAAACCG AACAGCGGCA AAAACGATGA CAAAGGCAAC AAAGGCAGCA GCAAACGTGA AGCGGCCACC
GACGACCCGT CGTCGTGGGA CTTGTTTGGC TTGTCGCCGT TTTTGCTACT GTTTCCGTTG TTTCCGTCGT CGTTTGCACT TCGCCGGTGG
+1 Leu Leu Gly Ser Ser Thr Leu Asn Lys Pro Asn Ser Gly Lys Asn Asp Asp Lys Gly Asn Lys Gly Ser Ser Lys Arg Glu Ala Ala Thr
181 GAAAGCGGCA AAACCGCCGT GGTTTTTAGC CTGAAAAACG AAGTGGGCGG TCTGGTGAAA GCGCTGCGTC TGTTTCAGGA AAAACGTGTG
CTTTCGCCGT TTTGGCGGCA CCAAAAATCG GACTTTTTGC TTCACCCGCC AGACCACTTT CGCGACGCAG ACAAAGTCCT TTTTGCACAC
+1 Glu Ser Gly Lys Thr Ala Val Val Phe Ser Leu Lys Asn Glu Val Gly Gly Leu Val Lys Ala Leu Arg Leu Phe Gln Glu Lys Arg Val
271 AACATGGTGC ATATTGAAAG CCGTAAAAGC CGTCGCCGTA GCAGCGAAGT GGAAATTTTT GTGGATTGCG AATGCGGCAA AACCGAATTT
TTGTACCACG TATAACTTTC GGCATTTTCG GCAGCGGCAT CGTCGCTTCA CCTTTAAAAA CACCTAACGC TTACGCCGTT TTGGCTTAAA
+1 Asn Met Val His Ile Glu Ser Arg Lys Ser Arg Arg Arg Ser Ser Glu Val Glu Ile Phe Val Asp Cys Glu Cys Gly Lys Thr Glu Phe
361 AACGAACTGA TTCAGCTGCT GAAATTTCAG ACCACCATTG TGACCCTGAA CCCGCCGGAA AACATTTGGA CCGAAGAGGA A
TTGCTTGACT AAGTCGACGA CTTTAAAGTC TGGTGGTAAC ACTGGGACTT GGGCGGCCTT TTGTAAACCT GGCTTCTCCT T
GAGCTGGAA
CTCGACCTT
+1 Asn Glu Leu Ile Gln Leu Leu Lys Phe Gln Thr Thr Ile Val Thr Leu Asn Pro Pro Glu Asn Ile Trp Thr Glu Glu Glu Glu Leu Glu
451 GATGTGCCGT GGTTTCCGCG TAAAATTAGC GAACTGGATA AATGCAGCCA TCGTGTGCTG ATGTATGGCA GCGAACTGGA TGCGGATCAT
CTACACGGCA CCAAAGGCGC ATTTTAATCG CTTGACCTAT TTACGTCGGT AGCACACGAC TACATACCGT CGCTTGACCT ACGCCTAGTA
+1 Asp Val Pro Trp Phe Pro Arg Lys Ile Ser Glu Leu Asp Lys Cys Ser His Arg Val Leu Met Tyr Gly Ser Glu Leu Asp Ala Asp His
541 CCGGGCTTTA AAGATAACGT GTATCGTCAG CGTCGCAAAT ATTTTGTGGA TGTGGCGATG GGCTATAAAT ATGGCCAGCC GATTCCGCGT
GGCCCGAAAT TTCTATTGCA CATAGCAGTC GCAGCGTTTA TAAAACACCT ACACCGCTAC CCGATATTTA TACCGGTCGG CTAAGGCGCA
DraI
+1 Pro Gly Phe Lys Asp Asn Val Tyr Arg Gln Arg Arg Lys Tyr Phe Val Asp Val Ala Met Gly Tyr Lys Tyr Gly Gln Pro Ile Pro Arg
631 GTGGAATATA CCGAAGAGGA AACCAAAACC TGGGGCGTGG TTTTTCGTGA ACTGAGCAAA CTGTATCCGA CCCATGCGTG CCGTGAATAT
CACCTTATAT GGCTTCTCCT TTGGTTTTGG ACCCCGCACC AAAAAGCACT TGACTCGTTT GACATAGGCT GGGTACGCAC GGCACTTATA
+1 Val Glu Tyr Thr Glu Glu Glu Thr Lys Thr Trp Gly Val Val Phe Arg Glu Leu Ser Lys Leu Tyr Pro Thr His Ala Cys Arg Glu Tyr
721 CTGAAAAACT TTCCGCTGCT GACCAAATAT TGCGGCTATC GTGAAGATAA CGTGCCGCAG CTGGAAGATG TGAGCATGTT TCTGAAAGAA
GACTTTTTGA AAGGCGACGA CTGGTTTATA ACGCCGATAG CACTTCTATT GCACGGCGTC GACCTTCTAC ACTCGTACAA AGACTTTCTT
+1 Leu Lys Asn Phe Pro Leu Leu Thr Lys Tyr Cys Gly Tyr Arg Glu Asp Asn Val Pro Gln Leu Glu Asp Val Ser Met Phe Leu Lys Glu
811 CGTAGCGGCT TTACCGTGCG TCCGGTGGCG GGCTATCTGA GCCCGCGTGA TTTTCTGGCG GGCCTGGCGT ATCGTGTGTT TCATTGCACC
GCATCGCCGA AATGGCACGC AGGCCACCGC CCGATAGACT CGGGCGCACT AAAAGACCGC CCGGACCGCA TAGCACACAA AGTAACGTGG
+1 Arg Ser Gly Phe Thr Val Arg Pro Val Ala Gly Tyr Leu Ser Pro Arg Asp Phe Leu Ala Gly Leu Ala Tyr Arg Val Phe His Cys Thr
901 CAGTATATTC GTCATGGCAG CGATCCGCTG TATACCCCGG AACCGGATAC CTGCCATGAA CTGCTGGGCC ATGTTCCGCT GCTGGCGGAT
GTCATATAAG CAGTACCGTC GCTAGGCGAC ATATGGGGCC TTGGCCTATG GACGGTACTT GACGACCCGG TACAAGGCGA CGACCGCCTA
+1 Gln Tyr Ile Arg His Gly Ser Asp Pro Leu Tyr Thr Pro Glu Pro Asp Thr Cys His Glu Leu Leu Gly His Val Pro Leu Leu Ala Asp
991 CCGAAATTTG CGCAGTTTAG CCAGGAAATT GGCCTGGCGA GCCTGGGCGC GAGCGATGAA GATGTGCAGA AACTGGCGAC CTGCTATTTC
GGCTTTAAAC GCGTCAAATC GGTCCTTTAA CCGGACCGCT CGGACCCGCG CTCGCTACTT CTACACGTCT TTGACCGCTG GACGATAAAG
+1 Pro Lys Phe Ala Gln Phe Ser Gln Glu Ile Gly Leu Ala Ser Leu Gly Ala Ser Asp Glu Asp Val Gln Lys Leu Ala Thr Cys Tyr Phe
1081 TTTACCATTG AATTTGGCCT GTGCAAACAG GAAGGCCAGC TGCGTGCCTA TGGTGCGGGC CTGCTGAGCA GCATTGGCGA ACTGAAACAT
AAATGGTAAC TTAAACCGGA CACGTTTGTC CTTCCGGTCG ACGCACGGAT ACCACGCCCG GACGACTCGT CGTAACCGCT TGACTTTGTA
+1 Phe Thr Ile Glu Phe Gly Leu Cys Lys Gln Glu Gly Gln Leu Arg Ala Tyr Gly Ala Gly Leu Leu Ser Ser Ile Gly Glu Leu Lys His
1171 GCGCTGAGCG ATAAAGCGTG CGTGAAAGCG TTTGATCCGA AAACCACCTG CCTGCAGGAA TGCCTGATTA CCACCTTTCA GGAAGCGTAT
CGCGACTCGC TATTTCGCAC GCACTTTCGC AAACTAGGCT TTTGGTGGAC GGACGTCCTT ACGGACTAAT GGTGGAAAGT CCTTCGCATA
+1 Ala Leu Ser Asp Lys Ala Cys Val Lys Ala Phe Asp Pro Lys Thr Thr Cys Leu Gln Glu Cys Leu Ile Thr Thr Phe Gln Glu Ala Tyr
1261 TTTGTGAGCG AAAGCTTTGA AGAGGCGAAA GAAAAAATGC GTGATTTTGC GAAAAGCATT ACCCGTCCGT TTAGCGTGTA TTTTAACCCG
AAACACTCGC TTTCGAAACT TCTCCGCTTT CTTTTTTACG CACTAAAACG CTTTTCGTAA TGGGCAGGCA AATCGCACAT AAAATTGGGC
HindIII
+1 Phe Val Ser Glu Ser Phe Glu Glu Ala Lys Glu Lys Met Arg Asp Phe Ala Lys Ser Ile Thr Arg Pro Phe Ser Val Tyr Phe Asn Pro
1351 TATACCCAGA GCATTGAAAT TCTGAAAGAT ACC
ATATGGGTCT CGTAACTTTA AGACTTTCTA TGG
CGTAGCA TTGAAAACGT GGTTCAGGAT CTGCGTAGCG ATCTGAACAC CGTGTGCGAT
GCATCGT AACTTTTGCA CCAAGTCCTA GACGCATCGC TAGACTTGTG GCACACGCTA
+1 Tyr Thr Gln Ser Ile Glu Ile Leu Lys Asp Thr Arg Ser Ile Glu Asn Val Val Gln Asp Leu Arg Ser Asp Leu Asn Thr Val Cys Asp
1441 GCGCTGAACA AAATGAACCA GTATCTGGGC ATTTGACTCG AG
CGCGACTTGT TTTACTTGGT CATAGACCCG TAAACTGAGC TC
XhoI
+1 Ala Leu Asn Lys Met Asn Gln Tyr Leu Gly Ile ***
Figure 4.5: DNA and protein sequence of huTPH2. The DNA sequence of the gene encoding huTPH2 is
shown with the flanking restriction sites NdeI/XhoI as well as the two unique internal restriction sites DraI
and HindIII. Above the DNA sequence the resulting protein sequence is shown in three letter code. The
bases corresponding to the catalytic domain are written in green. The figure was made with Vector NTI
AdvanceTM 10.3.0 (Invitrogen Life Sciences, 2006).
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1 CATATGCAGC CGGCGATGAT GATGTTTAGC AGCAAATATT GGGCGCGT
GTATACGTCG GCCGCTACTA CTACAAATCG TCGTTTATAA CCCGCGCA
GA T
CT A
GGCTTT
CCGAAA
GAT
CTA
CTGGATAGCG CGGTGCCGGA AGAGCATCAG
GACCTATCGC GCCACGGCCT TCTCGTAGTC
NdeI
+1 Met Gln Pro Ala Met Met Met Phe Ser Ser Lys Tyr Trp Ala Arg Asp Gly Phe Asp Leu Asp Ser Ala Val Pro Glu Glu His Gln
91 CTGCTGGGCA GCAGCACCCT GAACAAACCG AACAGCGGCA AAAACGATGA CAAAGGCAAC AAAGGCAGCA GCAAA
GACGACCCGT CGTCGTGGGA CTTGTTTGGC TTGTCGCCGT TTTTGCTACT GTTTCCGTTG TTTCCGTCGT CGTTT
GGC
CCG
GA AGCGGCCACC
CT TCGCCGGTGG
+1 Leu Leu Gly Ser Ser Thr Leu Asn Lys Pro Asn Ser Gly Lys Asn Asp Asp Lys Gly Asn Lys Gly Ser Ser Lys Gly Glu Ala Ala Thr
181 GAAAGCGGCA AAACCGCCGT GGTTTTTAGC CTGAAAAACG AAGTGGGCGG TCTGGTGAAA GCGCTGCGTC TGTTTCAGGA AAAA
CTTTCGCCGT TTTGGCGGCA CCAAAAATCG GACTTTTTGC TTCACCCGCC AGACCACTTT CGCGACGCAG ACAAAGTCCT TTTT
GAT
CTA
GTG
CAC
+1 Glu Ser Gly Lys Thr Ala Val Val Phe Ser Leu Lys Asn Glu Val Gly Gly Leu Val Lys Ala Leu Arg Leu Phe Gln Glu Lys Asp Val
271 AACATGGTGC AT
TTGTACCACG TA
ACC
TGG
GAAAG CCGTAAAAGC CGT
CTTTC GGCATTTTCG GCA
GATGCG
CTACGC
A GCAGCGAAGT GGAAATTTTT GTGGATTGCG AA
T CGTCGCTTCA CCTTTAAAAA CACCTAACGC TT
GAT
CTA
GGCAA AACCGAATTT
CCGTT TTGGCTTAAA
+1 Asn Met Val His Thr Glu Ser Arg Lys Ser Arg Asp Ala Ser Ser Glu Val Glu Ile Phe Val Asp Cys Glu Asp Gly Lys Thr Glu Phe
361 AACGAACTGA TTCAGCTGCT GAAATTTCAG ACCACCATTG TGACCCTGAA CCCGCCGGAA AAC
TTGCTTGACT AAGTCGACGA CTTTAAAGTC TGGTGGTAAC ACTGGGACTT GGGCGGCCTT TTG
ACC
TGG
TGGA CCGAAGAGGA A
ACCT GGCTTCTCCT T
GAGCTGGAA
CTCGACCTT
+1 Asn Glu Leu Ile Gln Leu Leu Lys Phe Gln Thr Thr Ile Val Thr Leu Asn Pro Pro Glu Asn Thr Trp Thr Glu Glu Glu Glu Leu Glu
451 GATGTGCCGT GGTTTCCGCG TAAAATTAGC GAACTGGATA AATGCAGCCA TCGTGTGCTG ATGTATGGCA GCGAACTGGA TGCGGATCAT
CTACACGGCA CCAAAGGCGC ATTTTAATCG CTTGACCTAT TTACGTCGGT AGCACACGAC TACATACCGT CGCTTGACCT ACGCCTAGTA
+1 Asp Val Pro Trp Phe Pro Arg Lys Ile Ser Glu Leu Asp Lys Cys Ser His Arg Val Leu Met Tyr Gly Ser Glu Leu Asp Ala Asp His
541 CCGGGCTTTA AAGATAACGT GTATCGTCAG CGTCGCAAAT ATTTTGTGGA TGTGGCGATG GGCTATAAAT ATGGCCAGCC GATTCCGCGT
GGCCCGAAAT TTCTATTGCA CATAGCAGTC GCAGCGTTTA TAAAACACCT ACACCGCTAC CCGATATTTA TACCGGTCGG CTAAGGCGCA
DraI
+1 Pro Gly Phe Lys Asp Asn Val Tyr Arg Gln Arg Arg Lys Tyr Phe Val Asp Val Ala Met Gly Tyr Lys Tyr Gly Gln Pro Ile Pro Arg
631 GTGGAATATA CCGAAGAGGA AACCAAAACC TGGGGCGTGG TTTTTCGTGA ACTGAGCAAA CTGTATCCGA CCCATGCGTG CCGTGAATAT
CACCTTATAT GGCTTCTCCT TTGGTTTTGG ACCCCGCACC AAAAAGCACT TGACTCGTTT GACATAGGCT GGGTACGCAC GGCACTTATA
+1 Val Glu Tyr Thr Glu Glu Glu Thr Lys Thr Trp Gly Val Val Phe Arg Glu Leu Ser Lys Leu Tyr Pro Thr His Ala Cys Arg Glu Tyr
721 CTGAAAAACT TTCCGCTGCT GACCAAATAT TGCGGCTATC GTGAAGATAA CGTGCCGCAG CTGGAAGATG TGAGCATGTT TCTGAAAGAA
GACTTTTTGA AAGGCGACGA CTGGTTTATA ACGCCGATAG CACTTCTATT GCACGGCGTC GACCTTCTAC ACTCGTACAA AGACTTTCTT
+1 Leu Lys Asn Phe Pro Leu Leu Thr Lys Tyr Cys Gly Tyr Arg Glu Asp Asn Val Pro Gln Leu Glu Asp Val Ser Met Phe Leu Lys Glu
811 CGTAGCGGCT TTACCGTGCG TCCGGTGGCG GGCTATCTGA GCCCGCGTGA TTTTCTGGCG GGCCTGGCGT ATCGTGTGTT TCATTGCACC
GCATCGCCGA AATGGCACGC AGGCCACCGC CCGATAGACT CGGGCGCACT AAAAGACCGC CCGGACCGCA TAGCACACAA AGTAACGTGG
+1 Arg Ser Gly Phe Thr Val Arg Pro Val Ala Gly Tyr Leu Ser Pro Arg Asp Phe Leu Ala Gly Leu Ala Tyr Arg Val Phe His Cys Thr
901 CAGTATATTC GTCATGGCAG CGATCCGCTG TATACCCCGG AACCGGATAC CTGCCATGAA CTGCTGGGCC ATGTTCCGCT GCTGGCGGAT
GTCATATAAG CAGTACCGTC GCTAGGCGAC ATATGGGGCC TTGGCCTATG GACGGTACTT GACGACCCGG TACAAGGCGA CGACCGCCTA
+1 Gln Tyr Ile Arg His Gly Ser Asp Pro Leu Tyr Thr Pro Glu Pro Asp Thr Cys His Glu Leu Leu Gly His Val Pro Leu Leu Ala Asp
991 CCGAAATTTG CGCAGTTTAG CCAGGAAATT GGCCTGGCGA GCCTGGGCGC GAGCGATGAA GATGTGCAGA AACTGGCGAC CTGCTATTTC
GGCTTTAAAC GCGTCAAATC GGTCCTTTAA CCGGACCGCT CGGACCCGCG CTCGCTACTT CTACACGTCT TTGACCGCTG GACGATAAAG
+1 Pro Lys Phe Ala Gln Phe Ser Gln Glu Ile Gly Leu Ala Ser Leu Gly Ala Ser Asp Glu Asp Val Gln Lys Leu Ala Thr Cys Tyr Phe
1081 TTTACCATTG AATTTGGCCT GTGCAAACAG GAAGGCCAGC TGCGTGCCTA TGGTGCGGGC CTGCTGAGCA GCATTGGCGA ACTGAAACAT
AAATGGTAAC TTAAACCGGA CACGTTTGTC CTTCCGGTCG ACGCACGGAT ACCACGCCCG GACGACTCGT CGTAACCGCT TGACTTTGTA
+1 Phe Thr Ile Glu Phe Gly Leu Cys Lys Gln Glu Gly Gln Leu Arg Ala Tyr Gly Ala Gly Leu Leu Ser Ser Ile Gly Glu Leu Lys His
1171 GCGCTGAGCG ATAAAGCGTG CGTGAAAGCG TTTGATCCGA AAACCACCTG CCTGCAGGAA TGCCTGATTA CCACCTTTCA GGAAGCGTAT
CGCGACTCGC TATTTCGCAC GCACTTTCGC AAACTAGGCT TTTGGTGGAC GGACGTCCTT ACGGACTAAT GGTGGAAAGT CCTTCGCATA
+1 Ala Leu Ser Asp Lys Ala Cys Val Lys Ala Phe Asp Pro Lys Thr Thr Cys Leu Gln Glu Cys Leu Ile Thr Thr Phe Gln Glu Ala Tyr
1261 TTTGTGAGCG AAAGCTTTGA AGAGGCGAAA GAAAAAATGC GTGATTTTGC GAAAAGCATT ACCCGTCCGT TTAGCGTGTA TTTTAACCCG
AAACACTCGC TTTCGAAACT TCTCCGCTTT CTTTTTTACG CACTAAAACG CTTTTCGTAA TGGGCAGGCA AATCGCACAT AAAATTGGGC
HindIII
+1 Phe Val Ser Glu Ser Phe Glu Glu Ala Lys Glu Lys Met Arg Asp Phe Ala Lys Ser Ile Thr Arg Pro Phe Ser Val Tyr Phe Asn Pro
1351 TATACCCAGA GCATT
ATATGGGTCT CGTAA
CAG
GTC
AT TCTGAAAGAT ACC
TA AGACTTTCTA TGG
GATGAT
CTACTA
A TTGAAAACGT GGTTCAGGAT CTGCGTAGCG ATCTGAACAC CGTGTGCGAT
T AACTTTTGCA CCAAGTCCTA GACGCATCGC TAGACTTGTG GCACACGCTA
+1 Tyr Thr Gln Ser Ile Gln Ile Leu Lys Asp Thr Asp Asp Ile Glu Asn Val Val Gln Asp Leu Arg Ser Asp Leu Asn Thr Val Cys Asp
1441 GCGCTGAACA AAATGAACCA GTATCTGGGC ATTTGACTCG AG
CGCGACTTGT TTTACTTGGT CATAGACCCG TAAACTGAGC TC
XhoI
+1 Ala Leu Asn Lys Met Asn Gln Tyr Leu Gly Ile ***
Figure 4.6: DNA and protein sequence of m12TPH2. The DNA sequence of the gene encoding m12TPH2
is shown with the flanking restriction sites NdeI/XhoI as well as the two unique internal restriction sites DraI
and HindIII. Above the DNA sequence the resulting protein sequence is shown in three letter code. The bases
corresponding to the catalytic domain are written in green and the mutated bases corresponding to 12 residues
are marked with violet. The figure was made with Vector NTI AdvanceTM 10.3.0 (Invitrogen Life Sciences, 2006).
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5 E. coli expression strains
for TPH2 - experimental
This section describes the protocols for the individual steps in preparing a bacterial
expression strain. All solutions were prepared using ultrapure 18.2 MΩ·cm water
from a MilliQ synthesis A10 system from Millipore (milliQ water) and both milliQ
water and growth media were sterilized by autoclaving before use.
5.1 Construction of E. coli expression strains
The gene of interest was produced by polymerase chain reaction (PCR) and cloned
into a PCR-Script Amp SK(+) cloning vector (Stratagene, 2008). The resulting
plasmid was transformed into E. coli DH5α cells and colonies amplified overnight.
The resulting culture was used for bacteria stock and to isolate amplified plasmid
DNA.
After an analytical digestion with restriction enzymes, the plasmid which con-
tained the expected fragments was junction sequenced to ensure that the sequence
was correct. The gene of interest was then cleaved from the PCR-Script Amp
SK(+) cloning vector by digestion with restriction enzymes and, after prepara-
tive gel electrophoresis and purification of the fragment of interest, ligated to the
appropriate vector digested with the same restriction enzymes.
The resulting plasmid was transformed into DH5α cells and amplified overnight.
A bacterial stock of the expression vector was made and amplified plasmid DNA
isolated, junction sequenced and transformed into E. coli BL21(DE3) cells. The
stock of expression vector in BL21(DE3) cells was later used for culturing for
production of protein.
An overview of all the steps is illustrated in figure 5.1 and the procedures are
described in the following sections.
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PCR amplification of gene 
Preparative gel electrophoresis 
Gel purification 
Analytical gel electrophoresis 
Ligation into cloning vector 
Tranformation into DH5 cells 
3 ml overnight culture 
Glycerol stocks DNA isolation 
Analytical digestion Preparative digestion 
Analytical gel electrophoresis 
Sequencing 
Preparative gel electrophoresis 
Gel purification 
Opening of vector by digestion 
Preparative gel electrophoresis 
Gel purification 
Analytical gel electrophoresis 
Ligation of vector and insert 
Transformation into DH5 cells 
3 ml overnight culture 
Glycerol stocks DNA isolation 
Analytical digestion Transformation into BL21(DE3) 
cells
Analytical gel electrophoresis 
Sequencing 
3 ml overnight culture 
Glycerol stock 
Figure 5.1: Preparation of bacterial expression strain. The steps from initial PCR production of the gene
of interest until the final expression strain in BL21(DE3) cells is present as glycerol stock.
5.1.1 Polymerase chain reaction
Polymerase chain reaction (PCR) was done using the Platinum R©Pfx DNA Poly-
merase kit from Invitrogen #11708-013.
Following components were mixed in a microcentrifuge tube:
Sterile milliQ water X µl for a final volume of 50.0 µl
10X Pfx amplification buffer 5.0 µl
10 mM dNTP mixture 1.5 µl
50 mM MgSO4 1.0 µl
0.015 nmol sense primer X µl dependent on primer concentration
0.015 nmol antisense primer X µl dependent on primer concentration
DNA template X µl usually 0.5 µl
Pfx DNA Polymerase 0.4 µl
After a brief centrifugation, the mixture was placed in the PCR machine and
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denatured at 94◦C for 2 minutes followed by 25-30 cycles of PCR amplification:
Denature: 94◦C for 15 s
Anneal: Tm for 30 s (Tm is calculated from primer composition)
Extension: 68◦C for 1 min per kb
The product was then analysed by agarose gel electrophoresis (see section 5.1.2)
before further processing.
Primers were individually designed according to the desired addition of restric-
tion site (the primer sequences are shown in section 4.2). The annealing part of
the primers contained about 20 basepairs with Tm ≈ 55◦C (see below). Moreover
the primers contained the extra bases according to the planned restriction site and
in case of primers covering the end of a gene some extra A’s in the 5’-end to avoid
problems due to 5’-3’ exonuclease activity during the PCR reaction. Primers were
synthesized by TAG Copenhagen A/S.
The annealing temperature, Tm, was calculated from the following formula:
Tm = (2 · (A+ T ) + 2 · (C +G))− 5
where (A+T) refers to the number of A and T bases in the annealing part of the
primer and (C+G) to the number of C and G bases in the annealing part of the
primer.
5.1.2 Agarose gel electrophoresis
Agarose gels were prepared according to the size of the linear DNA fragments to
be analysed.
Size of linear DNA fragment Gel % Agarose amount per gel
> 4 kb 0.8 % 0.20 g
0.8-4 kb 1.0 % 0.25 g
0.4-0.8 kb 1.2 % 0.30 g
< 0.4 kb 1.5 % 0.375 g
For preparation of one gel, the desired amount of agarose was mixed with 25 ml
of 1xTBE buffer (10.8 g/l Trizma base, 5.5 g/l boric acid (H3BO4) and 4.0 ml/l
0.5 M EDTA pH 8.0 diluted in milliQ water) in a 100 ml conical flask. The mixture
was heated to completely dissolve the agarose and when afterwards cooled to 50-
60◦C 0.20 µl 10 mg/ml EtBr (Ethidium bromide) was added. When further cooled
the gel was poured into the form assembled with the appropriate comb and allowed
to solidify.
For analytical gels a 10 well comb was used. All wells are equally sized and
contain 12 µl each. For a preparative gel a 2 well comb was used, this comb have
a smaller well for the marker containing 24 µl and a bigger well for the sample
containing 120 µl. The marker for both kind of gels consist of 1/24 1 kb Plus DNA
ladder (Invitrogen #10787-018), 4/24 loading dye (0.25 % bromphenolblue, 30 %
glycerol and 50 mM EDTA) and 19/24 milliQ water.
Loading dye was added to the samples to 1/5 of the final volume prior to
loading.
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The gel was placed in a running vessel containing running buffer (1xTBE buffer
with 25 µl/l EtBr added) and loaded with marker and samples. 100 V constant
voltage was applied for about 30 minutes or until satisfactory separation of bands
occurred.
EtBr binding to DNA results in orange fluorescence upon exposure to UV-light,
therefore bands were visualized using an UV-light table.
For preparative gels the piece of gel containing the appropriate DNA fragment
was cut free using a scalpel.
5.1.3 Extraction of DNA fragment from gel material
The DNA was extracted from agarose gel material using the Sephaglas BandPrep
Kit, GE Healthcare #27-9285-01. The protocol provided by GE Healthcare was
followed with the exception that DNA was eluted with milliQ water instead of the
provided elution buffer.
5.1.4 Ligation in PCR vector
Extracted DNA was ligated into the pPCR-ScriptTM Amp SK(+) Vector (Strata-
gene, 2008) following recommendations from the PCR-ScriptTM Amp Cloning Kit
(Stratagene #21188-5).
5.1.5 Transformation of constructs
For general DNA work the plasmid was transformed into MAX Efficiency R©
DH5αTM competent cells (Invitrogen #18258-012) and for protein expression the
plasmid was transformed into competent BL21(DE3) cells.
Transformation in DH5α cells
Competent cells were thawed on ice and 100 µl of cells were placed in a chilled
polypropylene tube. 1 µl DNA was added to the cells and gently mixed.
Cells and DNA were incubated 30 minutes on ice followed by 45 seconds heat-
shock in a 42◦C water bath and another 2 minutes on ice.
0.45 ml of room temperature Luria-Broth (LB) medium without antibiotics
was added to the mixture and the tube was placed in a shaking incubator at 37◦C,
140 rpm for 1 hour (incubation was skipped for plasmids with ampicillin (Amp)
resistance).
1/10 and 8/10 of the mixture were spread on two LB agar plates containing
the appropriate antibiotics and incubated overnight at 37◦C.
Transformation in BL21(DE3) cells
To make cells competent, glycerol stock HCB17 (BL21(DE3) cells) was plated on
a LB agar plate without antibiotics and incubated at 37◦C overnight.
One single colony was inoculated in 3 ml LB medium and incubated overnight
at 37◦C with 250 rpm shaking. The next day 0.25 ml of the culture was inoculated
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in 50 ml fresh LB medium and incubated at 37◦C, 250 rpm until 0.4 < OD600 nm
< 0.6.
The culture was transferred to a sterile 50 ml tube and centrifuged at 1900×g
for 10 minutes at +4◦C. The supernatant was immediately decanted and cells were
resuspended in 25 ml ice-cold 0.1 M CaCl2 and kept in ice-water bath for 1 hr.
After another centrifugation at 1900×g for 10 minutes at +4◦C and decantation
of supernatant, cells were resuspended in 4 ml ice-cold 0.1 M CaCl2 with 15 %
glycerol and kept on ice. If not used immediately competent cells were aliquoted
in sterile microcentrifuge tubes and stored at -80◦C.
For the transformation competent cells were thawed on ice and 100 µl of cells
were placed in a chilled polypropylene tube. 1 µl DNA was added to the cells and
gently mixed.
Cells and DNA were incubated 20 minutes on ice followed by 45 seconds heat-
shock in a 37◦C water bath and another 2 minutes on ice.
0.45 ml of room temperature LB medium without antibiotics was added to the
mixture and the tube was placed in a shaking incubator at 37◦C, 140 rpm for
1 hour.
1/10 and 8/10 of the mixture were spread on two LB agar plates containing
the appropriate antibiotics and incubated overnight at 37◦C.
5.1.6 Overnight cultures
Dependent on how much DNA was needed a single colony from an agar plate from
transformation (or from an existing glycerol stock plated) was inoculated in either
3 ml or 50 ml of LB medium containing the appropriate antibiotics and incubated
overnight at 37◦C, 140 rpm.
5.1.7 Preparation of bacterial stocks
To prepare bacterial stocks 500 µl cell suspension from an overnight culture was
mixed with 116 µl sterile 80 % glycerol and stored at -80◦C.
5.1.8 Purification of DNA from bacteria
Plasmid DNA was purified from cell suspension using the GenEluteTMPlasmid
Miniprep Kit (Sigma #PLN70-1KT) for 3 ml cultures and the GenEluteTMHP
Plasmid Midiprep Kit (Sigma #NAO200-1KT) for 50 ml cultures.
The purifications were conducted following the protocol provided by Sigma
(Spin Format protocol for the Midiprep kit) with the exception that the Elution
Solution provided in the kits was replaced by milliQ water.
After purification DNA from Midiprep was upconcentrated. 1 ml of the Midi-
prep preparation was mixed with 100 µl 3 M CH3COONa/CH3COOH, pH 5.2 and
700 µl 2-propanol and centrifuged at 16·103×g for 30 minutes at 4◦C.
The supernatant was discarded and the pellet resuspended in 500 µl freshly
made 70 % ethanol followed by another centrifugation at 16·103×g, 4◦C for 30 min-
utes. The supernatant was again discarded and the DNA was dissolved in 100 µl
milliQ water.
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5.1.9 Preparation of DNA for sequencing
The concentration of purified plasmid DNA was determined by UV/visible spec-
trophotometry at 260 nm and calculated from the formula below (DF = dilution
factor):
c(µg/ml) =
Abs260nm ·DF
0.02 ml/µg
The volume corresponding to 2.5 µg DNA (in the original solution) was mixed
with milliQ water to 50 µl and 5 µl 3 M CH3COONa/CH3COOH, pH 4.6 and
165 µl 96 % ethanol were added. The mixture was left at room temperature for
15 minutes.
The mixture was then centrifuged at 16·103×g for 20 minutes and the super-
natant removed. The pellet was resuspended in 250 µl freshly made 70 % ethanol
followed by another centrifugation at 16·103×g for 5 minutes. After removal of the
supernatant the pellet was again centrifuged at 16·103×g for 5 minutes.
The microcentrifuge tube was turned upside-down and left at room temperature
for 15-30 minutes until ethanol had evaporated. Sequence analysis of the dry DNA
pellet was conducted by Eurofins MWG Operon, which also synthesized the needed
primers for sequencing.
When DNA fragments contained more than ≈900 bp two samples of the same
plasmid were analysed, one sequencing from each end of the fragment. The primers
used for sequencing DNA in the PCR-Script vector (Stratagene, 2008) were T7 and
T3 and for the pET-26b vector (Novagen, 1998) T7 and T7T were used.
5.1.10 Digestion with restriction enzymes
Restriction enzymes were chosen to allow double digest (simultaneously cleaving)
according to the recommendations of New England Biolabs Inc. (New England
Biolabs Inc., 2009a). The used restriction enzymes are mentioned in sections 4.2
and 4.3.
Analytical cleavage was chosen to test if restriction fragments had the correct
size, whereas preparative cleavage was used when going to work on the isolated
fragment.
Analytical cleavage
8.4 µl plasmid DNA was mixed with 1.0 µl of the appropriate NEBuffer (New
England Biolabs Inc., 2009a,b) and 0.3 µl of each restriction enzyme. The mixture
was incubated at 37◦C for 1-2 hours and the sample was afterwards analysed using
analytical agarose gel electrophoresis (section 5.1.2).
Preparative cleavage
84 µl plasmid DNA was mixed with 10 µl of the appropriate NEBuffer (New
England Biolabs Inc., 2009a,b) and 3 µl of each restriction enzyme. The mixture
was incubated at 37◦C for 4 hours or overnight. To avoid self-ligation 1 µl CIP (calf
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intestinal alkaline phosphatase) was added to the digested vector plasmid mixture
and incubation continued for another hour.
Digested fragments were exposed to preparative agarose gel electrophoresis
(section 5.1.2) in order to isolate the correct fragments.
5.1.11 Ligation of insert and vector DNA
After digestion with the same restriction enzymes both insert and vector DNA were
purified as described in section 5.1.3. To estimate the ratio between concentration
of insert and vector DNA 2 µl samples of each were analysed with analytical agarose
gel electrophoresis (section 5.1.2).
T4 DNA Ligase (New England Biolabs #M0202S) was used for the ligation
reaction: 8 µl DNA (insert:vector volume ratio determined from analytical gel to
achieve 2-6 times molar excess of the insert DNA) was mixed with 1 µl 10X T4
DNA ligase buffer and 1 µl T4 DNA ligase. The mixture was incubated for 1 hour
at room temperature followed by transformation in DH5α cells (section 5.1.5).
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6 Construction of E. coli
TPH2 expression strains
In the following sections results from the construction of E. coli expression strains
for variants of tryptophan hydroxylase are presented and discussed.
6.1 Construction of huTPH2 expression strain
The TPH2 N-terminal domain, rTPH2 (aa1-182 of TPH2), was constructed by
PCR with HC744 (Ub-huTPH2(SacII/XhoI)-pET26 in DH5α, 30 µg/ml kana-
mycin sulfate (30 Kan) resistance) as the template and the primers HCP599 and
HCP600 shown in section 4.2, table 4.3. The resulting 561 bp DNA fragment
(figure 6.2) was analysed by agarose gel electrophoresis and purified to be ligated
into the PCR Script vector. The ligated plasmid was transformed into DH5α cells
to produce the strain HC1124 (rTPH2(NdeI/DraI)-PCR Script vector in DH5α,
100 µg/ml ampicillin (100 Amp) resistance).
Analytical cleavage of HC1124 DNA with NdeI/DraI resulted in several bands
rTPH2 fragment 
650
500
Figure 6.2: rTPH2 fragment created by PCR. The 561 bp fragment created by PCR was analysed by
agarose gel electrophoresis and visualized by illumination with UV light.
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rTPH2 fragment 
1000
850
650
500
400
vector fragment 
Figure 6.3: Insert and vector-fragments to create HC1155. Left: The 547 bp band corresponding to the
rTPH2 fragment. right: The ∼6 kb band corresponding to the vector. Both bands were cut free, extracted from
gel material and ligated together creating the gene encoding huTPH2 without Ub-tag.
on an analytical agarose gel (similar to the preparative gel shown in figure 6.3, left)
due to the presence of three DraI sites in the original PCR Script vector. Junction
sequencing with the primers T7/T3 confirmed that the HC1124 plasmid contained
the correct rTPH2 sequence (data not shown).
The rTPH2 part of HC1124 (insert) was preparatively cleaved with NdeI/DraI
and ligated to the vector HC744 likewise cleaved with NdeI/DraI and dephospho-
rylated with CIP. Preparative gels from the cleavages are shown in figure 6.3.
The ligated plasmid was transformed into DH5α cells to produce strain HC1155
(huTPH2(NdeI/XhoI)-pET26 in DH5α, 30 Kan resistance). The plasmid DNA
from this strain was analytically cleaved by NdeI/DraI and analysed by agarose
gel electrophoresis followed by sequencing with T7 primer. As sequencing con-
firmed that the insert sequence of HC1155 was identical to the sequence shown in
figure 4.5, section 4.3 the plasmid from this strain was transformed into BL21(DE3)
cells to produce the expression strain HC1164 (huTPH2 (NdeI/XhoI)-pET26 in
BL21(DE3), 30 Kan resistance).
6.2 Construction of m9TPH2 expression strain
A 768 bp construct containing the mutated regulatoric domain, m9rTPH2, flanked
by NdeI/DraI and the mutated tetramerisation domain, m3tTPH2, flanked by
HindIII/XhoI was ordered from GenScript. The mutations are shown in table 4.4,
section 4.3.
The 768 bp construct in pUC57 vector (GenScript Corporation, 1999) was
transformed into DHα cells (HC969) and multiplied. The plasmid was cleaved
using NdeI/DraI resulting in five bands on a preparative agarose gel (figure 6.4,
left) due to the presence of both NdeI and DraI restriction sites in the pUC57
vector. The 547 bp band corresponding to the m9rTPH2-fragment was cut free
and extracted from gel material.
The m9rTPH2 fragment was then ligated to the vector fragment of HC744
(Ub-huTPH2(SacII/XhoI)-pET26 in DH5α, 30 Kan resistance) also cleaved with
NdeI/DraI and dephosphorylated with CIP (figure 6.4, right). The ligated plasmid
was transformed into DH5α cells to produce strain HC980 (m9TPH2 (NdeI/XhoI)-
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m9rTPH2 fragment 
650
500
400
vector fragment 
Figure 6.4: Insert and vector-fragments to create HC980. Left: The 547 bp band corresponding to the
m9rTPH2 fragment. Right: The ∼6 kb band corresponding to the vector. Both bands were cut free, extracted
from gel material and ligated together creating the gene for m9TPH2.
pET26 in DH5α cells, 30 Kan resistance). The DNA from this strain was analy-
tically cleaved with NdeI/DraI yielding the correct bands of 547 bp and 6.16 kb
(data not shown), moreover the sequence was confirmed by junction sequencing
with T7 primer.
As HC980 contained the correct insert DNA sequence, the plasmid from this
strain was transformed into BL21(DE3) cells to produce the expression strain
HC989 (m9TPH2(NdeI/XhoI-pET26 in BL21(DE3) cells, 30 Kan resistance).
6.3 Construction of m12TPH2 expression strain
The HC969 plasmid (m9rTPH2(NdeI/XhoI)-m3tTPH2(HindIII/XhoI)-pUC57 in
DH5α cells, 100 Amp resistance) was cleaved with HindIII/XhoI and the 205 bp
band corresponding to m3tTPH2 was cut free and extracted from gel material
(figure 6.5, left).
The m9TPH2 plasmid (HC980) was also cleaved with HindIII/XhoI and de-
phosphorylated with CIP. The 6.5 kb fragment corresponding to the vector was
cut free and extracted from gel material (figure 6.5, right).
m3tTPH2 fragment
300
200
100
vector fragment 
Figure 6.5: Insert and vector-fragments to create HC992. Left: The 205 bp band corresponding to the
m3tTPH2 fragment. Right: The ∼6.5 kb band corresponding to the vector. Both bands were cut free, extracted
from gel material and ligated together creating the expression vector containing the gene encoding m12TPH2.
The 205 bp m3tTPH2 fragment and the 6.5 kb vector fragment were ligated
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together and transformed into DH5α cells producing strain HC992 (m12TPH2
(NdeI/XhoI)-pET26 in DH5α cells, 30 Kan resistance). Since analytical cleavage
with HindIII/XhoI resulted in the correct fragments of 205 bp and 6.5 kb (data not
shown) HC992 was sequenced from the 3’-end with T7T primer and the insertion of
m3tTPH2 confirmed. Since the HC992 sequence was correct the plasmid from this
strain was transformed into BL21(DE3) cells producing expression strain HC1012
(m12TPH2(NdeI/XhoI)-pET26 in BL21(DE3) cells, 30 Kan resistance).
6.4 Conclusion
Construction of expression strains for huTPH2, m9TPH2 and m12TPH2 was suc-
cessfully achieved. Table 6.1 shows an overview of the bacterial strains used/con-
structed in the process of making the huTPH2, m9TPH2 and m12TPH2 expression
strains.
Table 6.1: Bacterial strains for TPH2 variants used in this project. Bacterial strains constructed and/or
used to make expression strains for huTPH2, m9TPH2 and m12TPH2. Expression strains are written in bold.
Number Plasmid Cell type Resistance
HC744 Ub-huTPH2(SacII/XhoI)-pET26 DH5α 30 Kan
HC1124 rTPH2(NdeI/DraI)-PCR Script vector DH5α 100 Amp
HC1155 huTPH2(NdeI/XhoI)-pET26 DH5α 30 Kan
HC1164 huTPH2(NdeI/XhoI)-pET26 BL21(DE3) 30 Kan
HC969 m9rTPH2(NdeI/DraI)-
m3tTPH2(HindIII/XhoI)-pUC57 DH5α 100 Amp
HC980 m9TPH2(NdeI/XhoI)-pET26 DH5α 30 Kan
HC989 m9TPH2(NdeI/XhoI)-pET26 BL21(DE3) 30 Kan
HC992 m12TPH2(NdeI/XhoI)-pET26 DH5α 30 Kan
HC1012 m12TPH2(NdeI/XhoI)-pET26 BL21(DE3) 30 Kan
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tion of TPH2 variants
The following sections describe the protocols for production and purification of
huTPH2, m9TPH2 and m12TPH2.
7.1 Protein production in E. coli
In order to be able to compare the yields and later the purifications, culturing of
huTPH2, m9TPH2 and m12TPH2 followed the same protocol.
The relevant glycerol stock (huTPH2: HC1164, m9TPH2: HC989, m12TPH2:
HC1012, see section 6.4, table 6.1) were streaked on LB agar plates containing
30 µg/ml kanamycin sulfate (30 Kan) and incubated overnight at 37◦C. A single
colony from the agar plate was inoculated in 50 ml LB/30 Kan media and incubated
at 37◦C, 250 rpm until 0.6 < OD600 nm < 1.0. The culture was then stored at 4◦C
overnight.
The next day the culture was transferred into a 50 ml polypropylene tube
and cells were sedimented by centrifugation at 1100×g for 10 minutes at 4◦C.
The supernatant was discarded and cells resuspended in 50 ml fresh LB/30 Kan.
6×6.5 ml of this culture were inoculated in 6×650 ml LB/30 Kan and incubated at
30◦C, 250 rpm for 3.5 hours. The temperature was lowered to 20◦C and incubation
continued until 0.46 < OD600 nm < 0.6.
At this point protein expression was induced by addition of IPTG (isopropyl
β-D-1-thiogalactopyranoside) to a final concentration of 0.1 mM and incubation
was continued for approximately 4 hours.
Cells were harvested by centrifugation at 1800×g, 4◦C for 15 minutes. Then
the supernatant was discarded and cells transferred to 50 ml polypropylene tubes
with 20 ml 20 mM Tris/HCl, pH 8.2. After another centrifugation at 1800×g, 4◦C
for 15 minutes the supernatants were removed and the cells were stored at -80◦C.
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7.2 Purification of TPH2 variants
All protein purifications were performed on an A¨KTA Purifier 100 High Perfor-
mance Liquid Chromatography (HPLC) system using columns from GE Health-
care.
Since TPH2 carries an Fe(II)-ion in the active site two precautions were taken
to avoid oxidation of the iron during anion exchange. Just before use 0.3 mM
sodium dithionit (Na2S2O4) was added to buffer A and both buffers were flushed
with argon for an hour per liter buffer prior to equilibration of the column. Buffers
for both anion exchange and gel filtration are listed in table 7.2.
Table 7.2: Buffers for purification of TPH2 variants. The buffers used for anion exchange and gel filtration
of huTPH2, m9TPH2 and m12TPH2.
Buffer A Buffer B
Anion exchange 20 mM Tris/HCl, pH 8.2 20 mM Tris/HCl +
(0.3 mM Na2S2O4) 0.8 M (NH4)2SO4, pH 8.2
Gel filtration 20 mM Tris/HCl +
0.2 M (NH4)2SO4, pH 8.2
7.3 Preparation of cell extract
Cell extracts were prepared by thawing the desired number of tubes with frozen
cells on ice. When thawed cells were resuspended in 20 mM Tris/HCl, pH 8.2 with
0.3 mM sodium dithionit to a total volume of 40 ml per tube. The cells were lysed
on ice by 3×30 s sonication using a Satorius Labsonic P at 80 % amplitude with
30 s cooling on ice in between.
The cell extract was centrifuged (Eppendorf 5810R) 2×20 min at 18,500×g at
4◦C. The supernatant was collected and filtered through 0.45 µm GHP Acrodisc
GF syringe filters from Pall. If necessary the supernatant was diluted with milliQ
water to a conductivity of maximum 5 mS/cm. The diluted supernatant was loaded
on a Q Sepharose HP 16/10 column equilibrated with 20 mM Tris/HCl, pH 8.2
with 0.3 mM Na2S2O4. The purification protocols for the three variants of TPH2,
huTPH2, m9TPH2 and m12TPH2 are described in the following sections 7.4-7.6.
The cell extract was kept on ice until loaded on the column.
During preparation of the cell extract aliquots were collected for activity mea-
surements and SDS-Page (sodium dodecyl sulfate polyacrylamide gel electrophore-
sis, see section 7.7.1). 450 µl samples were collected for activity measurements and
for SDS-Page diluted samples of 20 µl were collected. For SDS-page samples from
raw extract (prior to centrifugation) were diluted 1:10 with milliQ water, whereas
samples from supernatant or pellet (resuspended in 40 ml/tube 20 mM Tris/HCl,
pH 8.2 with 0.3 mM sodium dithionit) were diluted 1:5.
60
7.4 Purification of huTPH2
7.4 Purification of huTPH2
The proteins of the diluted supernatant containing huTPH2 were separated on an
equilibrated Q Sepharose HP 16/10 column and eluted with a linear gradient of 0-
100 % buffer B (0-0.8 M (NH4)2SO4) over 10 column volumes (CV). The fractions
corresponding to peaks of absorbance at 280 nm were collected and analysed by
SDS-Page and activity measurements.
7.5 Purification of m9TPH2
Similar to huTPH2 the diluted supernatant containing m9TPH2 was loaded on a
equilibrated Q Sepharose HP 16/10 column and eluted with a linear gradient of
100 % buffer B (0-0.8 M (NH4)2SO4) over 10 CV. The fractions corresponding to
peaks of absorbance at 280 nm were collected and analysed by SDS-Page.
The procedure for purification of m9TPH2 was afterwards developed further
by Trine Vammen Vendelboe (Vendelboe, 2007) who suggested a buffer system of
20 mM Tris/HCl, pH 8.2 with 0.3 mM Na2S2O4 and 20 mM Tris/HCl + 0.8 M
(NH4)2SO4, pH 8.2 with 10 % (w/v) glycerol added to both buffers. Proteins were
eluted with a gradient of 0-50 % buffer B (0-0.4 M (NH4)2SO4) over 10 CV followed
by a gradient of 50-100 % buffer B (0.4-0.8 M (NH4)2SO4) over 1 CV (Vendelboe,
2007).
7.6 Purification of m12TPH2
For purification of m12TPH2 the diluted supernatant containing protein was
loaded on a equilibrated Q Sepharose HP 16/10 column and eluted with a lin-
ear gradient of either 0-50 % buffer B (0-0.4 M (NH4)2SO4) over 10 CV or 0-40 %
buffer B (0-0.32 M (NH4)2SO4) over 8 CV (in both cases 0.04 M (NH4)2SO4 per
CV) followed by a gradient of 50-100 % or 40-100 % respectively over 1 CV. The
fractions corresponding to peaks of absorbance at 280 nm were collected and anal-
ysed by SDS-Page and activity measurements.
Fractions containing m12TPH2 (peaks with conductivity 24.9-31.7 mS/cm and
31.7-35.5 mS/cm) were collected and pooled for each peak. Pooled fractions were
afterwards upconcentrated a factor 3 using a Vivacell 70 with 30,000 MWCO
(molecular weight cut off) polyethersulfone (PES) membrane. Concentrated frac-
tions were filtered through 0.45 µm GHP Acrodisc GF syringe filters from Pall
and loaded on a Superdex 200 26/60 gel filtration column equilibrated with 20 mM
Tris/HCl pH 8.2 containing 200 mM (NH4)2SO4. Fractions corresponding to peaks
of absorbance at 280 nm were collected and analysed by SDS-Page and activity
measurements.
7.7 Protein characterization
7.7.1 Sodium dodecyl sulfate polyacrylamide gel electrophoresis
For sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-page) 7.5 %
precast Tris/HCl gels from Bio-Rad were used. The marker was 0.5 µl low range
protein-standard (Bio-Rad #161-0304) mixed with 19.5 µl milliQ water and 5 µl
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5X sample buffer (see table 7.3). 20 µl samples were mixed with 5 µl 5X sample
buffer and both marker and samples were heated to 80◦C for 10 min followed by a
brief centrifugation prior to loading. Running buffer (table 7.3) was used in both
the inner and the outer chamber. 100 V constant voltage was applied to the gel
for 80 min allowing the proteins to separate. The gels were afterwards soaked in
fixative solution for 30 min followed by 1 hr in staining solution and destaining
overnight (solutions are described in 7.3).
Table 7.3: Buffers for SDS-page. Composition of the buffers used for SDS-page.
Buffer Composition
5X sample buffer 200 mM Tris/HCl pH 6.8
2 % SDS
40 % glycerol
0.04 % Coomassie G-250
Just before use 28 µl β-mercaptoethanol was added to an
aliquot of 190 µl 5X sample buffer
Running buffer 25 mM Tris base
192 mM glycine
0.1 % SDS
Fixative solution 500 ml milliQ water
400 ml 96 % ethanol
100 ml glacial acetic acid
Staining solution 900 ml milliQ water
100 ml glacial acetic acid
0.25 g Coomassie blue G-250
Destaining solution 900 ml milliQ water
100 ml glacial acetic acid
7.7.2 TPH activity assay
TPH activity was measured by a continuous, uncoupled fluorescence spectropho-
tometry assay developed by Moran and Fitzpatrick (1999) and modified in the
Metalloprotein Chemistry and Engineering Group (Nielsen, 2007; Windahl et al.,
2009). The assay is based on the different spectral properties of tryptophan and
5-hydroxytryptophan (shown in figure 7.6). By using an excitation wavelength of
300 nm 5-hydroxytryptophan is almost exclusively excited. Emission is measured
at 330 nm. At these wavelengths the initial rate of 5-OH-tryptophan formation is
measured (Moran and Fitzpatrick, 1999). The assay can be used for studying the
enzyme kinetics of TPH but in this context the assay was only used to identify
samples showing enzyme activity.
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Figure 7.6: Absorption and emission spectra for Trp and 5-OH-Trp. (—) is the absorption spectrum
for tryptophan and (· · · ) is the absorption spectrum for 5-OH-tryptophan. Emission spectra is shown with (- · -)
for Trp and (- - -) for 5-OH-Trp (Moran and Fitzpatrick, 1999). Reprinted with permission.
The assay solution consist of components which all have a function intended to
stabilize the enzyme and/or maximize the duration of product formation.
(NH4)2SO4 is added to stabilize TPH during the experiment. TPH require
Fe2+ for activity, this is added as (NH4)2Fe(SO4)2. Catalase is added to consume
any H2O2, that could be formed by autooxidation of BH4. The reductant DTT
keep iron in the reduced form and it also reduces q-BH2 to BH4. As mentioned
in section 2.1 4a-tetrahydro-BH4 is produced as a side product of the tryptophan
hydroxylation reaction, and decomposition of this produces q-BH2 which disturb
the fluorescence signal at 330 nm, moreover q-BH2 is produced from autooxidation
of BH4 (Moran and Fitzpatrick, 1999). The assay was used as optimized in the
Metalloprotein Chemistry and Engineering Group (Nielsen et al., 2008; Windahl
et al., 2009), concentrations of the compounds are shown in table 7.4.
Table 7.4: Components in the TPH activity assay. Composition of the reaction mixture used for the
activity assay for tryptophan hydroxylase. Concentrations of each component in the stock solutions and in the
reaction mixture are shown in the middle and right columns, respectively.
Assay component Concentration in stocks Concentration in assay
HEPES/NaOH pH 7.0 125 mM 50 mM
(NH4)2SO4 500 mM 200 mM
DTT 175 mM 7 mM
(NH4)2Fe(SO4)2 1.27 mM 25 µM
Catalase 1.25 mg/ml 25 µg/ml
Tryptophan 3.0 mM 70 µM
BH4 15 mM 300 µM
7.7.3 TPH activity measurements
Measurements were done on a Varian Cary Eclipse fluorescence spectrophotometer.
The excitation wavelength was 300 nm and the emission was measured at 330 nm.
63
7 Production and purification of TPH2 variants
Excitation and emission slits were 5 nm and the photomultiplier tube voltage was
650 V. The measurements were done in a 10.00 mm×10.00 mm QC quartz cuvette
with magnetic stirring. All measurements were carried out at 15◦C as described
in Nielsen (2007) and Nielsen et al. (2008). Since these experiments only were used
to identify samples with enzyme activity oxygen levels were not considered.
To avoid uncertainties from pipetting, a larger portion of the reaction mix-
ture was prepared prior to each measuring session. HEPES/NaOH + (NH4)2SO4
pH 7.0, DTT, (NH4)2Fe(SO4)2, catalase, tryptophan, the enzyme solution and
milliQ water to a total of 2450 µl were mixed in the reaction cuvette with mag-
netic stirring. Data-collection was started and after 30 seconds 50 µl BH4 was
added to initiate the reaction, data was collected for 2 minutes in total.
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Figure 7.7: Standard curves for 5-OH-Trp at different BH4 concentrations. The corrected initial rates
were calculated from the slope of the 300 µM BH4 standard curve. This curve has a slope of 7.7749±0.0835
(R2 = 0.9996). Standard curves were made by Ph.D. Michael S. Nielsen (Nielsen, 2007).
Addition of BH4 causes a decline in fluorescence intensity because of its ab-
sorption at 300 nm which leaves less light to excitation of 5-OH-Trp (Moran and
Fitzpatrick, 1999). The addition also initiate the reaction which produce a pro-
gression curve with the emission-intensity (fluorescence-intensity) of 5-OH-Trp as
function of time. To correct for the BH4 absorbance at 300 nm standard curves for
5-OH-Trp at different BH4 concentrations were made in the group (see figure 7.7).
The corrected initial rates were then calculated by division of the slope of the
progression curve tangent (intensity/min) with the slope of the relevant standard
curve (intensity/µM). The unit for the corrected initial rates was then µM/min.
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8 Production and
purification of huTPH2,
m9TPH2 and m12TPH2
In this chapter the results from production and purification of the TPH2 variants
are presented and discussed.
8.1 Expression and purification of huTPH2
huTPH2 was expressed in moderate amounts and only about half of it was solu-
ble. The expression was verified by SDS-page (see figure 8.8). Lanes 2-4 shows
20 µl samples taken during cultivation (from 650 ml batch) whereas lanes 5-7 from
preparation of cell extract contain 2 µl samples (from 40 ml cell suspension). The
difference in band intensity from lane 4 to lane 5 is probably caused by the fact
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Figure 8.8: Expression of huTPH2. SDS-page from huTPH2 cultivation and preparation of cell extract. Lane
1 is the marker. Lanes 2-4 are 20 µl samples from cultivation (650 ml batch) 1 hr, 2 hr and 4 hr, respectively,
after induction with IPTG. Lane 5 is the raw cell extract after sonication. Lane 6 is supernatant and lane 7 is
resuspended pellet. The samples in lanes 5-7 are 2 µl from 40 ml of the respective suspensions.
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that the samples in lanes 5-7 stem from cells that were frozen at -80◦C, thawed and
lysed by sonication whereas the samples in lanes 2-4 stem from cells that have only
been frozen at -20◦C and thawed, therefore the samples in lane 2-4 were probably
not fully lysed and could contain protein unavailable for staining in SDS-page.
The SDS-page shows that huTPH2 was divided between supernatant and pellet
(lane 6 and 7), that is in soluble and insoluble forms. The activity measurements
shown in figure 8.11 agrees that huTPH2 activity is present in both fractions. By
comparison of band intensity in lanes 5-7 it looks like some protein was lost during
centrifugation or separation of supernatant and pellet. The total amount of pro-
teins in lanes 6 and 7 should ideally equal the amount of protein in lane 5, which
seems not to be the case.
A chromatogram from the anion exchange of huTPH2 is shown in figure 8.9.
Samples from fractions 6-10 (flowthrough) and the peaks in fractions 34, 42, 46 and
54-55 were collected and tested for huTPH2 content using SDS-page and activity
measurements. The SDS-page from the purification is shown in figure 8.10 and the
result of the activity measurements is shown in figure 8.11. Both SDS-page and
activities show that huTPH2 most likely does not bind to the column but is instead
bleeding through the most of the purification. The higher activities in fractions
34, 42 and 46 compared with the loaded supernatant is due to an upconcentration,
but it does not agree with the factor 20 difference in volume (supernatant 40 ml,
each fraction of 2 ml).
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Figure 8.9: Anion exchange chromatogram of huTPH2. huTPH2 was purified on a Q Sepharose HP 16/10
column and eluted with a linear gradient of 100 % buffer B (0-0.8 M (NH4)2SO4) over 10 CV. Flowthrough
(fraction 6-10) and peaks (fractions 34, 42, 46 and 54-55) were collected.
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Figure 8.10: SDS-page from purifica-
tion of huTPH2. Lane 1 is the marker,
lane 2 is fraction 6-10 (flowthrough), lane 3
fraction 34, lane 4 fraction 42, lane 5 fraction
46 and lane 6 fractions 54-55 showing that
huTPH2 is bleeding through the column from
flowthrough to fraction 46.
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Figure 8.11: Activity measurements from huTPH2 pu-
rification. Activities in µM/min/ml. As shown in the SDS-
page from huTPH2 cultivation (figure 8.8) both supernatant
and pellet contain huTPH2. All tested fractions shows TPH
activity. the lower activity in fractions 6-10 correspond to the
larger volume of the pooled fractions.
The bleeding of huTPH2 through the purification indicates that huTPH2 does
not bind properly to the column under the conditions used. In the Metalloprotein
Chemistry and Engineering Group several other buffer systems and pH values have
been tested for purification of huTPH2. When these experiments were conducted
no better conditions were known, and focus were on the effect of introducing muta-
tions to improve the solubility and stability of TPH2 instead of testing purification
conditions.
8.2 Expression and purification of m9TPH2
m9TPH2 was expressed in large amounts (figure 8.12, lane 2) but only a small of
the protein was soluble (compare pellet and supernatant, figure 8.12, lanes 3 and
4).
The contents of the m9PTH2 containing supernatant were separated on a Q
Sepharose HP 16/10 anion exchange column, and a chromatogram is shown in
figure 8.13. The chromatogram contain several peaks and samples from fractions
11 (flowthrough), 34, 36, 42, 53, 59 and 64 were collected and tested for m9TPH2
content using SDS-page (figure 8.12). According to the SDS-page m9TPH2 is
present in all of the fractions tested, but most of it in fractions 42-59.
Trine Vammen Vendelboe further developed the purification procedure for
m9TPH2 (Vendelboe, 2007) and tried addition of 10 % (w/v) glycerol to both
buffers. The result was however not very different from the chromatogram shown
in figure 8.13.
Like huTPH2 m9TPH2 is found in many fractions throughout the purification,
most of it however elutes in the fractions 42-59. Since m9TPH2 is an unstable in-
termediate in the creation of the expression strain for m12TPH2 no further studies
were made with m9TPH2. This intermediate TPH2 variant were only briefly ana-
lysed to see if the solubility and stability were clearly improved and the additional
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Figure 8.12: SDS-page from m9TPH2 cultivation and purification. Lane 1 is the marker, lanes 2-4
are raw cell extract, pellet and supernatant and lane 5-11 is fractions 11, 34, 36, 42, 53, 59 and 64 from the
purification.
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Figure 8.13: Anion exchange chromatogram of m9TPH2. m9TPH2 was purified on a Q Sepha-
rose HP 16/10 column and eluted with a linear gradient of 100 % buffer B (0-0.8 M (NH4)2SO4) over 10 CV.
Flowthrough (fraction 11) and peaks (fractions 34, 36, 42, 53, 59 and 64) were collected.
mutations in m12TPH2 not necessary, but that seems not to be the case.
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8.3 Expression and purification of m12TPH2
m12TPH2 was expressed in moderate amounts with more than half of the protein
insoluble remaining in pellet (see figure 8.14, left gel lanes 2-4).
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Figure 8.14: SDS-page from cultivation and anion exchange of m12TPH2. Left gel: Lane 1 is the
marker, lanes 2-4 are raw cell extract, supernatant and pellet respectively and lanes 5-10 represent samples from
fractions B2-B7 of the anion exchange. Right gel: Lane 1 is the marker, lanes 2-8 are fractions B8-C2 from the
anion exchange.
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Figure 8.15: Anion exchange chromatogram of m12TPH2. m12TPH2 was purified on a Q Sepha-
rose HP 16/10 column and eluted with a linear gradient of 0-40 % B (0-0.32 M (NH4)2SO4) over 8 CV followed
by a gradient of 40-100 % B over 1 CV. Fractions B2-B9 and B10-C2 containing m12TPH2 was collected for gel
filtration.
A chromatogram from anion exchange of m12TPH2 is shown in figure 8.15.
m12TPH2 was purified on a Q Sepharose HP 16/10 column and eluted with a linear
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gradient of 0-40 % buffer B (0-0.32 M (NH4)2SO4) over 8 CV followed by a gradient
of 40-100 % buffer B over 1 CV. The chromatogram contains several peaks but
it has previously been found (data not shown) that most m12TPH2 elutes in two
peaks around 24.9-31.7 mS/cm (fractions B2-B9) and 31.7-35.5 mS/cm (fractions
B10-C2). These fractions were collected and analysed with SDS-page (figure 8.14)
and activity measurements (figure 8.16).
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Figure 8.16: Activity measurements of m12TPH2. m12TPH2 from anion exchange was tested for activity.
Light blue columns represent m12TPH2 before purification, dark blue columns correspond to fractions belonging to
the peak around 24.9-31.7 mS/cm and plum columns are fractions belonging to the peak around 31.7-35.5 mS/cm.
SDS-page shows that m12TPH2 is present in all tested fractions (fractions B2-
B7 is in lanes 5-10 on the left gel and fractions B8-C2 is in lanes 2-8 on the gel
to the right). Activity measurements also shows that fractions B2-B9 (dark blue
columns in figure 8.16) and B10-C2 (plum columns in figure 8.16) contain TPH
activity higher than in the loaded supernatant corresponding to an upconcentration
of m12TPH2 in these two peaks.
Fractions B2-B9 and B10-C2 respectively were pooled, upconcentrated to 7 ml
and gel filtrated on a Superdex 200 26/60 column using 20 mM Tris/HCl pH 8.2
with 200 mM (NH4)2SO4 buffer. The chromatogram from gel filtration of fractions
B2-B9 is shown in figure 8.17, it contains four peaks at 280 nm. Fractions cor-
responding to these peaks were collected and tested with SDS-page (figure 8.18)
and activity measurements (figure 8.19). According to SDS-page most m12TPH2
elutes in peak 2 (lane 4 in figure 8.18) whereas activity measurements found most
activity in peak 3 (figure 8.19). A similar chromatogram (not shown) was the result
of gel filtration of fractions B10-C2 except that the peaks in this chromatogram
were significantly lower.
Most activity was lost during upconcentration of the pooled fractions from the
anion exchange. The average activity of fractions B2-B9 was 2.24 µM/min/ml
whereas the sample loaded on the gel filtration column only had an activity of
0.49 µM/min/ml. Moreover SDS-page does not agree with the chromatogram
and activity measurements if most m12TPH2 is found in peak 2 or peak 3 of the
chromatogram (see figures 8.17, 8.18 and 8.19). The hight of peak 3 is most likely
caused by the protein giving rise to the intense band of ∼75 kDa in lane 5 in
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Figure 8.17: Gel filtration chromatogram of m12TPH2. m12TPH2 from fractions B2-B9 of the anion
exchange (figure 8.15) was upconcentrated and further purified on a Superdex 200 26/60 gel filtration column.
The buffer used was 20 mM Tris/HCl pH 8.2 with 200 mM (NH4)2SO4.
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Figure 8.18: SDS-page from gel filtra-
tion of m12TPH2. Lane 1 is the marker,
lane 2 the sample loaded for gel filtration and
lanes 3-6 correspond to the peaks 1-4 in the
chromatogram.
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Figure 8.19: Activity measurements from gel filtration
of m12TPH2. TPH activity is found in peaks 2 and 3.Activ-
ity measurements from gel filtration of m12TPH2. TPH
activity is found in peaks 2 and 3.
figure 8.18, but SDS-page still shows that most TPH2 elutes in peak 2 whereas
most TPH activity is found in peak 3. Since no other bands in the SDS-page are
more likely to correspond to m12TPH2 (56 kDa), the m12TPH2 found in peak 2
could have lost the active site iron (see sections 2.2-2.6) or is not properly folded.
Altogether m12TPH2 did not seem to be stable and less than half of the protein
was soluble.
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8.4 Overall discussion of the expression and purification of
TPH2 variants
huTPH2 and m12TPH2 were expressed in moderate amounts with about half of
the protein soluble. m9TPH2 was expressed in large amounts, on the other hand
only a small part of it was soluble. Compared to huTPH2 the introduction of
mutations in TPH2 did not result in larger amounts of soluble protein available
for purification.
Also the purifications of huTPH2, m9TPH2 and m12TPH2 were not very dif-
ferent. huTPH2 and m9TPH2 did not bind to the anion exchange column and
protein was seen in most fractions of the chromatogram (figures 8.9 and 8.13).
m12TPH2 was partly purified on the anion exchange column resulting in two
peaks containing m12TPH2 with higher activity compared to the sample loaded on
the column. Unfortunately most activity was lost during upconcentration which
indicate that this protein was not very stable.
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E. coli expression strains for huTPH2, m9TPH2 and m12TPH2 were successfully
prepared. As earlier reported TPH2 is an unstable protein which is very difficult to
produce in a soluble and active form (McKinney et al., 2005; McKinney et al., 2004;
Windahl et al., 2009). The problems with instability and low solubility were also
seen with huTPH2 as well as m9TPH2 and m12TPH2 in this project. Therefore it
can be concluded that introduction of the 9 or 12 mutations respectively in TPH2
did not result in more soluble or very stable protein. In agreement with these
results, other new studies have indicated that there were no correlation between
the solubility predictions based on the Wilkinson-Harrison model and the empirical
results (Gra¨slund et al., 2008; Idicula-Thomas et al., 2006; Smialowski et al., 2007).
The instability index for m12TPH2 was calculated to 39.65 (see section 4.1.1)
which classifies the protein as stable, but is very close to the stability limit of
40.00 (Guruprasad et al., 1990), therefore the II of a mutated protein might need
to be even lower compared to the stability limit.
Since the introduction of mutations did not give more soluble or stable protein
the purification of TPH2 was not improved either.
9.1 Further work on TPH2
The introduction of mutations in TPH2 did not improve the properties of this
protein, and other purification strategies have already been tried in the Metallo-
protein Chemistry and Engineering Group. Moreover only 10-20 % of eukaryote
proteins can be expressed in E. coli in soluble form (Bu¨ssow et al., 2005; Gra¨slund
et al., 2008). Therefore it was decided to try an eukaryote expression system for
TPH2 hoping that such a system would result in more stable and soluble TPH2.
Expression of TPH2 in Drosophila Melanogaster cells is described in part III of
this dissertation.
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Part III:
TPH2 and DβH production in
an eukaryotic expression system
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Introduction to part III
Part III of this dissertation concerns expression of TPH2 and DβH in an eukaryotic
system namely cells from the fruit fly Drosophila melanogaster.
Many attempts have been done to express tryptophan hydroxylase in bacterial
systems including part II of this dissertation, but only expression of truncated ver-
sions have been successful (Nielsen et al., 2008; Windahl et al., 2009, 2008). Also
expression of dopamine β-hydroxylase in different bacterial systems have been
tried (Vendelboe, 2007), but only very small amounts of soluble protein were ob-
tained.
Since this project concern human TPH2 and human DβH it was decided to
try expression of these proteins in an eukaryotic expression system. Expression of
DβH in D. melanogaster S2 cells was earlier reported (Li et al., 1996) and therefore
this system was chosen, as DβH then could act as a control for TPH2 regarding
handling of the cells, which was a new discipline in the Metalloprotein Chemistry
and Engineering Group.
After an introduction to the D. melanogaster S2 cells, the vector used for ex-
pression and the strategy for expression of TPH2 and DβH with and without
the immunoglobulin binding protein (BiP) secretion signal sequence are described.
Also the methods for transfection and selection of transfected cells are outlined.
The following chapters describe the protocols and results for preparation of re-
combinant DNA for transfection, the actual transfections, large scale culturing of
transfected cells and harvest of proteins and the purifications of eukaryotic pro-
duced DβH.
Stable transfected cell lines for TPH2, BiP-TPH2, DβH and BiP-DβH were
obtained. Unfortunately expression of TPH2, which is known as a notoriously
unstable protein that is very difficult to produce recombinant (McKinney et al.,
2005; McKinney et al., 2004; Windahl et al., 2009), was also problematic in the
S2 cells and was only found in the insoluble fraction.
DβH on the other hand was produced in amounts comparable to amounts
reported earlier, in this project up to 1.4 mg glycosylated tetrameric DβH and
1.0 mg glycosylated dimeric DβH per liter culture was obtained. Moreover I was
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able to deglycosylate DβH and afterwards separate it from the deglycosylation
enzyme PNGase F in a third purification step in preparation for crystallization
experiments.
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10 Strategy for expression in
Drosophila Melanogaster
cells
The present chapter briefly describes the differences between prokaryote and eu-
karyote expression systems in general. The Drosophila Melanogaster (D. Melano-
gaster) Schneider 2 cells will be introduced and the strategy for construction of
protein expression vectors will be described.
10.1 Eukaryote expression host
Since the ultimate goal of this project is to help people suffering from neurological
disorders related to the level and regulation of serotonin and the catecholamine
neurotransmitters (see sections 2.8 and 3.7), an eukaryote expression system for
tryptophan hydroxylase and dopamine β-hydroxylase will give proteins that are
more similar to those found in the human brain than proteins produced in the E.
coli system.
Although the basic mechanisms of gene expression, transcription of DNA into
RNA and translation of RNA into protein, are quite similar in all organisms,
some significant differences exist between prokaryotes and eukaryotes. In contrast
to prokaryotes eukaryotes are able to make posttranslational modification as for
example glycosylations and phosphorylations on proteins (Alberts et al., 2002).
Glycosylations on proteins aid folding and transport and it can alter the properties
of the nascent protein, whereas phosporylation is involved in regulation of the
protein function (Alberts et al., 2002).
Since the properties of the mature protein in prokaryotes and eukaryotes differ
(due to posttranslational modifications and the effect of these), it is desirable to
establish an eukaryotic expression system for the metal-containing monooxygenases
dopamine β-hydroxylase and tryptophan hydroxylase in order to investigate the
enzymes in the form most similar to that in the human brain.
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10.2 Drosophila melanogaster Schneider 2 cells
The system chosen for eukaryotic expression of the metal-containing monooxy-
genases is D. melanogaster Schneider 2 cells (S2 cells). Previous research has
shown that yeast is not a suitable host for expression of TPH (McKinney et al.,
2004), whereas S2 cells earlier have been used successfully to express dopamine β-
hydroxylase with glycosylations (Li et al., 1996). Therefore this relatively simple
eukaryotic system were chosen.
The S2 cell line is one of three D. melanogaster cell lines established by Schnei-
der in 1972. This cell line was subcultured from a 3 month primary culture of
20-24 hours old (late stage) D. melanogaster embryos (Schneider, 1972). S2 cells
grow at room temperature without CO2 as a loose, semi-adherent monolayer in
tissue culture flasks (Invitrogen life technologies, 2002).
10.3 Strategy for preparation of expression strains
To express tryptophan hydroxylase 2 and dopamine β-hydroxylase in the D. mela-
nogaster S2 cells appropriate vectors containing the two genes were constructed.
Two versions of each gene were used; the E. coli codon optimized genes encoding
TPH2 and DβH already available in the research group (see section 10.3.2-10.3.3)
and newly produced D. melanogaster codon optimized genes for TPH2 and DβH
fused to a D. melanogaster immunoglobulin binding protein (BiP) which acts as a
secretion signal (Kirkpatrick et al., 1995) (see section 10.3.4).
The expression vector used in this project is the pMT/V5-His A vector designed
by Invitrogen (Invitrogen life technologies, 2001b). The vector of 3.5 kb contains
the well characterised D. melanogaster metallothionein promotor for tightly regu-
lated high-level, metal-inducible expression of the desired gene (Angelichio et al.,
1991; Bunch et al., 1988; Maroni et al., 1986; Olsen et al., 1992), a multiple cloning
site and an ampicillin resistance gene for selection of transformants in E. coli (In-
vitrogen life technologies, 2001b). The vector furthermore codes for a C-terminal
peptide containing V5 epitope and a polyhistidine (6xHis) tag and is available in
three reading frames (A-C) in order to clone the desired gene in-frame with the
peptide. The V5 epitope and the polyhistidine tag are not utilised in this project,
though.
The pMT/V5-His A vector however does not contain the Kozak consensus
sequence for proper initiation of translation in eukaryotes (Kozak, 1987, 1991a).
The sequence
(G/A)CCATGG
was recognized by Kozak in 1987 to be the optimal context for proper initiation
of translation in eukaryotes (Kozak, 1987, 1990, 1991a,b). The Kozak sequence
contains the startcodon (underlined) and the bases at position -3 and +4 (shown
in bold; when the A in the startcodon is designated +1 with positive and negative
integers proceeding 3’ and 5’ respectively) are the most critical for function and
they are highly conserved. 97% of vertebrate mRNAs have a purine in position -3
and 46% have a G in position +4 (Kozak, 1987, 1991a,b).
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10.3.1 Design of constructs
Because the pMT/V5-His A vector does not contain the Kozak sequence, the
genes were designed with this sequence around the startcodon. Part of the Kozak
sequence (CCATGG) is also the recognition site for the restriction endonucle-
ase NcoI which fortunately could be used for simultaneous double digestion with
XhoI (New England Biolabs Inc., 2008), because this restriction site was already
present at the 3’ end of the tryptophan hydroxylase 2 and dopamine β-hydroxylase
constructs available in our research group.
Unfortunately the pMT/V5-His A does not have a restriction site for NcoI in
the multiple cloning site, but it contains a XhoI site at 906-911 bp and a KpnI
site at 849-854 bp. Since KpnI and XhoI also can be used in simultaneous double
digest (New England Biolabs Inc., 2008), a TPH2 gene construct was designed with
KpnI and NcoI in Kozak sequence at the 5’ end and the XhoI site already present
in the 3’ end of the gene for TPH2. First the gene encoding TPH2 was cloned into
the pMT/V5-His A vector using KpnI and XhoI to make the expression vector
for TPH2 (see overview in figure 10.1). After that the TPH2 gene was removed
from the vector using NcoI and XhoI and to make the expression vector for DβH
it was replaced by the DβH gene cut with NcoI and XhoI to restore the Kozak
sequence around the startcodon (see figure 10.2). The BiP-containing constructs
were similarly made by replacing the gene encoding DβH from the DβH expression
vector with the BiP-TPH2 and BiP-DβH genes respectively.
10.3.2 Construction of the huTPH2-pMT/V5-His A vector
The gene for TPH2 to be cloned into the pMT/V5-His A vector was made with
PCR using the gene for TPH2 in pET26Ub vector (derivative of pET-26b(+) (No-
vagen, 1998), internal number HC744) as a template. The primers used (HCP621
and HCP622) are shown in table 10.1. Primers were designed to make a KpnI-site
just upstream of the startcodon, the Kozak sequence with a NcoI-site and the
startcodon inside, and to keep the already existing XhoI site at the 3’ end of the
gene.
According to the Kozak sequence the G in position +4 is very important,
however changing position +4 into a G causes a mutation of the original glutamine
(CAG) into glutamic acid (GAG). Since this mutation would introduce a negative
charge it was decided to change the whole codon into GCC coding for alanine which
is smaller and uncharged, but nonpolar as opposed to glutamine. Substitution of
glutamine into alanine was chosen since this is the most similar amino acid which
is encoded by a codon with G in the first position (compared to glutamic acid,
aspartic acid, valine and glycine). An overview of the construction of eukaryote
TPH2 expression vector is shown in figure 10.1.
10.3.3 Construction of the DβH-pMT/V5-His A vector
The wildtype gene for dopamine β-hydroxylase contains internal restriction sites
for both KpnI and NcoI and since the required Kozak sequence contains a NcoI site
it was desired to silently mutate the internal NcoI site and clone the gene into the
pMT/V5-His A vector using NcoI and XhoI. Because the native pMT/V5-His A
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 AAAA GGT ACC GCC ATG GCC CCG GCG ATG ATG ATG TTT AG...                              ...CTG GGC ATT TGA CTC GAG AAAA 
KpnI      NcoI                                                                                                                                        *         XhoI
Kozak
huTPH2
huTPH2/SacII/XhoI-pET26Ub
HC744
6935 bp
huTPH2
XhoI (159)
SacII (1645)
Ub
NdeI (1864)
PCR
Primer HCP621
Primer HCP622
PCR Script Amp SK(+) Cloning Vector
T4 DNA Ligase
huTPH2/KpnI/XhoI-PcrScript
HC1500
4449 bp
huTPH2
KpnI (658)
XhoI (669)
XhoI (2212)
KpnI (734)
NcoI (737)
pMT/V5-His A
HC1440
3538 bp
Metallothionein 
promotor
KpnI (854)
XhoI (907)
Enzyme digestion
KpnI/XhoI
T4 DNA Ligase
Metallothionein promotor
huTPH2
KpnI (854)
NcoI (857)
XhoI (2332)
XhoIKpnI
NcoI
huTPH2/KpnI/XhoI-pMT/V5-His A
HC2027
4963 bp
Figure 10.1: Construction of eukaryote TPH2 expression vector. Broad overview of the construction
of the TPH2 expression vector, only features relevant for the construction is shown on the vector maps. Vector
maps were made with Vector NTI AdvanceTM 10.3.0 (Invitrogen Life Sciences, 2006).
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Table 10.1: Primer sequences. Base composition of the primers used for PCR production of TPH2 and DβH
for insertion in the pMT/V5-His A vector. Bases which differ from the template are marked with red.
Gene product Template and primers
TPH2, Q2A Template HC744: TPH2 in pET26Ub vector
(KpnI/NcoI/XhoI) Sense primer HCP621:
5’-AAAA GGT ACC GCC ATG GCC CCG GCG ATG ATG ATG TTT AG-3’
Antisense primer HCP622:
5’-T TTT CTC GAG TCA AAT GCC CAG-3’
DβH Template HC1147: DβH in pUC57 vector
(NdeI/HindIII) Sense primer HCP623:
no internal NcoI 5’-CG AGC GAT GCC TGC ACG ATG GAA GTT CAG G-3’
Antisense primer HCP624:
5’-C CTG AAC TTC CAT CGT GCA GGC ATC GCT CG-3’
DβH, S2A Template HC1502: DβH without internal NcoI-site in pUC57 vector
(NcoI/XhoI) Sense primer HCP625:
no internal NcoI 5’-AAA ACC ATG GCC GCG CCG CGT GAA AGC CC-3’
Antisense primer HCP626:
5’-TTTT CTC GAG TTA GCC TTT GCC GCC G-3’
vector does not have a NcoI site the vector containing the gene for TPH2 was used.
This vector has a NcoI site and the TPH2 gene can be cut out and replaced by
the gene encoding DβH.
First step was elimination of the internal NcoI site. The PCR reaction was
carried out with the primers HCP623 and HCP624 shown in table 10.1 and the
DβH gene in pUC57 (GenScript Corporation, 1999) (internal number HC1147)
as the template. This strategy resulted in a one-base substitution from C to G
changing codon 199 from ACC to ACG both coding for threonine. The resulting
PCR product was cloned into PCR-Script Amp SK(+) cloning vector (Stratagene,
2008) and the resulting vector (internal number HC1502) was used as template
for a PCR reaction with the primers HCP625 and HCP626 (table 10.1) to make
a gene for dopamine β-hydroxylase with NcoI at the 5’-end and XhoI at the 3’-
end. The original DβH template HC1147 had a one-base insertion destroying the
XhoI-site therefore this site was reestablished in the second PCR reaction. Equal
to the situation with TPH2 the Kozak sequence placed a G in position +4 of the
gene, for DβH this caused a mutation of serine (AGC) to alanine (GCC, codon
is optimized for D. melanogaster). An overview of the construction of eukaryote
expression vector for DβH is shown in figure 10.2.
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PCR 
Primer HCP623
Primer HCP624
(removal of internal NcoI-site)
DβH/NdeI/HindIII-pUC57
HC1147
4460 bp
DβH
NdeI (185)
KpnI (413)
NdeI (434)
KpnI (779)
NcoI (959)
HindIII (2222)
...CG AGC GAT GCC TGC ACG ATG GAA GTT CAG G...
                                        C - G Silent mutation
Ser      Asp     Ala      Cys     Thr      Met     Glu     Val      Gln
DβH/NdeI/HindIII-pUC57,
no internal NcoI-site
HC1502
4460 bp
mutated NcoI-site (C-G)
DβHNdeI (185)
NdeI (434)
HindIII (2222)
PCR 
Primer HCP625
Primer HCP626
DβH
NcoI
KpnI XhoI
                                    
AAA ACC ATG GCC GCG CCG CGT GAA AGC CC...
  NcoI
...C GGC GGC AAA GGC TAA CTC GAG  AAAA
*         XhoI
DβH/NcoI/XhoI-PcrScript
HC1849
4709 bp
DβH
PCR Script Amp SK(+) Cloning Vector
T4 DNA Ligase
KpnI (658)
KpnI (1075)
XhoI (669)
XhoI (2472)
NcoI (730)
Enzyme digestion
NcoI/XhoI
T4 DNA Ligase
Metallothionein 
promotor
huTPH2
KpnI (854)
NcoI (857)
XhoI (2332)
DβH 
Metallothionein 
promotor
KpnI (854)
KpnI (1202)
NcoI (857)
XhoI (2599)
DβH/NcoI/XhoI i pMT/V5-His A
HC1903
5230 bp
huTPH2/KpnI/XhoI-pMT/V5-His A
HC2027
4963 bp
Figure 10.2: Construction of eukaryote DβH expression vector. Broad overview of the construction of
the DβH expression vector, only relevant features are shown on the vector maps. Vector maps were made with
Vector NTI AdvanceTM 10.3.0 (Invitrogen Life Sciences, 2006).
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10.3.4 Construction of expression vectors for TPH2 and DβH with BiP
secretion signal
Immunoglobulin binding protein (BiP) is a member of the stress 70 protein fam-
ily, it functions as a chaperone in the endoplasmatic reticulum (ER) of eukaryotic
cells where it support proper protein folding and transport into ER lumen. The D.
melanogaster BiP homologue is 80% identical to the human protein and have a sim-
ilar function (Kirkpatrick et al., 1995). The secretion signal of the D. melanogaster
BiP protein is very effective in targeting BiP for the ER of the S2 cells, where it
enters the secretory pathway (Invitrogen life technologies, 2001a; Lodish et al.,
2000), therefore this signal sequence is fused to the proteins of interest to ensure
secretion.
D. melanogaster codon optimized DNA sequences for BiP-TPH2 and BiP-DβH
were ordered from GenScript Corporation (sequences are shown in figures 10.3
and 10.4). Both sequences were flanked by unique NcoI and XhoI restriction sites
in order to insert them in the pMT/V5-His A vector by replacement of the existing
gene for DβH in the DβH expression vector (see section 10.3.3).
10.3.5 Calcium phosphate transfection
Delivery of DNA into eukaryotic cells can be mediated by both chemical, biological
(viral vectors) and physical methods. The chemical methods make use of synthetic
vectors which are relatively simple, easy to produce and have a low toxicity to the
cells. Delivery of the synthetic vectors are mediated by four major types of chem-
ical reagents: calcium phosphate, DEAE-dextran (diethylaminoethyl-dextran),
cationic lipid, and cationic polymer (Liu et al., 2004). Only the calcium phos-
phate procedure is described here, as this was the method used for transfection of
D. melanogaster S2 cells (see section 11.3.1-11.3.2).
The calcium phosphate method was developed in 1973 by Graham and Van der
Eb (Conn et al., 1998; Liu et al., 2004) and has been one of the most commonly
used methods especially for D. melanogaster S2 cells (Han, 1996). The method
make use of calcium phosphate-DNA co-precipitates which form spontaneously in
supersaturated solutions, the co-precipitates adsorb to the cell surfaces and can
be taken into the cell by calcium-dependent endocytosis. The exact mechanism
however is not known (Conn et al., 1998; Liu et al., 2004). Once inside the cell some
of the DNA avoid degradation and enter the nucleus, where it can be transiently
expressed and/or incorporated into the chromosome for stable expression (Conn
et al., 1998; Liu et al., 2004). Various protocols exist for the calcium phosphate
transfection method, these differ among cell lines and to a lesser extend for the
buffer system used (Liu et al., 2004).
10.3.6 Selection with blasticidin
Blasticidin S (figure 10.5) is a potent protein synthesis inhibitor in both prokaryotes
and eukaryotes (Kimura et al., 1994), where it inhibits the peptide bond formation
in the ribosomal machinery. Blasticidin S is converted to a non-toxic deamino-
hydroxy derivative by the drug inactivating enzyme Blasticidin S deaminase (BSD)
produced by Aspergillus terreus.
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1 GCCATGGCC
CGGTACCGG
A TGAAGTTATG CATATTACTG GCCGTCGTGG CCTTTGTTGG CCTCTCGCTC GGG
T ACTTCAATAC GTATAATGAC CGGCAGCACC GGAAACAACC GGAGAGCGAG CCC
TCAGCCC CCAGGGAATC
AGTCGGG GGTCCCTTAG
NcoI
+1 Met Ala Met Lys Leu Cys Ile Leu Leu Ala Val Val Ala Phe Val Gly Leu Ser Leu Gly Ser Ala Pro Arg Glu Ser·
81 CCCTCTGCCC TATCACATCC CCCTGGACCC AGAGGGCAGT CTGGAGCTCT CCTGGAATGT GAGCTACACT CAAGAGGCTA
GGGAGACGGG ATAGTGTAGG GGGACCTGGG TCTCCCGTCA GACCTCGAGA GGACCTTACA CTCGATGTGA GTTCTCCGAT
+1 ·Ser Pro Leu Pro Tyr His Ile Pro Leu Asp Pro Glu Gly Ser Leu Glu Leu Ser Trp Asn Val Ser Tyr Thr Gln Glu Ala Ile·
161 TCCACTTCCA GCTCTTGGTG AGAAGGTTGA AGGCTGGAGT GCTGTTTGGA ATGAGTGACA GGGGAGAGCT GGAGAATGCT
AGGTGAAGGT CGAGAACCAC TCTTCCAACT TCCGACCTCA CGACAAACCT TACTCACTGT CCCCTCTCGA CCTCTTACGA
+1 ·Ile His Phe Gln Leu Leu Val Arg Arg Leu Lys Ala Gly Val Leu Phe Gly Met Ser Asp Arg Gly Glu Leu Glu Asn Ala
241 GACCTGGTGG TCCTGTGGAC AGATGGAGAC ACAGCATACT TTGCTGATGC ATGGAGTGAT CAGAAGGGAC AGATACACCT
CTGGACCACC AGGACACCTG TCTACCTCTG TGTCGTATGA AACGACTACG TACCTCACTA GTCTTCCCTG TCTATGTGGA
+1 Asp Leu Val Val Leu Trp Thr Asp Gly Asp Thr Ala Tyr Phe Ala Asp Ala Trp Ser Asp Gln Lys Gly Gln Ile His Leu·
321 GGACCCTCAG CAGGATTATC AGCTGCTGCA GGTGCAAAGG ACTCCAGAGG GACTGACACT GCTGTTCAAG AGACCTTTTG
CCTGGGAGTC GTCCTAATAG TCGACGACGT CCACGTTTCC TGAGGTCTCC CTGACTGTGA CGACAAGTTC TCTGGAAAAC
+1 ·LeuAsp Pro Gln Gln Asp Tyr Gln Leu Leu Gln Val Gln Arg Thr Pro Glu Gly Leu Thr Leu Leu Phe Lys Arg Pro Phe Gly·
401 GCACATGTGA CCCCAAGGAT TACCTGATTG AAGATGGCAC AGTTCACCTG GTGTATGGAA TCCTGGAAGA GCCATTCAGG
CGTGTACACT GGGGTTCCTA ATGGACTAAC TTCTACCGTG TCAAGTGGAC CACATACCTT AGGACCTTCT CGGTAAGTCC
+1 ·Gly Thr Cys Asp Pro Lys Asp Tyr Leu Ile Glu Asp Gly Thr Val His Leu Val Tyr Gly Ile Leu Glu Glu Pro Phe Arg
481 TCCTTGGAAG CTATTAATGG CAGTGGACTG CAGATGGGCC TGCAGAGAGT TCAGTTGCTG AAACCCAACA TCCCAGAACC
AGGAACCTTC GATAATTACC GTCACCTGAC GTCTACCCGG ACGTCTCTCA AGTCAACGAC TTTGGGTTGT AGGGTCTTGG
+1 Ser Leu Glu Ala Ile Asn Gly Ser Gly Leu Gln Met Gly Leu Gln Arg Val Gln Leu Leu Lys Pro Asn Ile Pro Glu Pro·
561 AGAGTTGCCT AGTGATGCCT GCACTATGGA GGTTCAAGCC CCAAATATCC AGATCCCCAG CCAAGAGACT ACCTATTGGT
TCTCAACGGA TCACTACGGA CGTGATACCT CCAAGTTCGG GGTTTATAGG TCTAGGGGTC GGTTCTCTGA TGGATAACCA
+1 ·Pro Glu Leu Pro Ser Asp Ala Cys Thr Met Glu Val Gln Ala Pro Asn Ile Gln Ile Pro Ser Gln Glu Thr Thr Tyr Trp Cys·
641 GCTACATCAA GGAGCTGCCC AAGGGCTTCT CCAGGCATCA TATCATCAAG TATGAACCTA TAGTGACCAA GGGCAATGAG
CGATGTAGTT CCTCGACGGG TTCCCGAAGA GGTCCGTAGT ATAGTAGTTC ATACTTGGAT ATCACTGGTT CCCGTTACTC
+1 ·Cys Tyr Ile Lys Glu Leu Pro Lys Gly Phe Ser Arg His His Ile Ile Lys Tyr Glu Pro Ile Val Thr Lys Gly Asn Glu
721 GCCTTGGTGC ATCACATGGA GGTGTTCCAA TGTGCCCCTG AGATGGATTC TGTGCCCCAC TTCTCAGGCC CCTGTGATTC
CGGAACCACG TAGTGTACCT CCACAAGGTT ACACGGGGAC TCTACCTAAG ACACGGGGTG AAGAGTCCGG GGACACTAAG
+1 Ala Leu Val His His Met Glu Val Phe Gln Cys Ala Pro Glu Met Asp Ser Val Pro His Phe Ser Gly Pro Cys Asp Ser·
801 CAAGATGAAG CCAGATAGGT TGAACTACTG TAGACATGTG TTGGCTGCAT GGGCCCTGGG TGCAAAGGCC TTCTACTACC
GTTCTACTTC GGTCTATCCA ACTTGATGAC ATCTGTACAC AACCGACGTA CCCGGGACCC ACGTTTCCGG AAGATGATGG
+1 ·Ser Lys Met Lys Pro Asp Arg Leu Asn Tyr Cys Arg His Val Leu Ala Ala Trp Ala Leu Gly Ala Lys Ala Phe Tyr Tyr Pro·
881 CTGAGGAAGC TGGTTTGGCC TTTGGTGGCC CAGGTAGCAG CAGGTATCTG AGATTGGAGG TTCATTACCA CAACCCACTG
GACTCCTTCG ACCAAACCGG AAACCACCGG GTCCATCGTC GTCCATAGAC TCTAACCTCC AAGTAATGGT GTTGGGTGAC
+1 ·Pro Glu Glu Ala Gly Leu Ala Phe Gly Gly Pro Gly Ser Ser Arg Tyr Leu Arg Leu Glu Val His Tyr His Asn Pro Leu
961 GTCATTGAGG GCAGAAATGA CAGCAGTGGA ATCAGGTTGT ACTATACAGC CAAGCTGAGA AGGTTTAATG CAGGAATCAT
CAGTAACTCC CGTCTTTACT GTCGTCACCT TAGTCCAACA TGATATGTCG GTTCGACTCT TCCAAATTAC GTCCTTAGTA
+1 Val Ile Glu Gly Arg Asn Asp Ser Ser Gly Ile Arg Leu Tyr Tyr Thr Ala Lys Leu Arg Arg Phe Asn Ala Gly Ile Met·
1041 GGAGCTGGGC CTGGTGTACA CCCCTGTCAT GGCCATCCCC CCCAGAGAGA CTGCATTTAT TTTGACAGGA TACTGCACTG
CCTCGACCCG GACCACATGT GGGGACAGTA CCGGTAGGGG GGGTCTCTCT GACGTAAATA AAACTGTCCT ATGACGTGAC
+1 ·Met Glu Leu Gly Leu Val Tyr Thr Pro Val Met Ala Ile Pro Pro Arg Glu Thr Ala Phe Ile Leu Thr Gly Tyr Cys Thr Asp·
1121 ACAAGTGCAC CCAGCTGGCC CTCCCCCCAA GTGGCATACA CATATTTGCC TCTCAGCTGC ACACACACTT GACAGGCAGA
TGTTCACGTG GGTCGACCGG GAGGGGGGTT CACCGTATGT GTATAAACGG AGAGTCGACG TGTGTGTGAA CTGTCCGTCT
+1 ·Asp Lys Cys Thr Gln Leu Ala Leu Pro Pro Ser Gly Ile His Ile Phe Ala Ser Gln Leu His Thr His Leu Thr Gly Arg
1201 AAAGTGGTGA CAGTGCTGGT GAGAGATGGC AGGGAGTGGG AGATTGTGAA CCAGGATAAC CATTATAGCC CACATTTCCA
TTTCACCACT GTCACGACCA CTCTCTACCG TCCCTCACCC TCTAACACTT GGTCCTATTG GTAATATCGG GTGTAAAGGT
+1 Lys Val Val Thr Val Leu Val Arg Asp Gly Arg Glu Trp Glu Ile Val Asn Gln Asp Asn His Tyr Ser Pro His Phe Gln·
1281 GGAGATTAGG ATGCTGAAGA AAGTGGTCAG TGTCCACCCA GGAGATGTTT TGATCACCAG CTGTACCTAC AATACTGAGG
CCTCTAATCC TACGACTTCT TTCACCAGTC ACAGGTGGGT CCTCTACAAA ACTAGTGGTC GACATGGATG TTATGACTCC
+1 ·Gln Glu Ile Arg Met Leu Lys Lys Val Val Ser Val His Pro Gly Asp Val Leu Ile Thr Ser Cys Thr Tyr Asn Thr Glu Asp·
1361 ATAGGGAGCT GGCCACAGTG GGTGGTTTTG GAATCCTGGA GGAGATGTGT GTGAACTATG TCCATTACTA CCCACAGACT
TATCCCTCGA CCGGTGTCAC CCACCAAAAC CTTAGGACCT CCTCTACACA CACTTGATAC AGGTAATGAT GGGTGTCTGA
+1 ·Asp Arg Glu Leu Ala Thr Val Gly Gly Phe Gly Ile Leu Glu Glu Met Cys Val Asn Tyr Val His Tyr Tyr Pro Gln Thr
1441 CAGCTGGAAT TGTGCAAGTC TGCAGTTGAT GCTGGATTCC TCCAAAAGTA TTTTCACTTG ATCAACAGGT TTAACAATGA
GTCGACCTTA ACACGTTCAG ACGTCAACTA CGACCTAAGG AGGTTTTCAT AAAAGTGAAC TAGTTGTCCA AATTGTTACT
+1 Gln Leu Glu Leu Cys Lys Ser Ala Val Asp Ala Gly Phe Leu Gln Lys Tyr Phe His Leu Ile Asn Arg Phe Asn Asn Glu·
1521 GGATGTCTGC ACCTGCCCAC AGGCATCTGT TAGTCAGCAG TTCACCAGTG TTCCTTGGAA TTCCTTCAAC AGGGATGTGC
CCTACAGACG TGGACGGGTG TCCGTAGACA ATCAGTCGTC AAGTGGTCAC AAGGAACCTT AAGGAAGTTG TCCCTACACG
+1 ·GluAsp Val Cys Thr Cys Pro Gln Ala Ser Val Ser Gln Gln Phe Thr Ser Val Pro Trp Asn Ser Phe Asn Arg Asp Val Leu·
1601 TCAAAGCTCT GTACAGCTTT GCACCCATAT CCATGCACTG CAACAAGTCT TCAGCAGTTA GGTTTCAAGG AGAGTGGAAC
AGTTTCGAGA CATGTCGAAA CGTGGGTATA GGTACGTGAC GTTGTTCAGA AGTCGTCAAT CCAAAGTTCC TCTCACCTTG
+1 ·Leu Lys Ala Leu Tyr Ser Phe Ala Pro Ile Ser Met His Cys Asn Lys Ser Ser Ala Val Arg Phe Gln Gly Glu Trp Asn
1681 CTGCAACCTC TGCCCAAAGT GATTTCCACC CTGGAGGAGC CCACCCCCCA GTGCCCCACA TCACAGGGTA GAAGCCCAGC
GACGTTGGAG ACGGGTTTCA CTAAAGGTGG GACCTCCTCG GGTGGGGGGT CACGGGGTGT AGTGTCCCAT CTTCGGGTCG
+1 Leu Gln Pro Leu Pro Lys Val Ile Ser Thr Leu Glu Glu Pro Thr Pro Gln Cys Pro Thr Ser Gln Gly Arg Ser Pro Ala·
1761 TGGACCCACT GTGGTGTCAA TTGGTGGAGG CAAGGGCTAG CTCGAG
ACCTGGGTGA CACCACAGTT AACCACCTCC GTTCCCGATC GAGCTC
XhoI
+1 ·Ala Gly Pro Thr Val Val Ser Ile Gly Gly Gly Lys Gly ***
Figure 10.3: BiP-DβH DNA sequence. DNA sequence of the gene for BiP-DβH, which was ordered from
GenScript. The gene is flanked by an NcoI site upstream of BiP (marked with red) and a XhoI site just after the
stopcodon. The figure was made with Vector NTI AdvanceTM 10.3.0 (Invitrogen Life Sciences, 2006).
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1 GCCATGGCC
CGGTACCGG
A TGAAGTTATG CATATTACTG GCCGTCGTGG CCTTTGTTGG CCTCTCGCTC GGG
T ACTTCAATAC GTATAATGAC CGGCAGCACC GGAAACAACC GGAGAGCGAG CCC
ATGCAAC CAGCTATGAT
TACGTTG GTCGATACTA
NcoI
+1 Met Ala Met Lys Leu Cys Ile Leu Leu Ala Val Val Ala Phe Val Gly Leu Ser Leu Gly Met Gln Pro Ala Met Met·
81 GATGTTCTCT AGCAAGTACT GGGCCAGGAG AGGTTTTTCA CTGGATAGTG CTGTCCCAGA GGAACACCAG CTGCTGGGCT
CTACAAGAGA TCGTTCATGA CCCGGTCCTC TCCAAAAAGT GACCTATCAC GACAGGGTCT CCTTGTGGTC GACGACCCGA
+1 ·Met Met Phe Ser Ser Lys Tyr Trp Ala Arg Arg Gly Phe Ser Leu Asp Ser Ala Val Pro Glu Glu His Gln Leu Leu Gly Ser·
161 CCAGCACTCT GAACAAGCCT AACAGTGGCA AGAATGATGA TAAGGGAAAT AAGGGCAGCT CTAAGAGGGA GGCTGCCACT
GGTCGTGAGA CTTGTTCGGA TTGTCACCGT TCTTACTACT ATTCCCTTTA TTCCCGTCGA GATTCTCCCT CCGACGGTGA
+1 ·Ser Ser Thr Leu Asn Lys Pro Asn Ser Gly Lys Asn Asp Asp Lys Gly Asn Lys Gly Ser Ser Lys Arg Glu Ala Ala Thr
241 GAGAGTGGCA AAACTGCAGT TGTTTTCTCC CTGAAGAATG AGGTGGGAGG TTTGGTTAAG GCACTGAGGC TGTTCCAAGA
CTCTCACCGT TTTGACGTCA ACAAAAGAGG GACTTCTTAC TCCACCCTCC AAACCAATTC CGTGACTCCG ACAAGGTTCT
+1 Glu Ser Gly Lys Thr Ala Val Val Phe Ser Leu Lys Asn Glu Val Gly Gly Leu Val Lys Ala Leu Arg Leu Phe Gln Glu·
321 GAAGAGAGTC AACATGGTGC ATATAGAAAG CAGAAAAAGC AGGAGAAGGA GTTCTGAGGT TGAAATATTT GTTGATTGTG
CTTCTCTCAG TTGTACCACG TATATCTTTC GTCTTTTTCG TCCTCTTCCT CAAGACTCCA ACTTTATAAA CAACTAACAC
+1 ·Glu Lys Arg Val Asn Met Val His Ile Glu Ser Arg Lys Ser Arg Arg Arg Ser Ser Glu Val Glu Ile Phe Val Asp Cys Glu·
401 AGTGTGGCAA AACAGAGTTT AATGAATTGA TCCAGTTGCT GAAGTTTCAG ACCACCATTG TCACCCTGAA TCCTCCAGAG
TCACACCGTT TTGTCTCAAA TTACTTAACT AGGTCAACGA CTTCAAAGTC TGGTGGTAAC AGTGGGACTT AGGAGGTCTC
+1 ·GluCys Gly Lys Thr Glu Phe Asn Glu Leu Ile Gln Leu Leu Lys Phe Gln Thr Thr Ile Val Thr Leu Asn Pro Pro Glu
481 AACATCTGGA CTGAGGAGGA GGAGCTGGAG GATGTCCCCT GGTTCCCTAG GAAGATATCA GAGCTGGACA AGTGCTCACA
TTGTAGACCT GACTCCTCCT CCTCGACCTC CTACAGGGGA CCAAGGGATC CTTCTATAGT CTCGACCTGT TCACGAGTGT
+1 Asn Ile Trp Thr Glu Glu Glu Glu Leu Glu Asp Val Pro Trp Phe Pro Arg Lys Ile Ser Glu Leu Asp Lys Cys Ser His·
561 CAGAGTGCTC ATGTATGGCT CTGAGCTGGA TGCTGATCAT CCAGGATTCA AGGACAATGT GTACAGACAA AGAAGAAAGT
GTCTCACGAG TACATACCGA GACTCGACCT ACGACTAGTA GGTCCTAAGT TCCTGTTACA CATGTCTGTT TCTTCTTTCA
+1 ·His Arg Val Leu Met Tyr Gly Ser Glu Leu Asp Ala Asp His Pro Gly Phe Lys Asp Asn Val Tyr Arg Gln Arg Arg Lys Tyr·
641 ATTTTGTTGA TGTGGTCATG GGATACAAAT ATGGTCAGCC TATTCCAAGA GTGGAGTACA CTGAGGAAGA GACCAAGACC
TAAAACAACT ACACCAGTAC CCTATGTTTA TACCAGTCGG ATAAGGTTCT CACCTCATGT GACTCCTTCT CTGGTTCTGG
+1 ·Tyr Phe Val Asp Val Val Met Gly Tyr Lys Tyr Gly Gln Pro Ile Pro Arg Val Glu Tyr Thr Glu Glu Glu Thr Lys Thr
721 TGGGGTGTGG TCTTTAGGGA GCTGAGCAAG CTGTACCCAA CCCATGCCTG CAGGGAGTAC TTGAAGAATT TCCCCCTGCT
ACCCCACACC AGAAATCCCT CGACTCGTTC GACATGGGTT GGGTACGGAC GTCCCTCATG AACTTCTTAA AGGGGGACGA
+1 Trp Gly Val Val Phe Arg Glu Leu Ser Lys Leu Tyr Pro Thr His Ala Cys Arg Glu Tyr Leu Lys Asn Phe Pro Leu Leu·
801 GACCAAGTAC TGTGGATACA GGGAGGATAA TGTGCCCCAG CTGGAGGATG TGAGCATGTT CCTGAAGGAG AGGTCAGGTT
CTGGTTCATG ACACCTATGT CCCTCCTATT ACACGGGGTC GACCTCCTAC ACTCGTACAA GGACTTCCTC TCCAGTCCAA
+1 ·Leu Thr Lys Tyr Cys Gly Tyr Arg Glu Asp Asn Val Pro Gln Leu Glu Asp Val Ser Met Phe Leu Lys Glu Arg Ser Gly Phe·
881 TCACTGTGAG ACCTGTGGCA GGTTATCTGT CTCCCAGGGA CTTCCTGGCT GGCTTGGCTT ACAGGGTGTT TCACTGCACC
AGTGACACTC TGGACACCGT CCAATAGACA GAGGGTCCCT GAAGGACCGA CCGAACCGAA TGTCCCACAA AGTGACGTGG
+1 ·Phe Thr Val Arg Pro Val Ala Gly Tyr Leu Ser Pro Arg Asp Phe Leu Ala Gly Leu Ala Tyr Arg Val Phe His Cys Thr
961 CAGTATATCA GACATGGCTC TGATCCCCTG TACACCCCTG AGCCTGATAC CTGCCATGAG TTGCTGGGAC ATGTGCCTCT
GTCATATAGT CTGTACCGAG ACTAGGGGAC ATGTGGGGAC TCGGACTATG GACGGTACTC AACGACCCTG TACACGGAGA
+1 Gln Tyr Ile Arg His Gly Ser Asp Pro Leu Tyr Thr Pro Glu Pro Asp Thr Cys His Glu Leu Leu Gly His Val Pro Leu·
1041 GCTGGCAGAC CCAAAGTTTG CCCAGTTTAG TCAGGAGATT GGACTGGCCA GTCTGGGAGC CAGTGATGAG GATGTTCAGA
CGACCGTCTG GGTTTCAAAC GGGTCAAATC AGTCCTCTAA CCTGACCGGT CAGACCCTCG GTCACTACTC CTACAAGTCT
+1 ·Leu Leu Ala Asp Pro Lys Phe Ala Gln Phe Ser Gln Glu Ile Gly Leu Ala Ser Leu Gly Ala Ser Asp Glu Asp Val Gln Lys·
1121 AGCTGGCTAC CTGCTACTTC TTCACCATTG AGTTTGGCCT GTGCAAGCAA GAGGGCCAGC TGAGGGCATA TGGAGCTGGT
TCGACCGATG GACGATGAAG AAGTGGTAAC TCAAACCGGA CACGTTCGTT CTCCCGGTCG ACTCCCGTAT ACCTCGACCA
NdeI
+1 ·Lys Leu Ala Thr Cys Tyr Phe Phe Thr Ile Glu Phe Gly Leu Cys Lys Gln Glu Gly Gln Leu Arg Ala Tyr Gly Ala Gly
1201 CTGCTGTCCA GCATTGGAGA GCTGAAACAT GCCTTGAGTG ATAAGGCTTG TGTGAAGGCC TTTGATCCAA AGACAACCTG
GACGACAGGT CGTAACCTCT CGACTTTGTA CGGAACTCAC TATTCCGAAC ACACTTCCGG AAACTAGGTT TCTGTTGGAC
+1 Leu Leu Ser Ser Ile Gly Glu Leu Lys His Ala Leu Ser Asp Lys Ala Cys Val Lys Ala Phe Asp Pro Lys Thr Thr Cys·
1281 TCTGCAGGAG TGCCTGATCA CTACTTTCCA GGAGGCCTAT TTTGTTTCTG AGAGCTTTGA GGAGGCTAAG GAGAAGATGA
AGACGTCCTC ACGGACTAGT GATGAAAGGT CCTCCGGATA AAACAAAGAC TCTCGAAACT CCTCCGATTC CTCTTCTACT
+1 ·Cys Leu Gln Glu Cys Leu Ile Thr Thr Phe Gln Glu Ala Tyr Phe Val Ser Glu Ser Phe Glu Glu Ala Lys Glu Lys Met Arg·
1361 GAGACTTTGC TAAGTCAATC ACTAGGCCCT TCTCAGTCTA CTTCAACCCC TACACTCAGT CCATTGAGAT CTTGAAGGAT
CTCTGAAACG ATTCAGTTAG TGATCCGGGA AGAGTCAGAT GAAGTTGGGG ATGTGAGTCA GGTAACTCTA GAACTTCCTA
+1 ·Arg Asp Phe Ala Lys Ser Ile Thr Arg Pro Phe Ser Val Tyr Phe Asn Pro Tyr Thr Gln Ser Ile Glu Ile Leu Lys Asp
1441 ACTAGGAGTA TTGAGAATGT GGTGCAGGAC CTGAGATCTG ATCTGAACAC TGTGTGTGAT GCCTTGAATA AGATGAACCA
TGATCCTCAT AACTCTTACA CCACGTCCTG GACTCTAGAC TAGACTTGTG ACACACACTA CGGAACTTAT TCTACTTGGT
+1 Thr Arg Ser Ile Glu Asn Val Val Gln Asp Leu Arg Ser Asp Leu Asn Thr Val Cys Asp Ala Leu Asn Lys Met Asn Gln·
1521 GTACCTGGGC ATTTAGCTCG AG
CATGGACCCG TAAATCGAGC TC
XhoI
+1 ·Gln Tyr Leu Gly Ile ***
Figure 10.4: BiP-TPH2 DNA sequence. DNA sequence of the gene encoding BiP-TPH2, which was ordered
from GenScript. The gene is flanked by an NcoI site upstream of BiP (marked with red) and a XhoI site just
after the stopcodon. The figure was made with Vector NTI AdvanceTM 10.3.0 (Invitrogen Life Sciences, 2006)
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Figure 10.5: Blasticidin S is a potent inhibitor of cell growth in both prokaryotes and eukaryotes by inhibiting
the peptide bond formation in protein synthesis (Kimura et al., 1994).
The pCoBlast selection vector (figure 10.6) contains the Blasticidin S deami-
nase gene (blasticidin resistance gene) under control of the D. melanogaster copia
promotor. When co-transfecting the pCoBlast vector with one of the protein ex-
pression vectors transfected cells can be selected with blasticidin (Invitrogen life
technologies, 2003b). As blasticidin rapidly inhibit cell growth the selection pro-
cess is shorter compared to other inhibitors and furthermore blasticidin remains
stable in the culture medium (Kimura et al., 1994).
pCoBlast
HC2196
3907 bp 
Ampicillin
resistance gene
Blasticidin
resistance gene
copia promotor
bla promotor
Figure 10.6: pCoBlast selection vector. The selection vector pCoBlast contains the blasticidin resistance
gene under control of the D. melanogaster copia promotor for selection of stably transfected S2 cells. Fur-
thermore it contains the ampicillin gene under control of the E. coli bla promotor for selection in E. coli cells
when multiplying the plasmid (Invitrogen life technologies, 2003b). The vector map was made with Vector NTI
AdvanceTM 10.3.0 (Invitrogen Life Sciences, 2006).
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11 Experimental work with
Drosophila Melanogaster
cells
The work with the D. Melanogaster S2 was conducted at Department of Medicinal
Chemistry, Faculty of Pharmaceutical Sciences at University of Copenhagen. The
recombinant DNA used for transfection of the S2 cells were prepared in E. coli
cells, therefore part of this section concerns experiments carried out in bacteria.
Moreover general handling of S2 cells and the experiments with these are described.
In the end is the protocol for western blotting which was used for analysis of protein
expression.
11.1 Preparation of DNA for transfection
This section describes the protocols for the individual steps in preparing DNA for
transfection in D. Melanogaster S2 cells. All solutions were prepared using ultra-
pure 18.2 MΩ·cm water from a MilliQ synthesis A10 system from Millipore (milliQ
water) and both milliQ water and growth media were sterilized by autoclaving be-
fore use.
The gene of interest was produced by polymerase chain reaction (PCR) and
cloned into a PCR-Script Amp SK(+) cloning vector (Stratagene, 2008). The
resulting plasmid was transformed into E. coli DH5α cells and colonies amplified
overnight. The resulting culture media was used for bacteria stock and to isolate
amplified plasmid DNA.
After an analytical digestion with restriction enzymes, the DNA which gave
the expected fragments was junction sequenced to ensure that the sequence was
correct. The gene of interest was then cleaved from the PCR-Script Amp SK(+)
cloning vector by digestion with restriction enzymes and, after preparative gel
electrophoresis and purification of the right fragment, ligated to the appropriate
vector digested with the same restriction enzymes.
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The resulting plasmid was transformed into DH5α cells and amplified overnight.
A bacterial stock of the expression vector was made and amplified plasmid DNA
isolated and junction sequenced. The recombinant DNA was then ready for trans-
formation in S2 cells.
An overview of all the steps is shown in figure 11.1 and the procedures are
described in the following sections.
PCR amplification of gene 
Preparative gel electrophoresis 
Gel purification 
Analytical gel electrophoresis 
Ligation into cloning vector 
Tranformation into DH5 cells 
3 ml overnight culture 
Glycerol stocks DNA isolation 
Analytical digestion Preparative digestion 
Analytical gel electrophoresis 
Sequencing 
Preparative gel electrophoresis 
Gel purification 
Opening of vector by digestion 
Preparative gel electrophoresis 
Gel purification 
Analytical gel electrophoresis 
Ligation of vector and insert 
Transformation into DH5 cells 
3 ml overnight culture 
Glycerol stocks DNA isolation 
Analytical digestion Transfection into S2 cells 
Analytical gel electrophoresis 
Sequencing 
Expansion of cells 
Frozen stock 
Figure 11.1: Preparation of S2 expression strain. The steps from initial PCR production of the gene of
interest until the final expression strain in D. melanogaster S2 cells is present.
11.1.1 Polymerase chain reaction
Polymerase chain reaction (PCR) was done using the Platinum R©Pfx DNA Poly-
merase kit from Invitrogen #11708-013.
Following components were mixed in a microcentrifuge tube:
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Sterile milliQ water X µl for a final volume of 50.0 µl
10X Pfx amplification buffer 5.0 µl
10 mM dNTP mixture 1.5 µl
50 mM MgSO4 1.0 µl
0.015 nmol sense primer X µl depend on primer concentration
0.015 nmol antisense primer X µl depend on primer concentration
DNA template X µl usually 0.5 µl
Pfx DNA Polymerase 0.4 µl
After a brief centrifugation, the mixture was placed in the PCR machine and
denatured at 94◦C for 2 minutes followed by 25-30 cycles of PCR amplification:
Denature: 94◦C for 15 s
Anneal: Tm for 30 s (Tm is calculated from primer composition)
Extension: 68◦C for 1 min per kb
The product was then analysed by agarose gel electrophoresis (section 11.1.2)
before further processing.
Primers were individually designed according to the desired addition of restric-
tion sites (the primer sequences are shown in section 10.3.2). The annealing part of
the primers contained about 20 basepairs with Tm ≈ 55◦C (see below). Moreover
the primers contained the extra bases according to the planned restriction sites
and when primers covered the end of a gene some extra A’s in the 5’-end to avoid
problems due to 5’-3’ exonuclease activity during the PCR reaction. Primers were
synthesized by TAG Copenhagen A/S.
The annealing temperature, Tm, were calculated from the following formula:
Tm = (2 · (A+ T ) + 2 · (C +G))− 5
where (A+T) refers to the number of A and T bases in the annealing part of the
primer and (C+G) to the C and G content in the annealing part of the primer.
11.1.2 Agarose gel electrophoresis
Agarose gels were prepared according to the size of the linear DNA fragments to
be analysed.
Size of linear DNA fragment Gel % Agarose amount per gel
> 4 kb 0.8 % 0.20 g
0.8-4 kb 1.0 % 0.25 g
0.4-0.8 kb 1.2 % 0.30 g
< 0.4 kb 1.5 % 0.375 g
For preparation of one gel, the desired amount of agarose was mixed with 25 ml
of 1xTBE buffer (10.8 g/l Trizma base, 5.5 g/l boric acid (H3BO4) and 4.0 ml/l
0.5 M EDTA pH 8.0 diluted in milliQ water) in a 100 ml conical flask. The mixture
was heated to completely dissolve the agarose and when afterwards cooled to 50-
60◦C 0.20 µl 10 mg/ml EtBr (Ethidium bromide) was added. When further cooled
the gel was poured into the form assembled with the appropriate comb and allowed
to solidify.
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For analytical gels a 10 well comb was used. All wells are equally sized and
contain 12 µl each. For a preparative gel a 2 well comb was used, this comb have
a smaller well for the marker containing 24 µl and a bigger well for the sample
containing 120 µl. The marker for both kind of gels consist of 1/24 1 kb Plus DNA
ladder (Invitrogen #10787-018), 4/24 loading dye (0.25 % bromphenolblue, 30 %
glycerol and 50 mM EDTA) and 19/24 milliQ water.
Samples were mixed with loading dye to 1/5 of the final volume before loading.
The gel was placed in a running vessel containing running buffer (1xTBE buffer
with 25 µl/l EtBr added) and loaded with marker and samples. 100 V constant
voltage was applied for about 30 minutes or until satisfactory separation of bands
occurred.
EtBr binding to DNA results in orange fluorescence upon exposure to UV-light,
therefore bands were visualized using an UV-light table.
For preparative gels the piece of gel containing the appropriate DNA fragment
was cut free using a scalpel.
11.1.3 Extraction of DNA fragment from gel material
The DNA was extracted from agarose gel material using the Viogene #EG1001
Gel-MTM Gel Extraction System. The Spin Method Protocol recommended by
Viogene was followed with the exception that DNA was eluted with milliQ water.
11.1.4 Ligation in PCR vector
Extracted DNA was ligated into the pPCR-ScriptTM Amp SK(+) Vector (Strata-
gene, 2008) following recommendations from Stratagene (PCR-ScriptTM Amp Clo-
ning Kit #21188-5).
For DNA sequences containing an internal Srf I site, this restriction enzyme
was omitted from the reaction mixture and blue/white screening was applied in
transformation (see section 11.1.5).
11.1.5 Transformation of constructs
Transformation in DH5α cells
MAX Efficiency R© DH5αTM competent cells (Invitrogen #18258-012) were thawed
on ice and 100 µl of cells were placed in a chilled polypropylene tube. 1 µl DNA
was added to the cells and gently mixed.
Cells and DNA were incubated 30 minutes on ice followed by 45 seconds heat-
shock in a 42◦C water bath and another 2 minutes on ice.
0.45 ml of room temperature Luria-Broth (LB) medium without antibiotics
was added to the mixture and 1/10 and 8/10 of the mixture were spread on two
LB agar plates containing 100 µg/ml ampicillin and incubated overnight at 37◦C.
Blue/white screening
When cloning in PCR-Script vector was performed without the Srf I restriction en-
zyme, X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) was used to indi-
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cate whether a bacterial colony expressed the β-galactosidase enzyme or not. X-gal
is cleaved by β-galactosidase and after oxidation of the product an insoluble blue
product is produced. Thus, if X-gal and IPTG (Isopropyl β-D-1-thiogalactopyrano-
side, an inducer of β-galactosidase) is in the agar on a culture plate, colonies
expressing functional β-galactosidase will appear blue.
Since the Sfr I restriction site is placed in the coding region for the β-galactosi-
dase gene in the PCR-Script vector (Stratagene, 2008) DNA will be inserted in
this position upon ligation and β-galactosidase will not be expressed. That is,
upon blue/white screening colonies containing the DNA fragment of interest will
be white and colonies without the insert DNA will be blue.
When transformating in DH5α cells agar plates containing 100 µg/ml ampi-
cillin were prepared with 20 µl 200 mM IPTG and 20 µl 10 % X-gal (GibcoBRL
#15520 34) which were spread on the plate and allowed to dry before the cell mix-
ture was applied. After incubation at 37◦C overnight only white single colonies
were picked up for further processing.
11.1.6 Overnight cultures
Dependent on how much DNA was needed a single colony from an agar plate from
transformation (or from an existing glycerol stock plated) was inoculated in either
3 ml or 50 ml of LB medium containing the appropriate antibiotics and incubated
overnight at 37◦C, 140 rpm.
11.1.7 Preparation of bacterial stocks
Bacterial stocks were made by mixing of 500 µl cell suspension from an overnight
culture and 116 µl sterile 80 % glycerol, the stocks were then stored at -80◦C.
11.1.8 Purification of DNA from bacteria
Plasmid DNA was purified from cell suspension using the GenEluteTMPlasmid
Miniprep Kit (Sigma #PLN70-1KT) for 3 ml cultures and the GenEluteTMHP
Plasmid Midiprep Kit (Sigma #NAO200-1KT) for 50 ml cultures.
The purifications were conducted according to the protocol provided by Sigma
(Spin Format protocol for the Midiprep kit) with the exception that the Elution
Solution provided in the kits was replaced by milliQ water.
After purification DNA from Midiprep was upconcentrated. 1 ml of the Midi-
prep preparation was mixed with 100 µl 3 M CH3COONa/CH3COOH, pH 5.2 and
700 µl 2-propanol and centrifuged at 16·103×g for 30 minutes at 4◦C.
The supernatant was discarded and the pellet resuspended in 500 µl freshly
made 70 % ethanol followed by another centrifugation at 16·103×g, 4◦C for 30 min-
utes. The supernatant was again discarded and the DNA was dissolved in 100 µl
milliQ water.
11.1.9 Preparation of DNA for sequencing
The concentration of purified plasmid DNA was determined by UV/visible spec-
trophotometry at 260 nm and calculated from the following formula (DF = dilution
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factor):
c(µg/ml) =
Abs260nm ·DF
0.02 ml/µg
The volume corresponding to 2.5 µg DNA (in the original solution) was mixed
with milliQ water to 50 µl and 5 µl 3 M CH3COONa/CH3COOH, pH 4.6 and
165 µl 96 % ethanol were added. The mixture was left at room temperature for
15 minutes.
The mixture was then centrifuged at 16·103×g for 20 minutes and the super-
natant removed. The pellet was resuspended in 250 µl freshly made 70 % ethanol
followed by another centrifugation at 16·103×g for 5 minutes. After removal of the
supernatant the pellet was again centrifuged at 16·103×g for 5 minutes.
The microcentrifuge tube was turned upside-down and left at room temperature
for 15-30 minutes until ethanol had evaporated. Sequence analysis of the dry DNA
pellet was conducted by Eurofins MWG Operon, which also synthesized the needed
primers for sequencing.
When DNA fragments contained more than ≈900 bp two samples of the same
plasmid were analysed, one sequencing from each end of the fragment. The primers
used for sequencing DNA in the PCR-Script vector (Stratagene, 2008) were T7
and T3 and for the pMT/V5-His A vector (Invitrogen life technologies, 2001b)
MT forward and BGH reverse were used.
MT forward: 5’-CATCTCAGTGCAACTAAA-3’
BGH reverse: 5’-TAGAAGGCACAGTCGAGG-3’
11.1.10 Digestion with restriction enzymes
Restriction enzymes were chosen to allow double digest (simultaneously cleaving)
according to the recommendations of New England Biolabs Inc. (New England Bi-
olabs Inc., 2009a). The used restriction enzymes are mentioned in sections 10.3.1-
10.3.4.
Analytical cleavage was chosen to test if restriction fragments had the correct
size, whereas preparative cleavage was used when going to work on the isolated
fragment.
Analytical cleavage
8.4 µl plasmid DNA was mixed with 1.0 µl of the appropriate NEBuffer (New
England Biolabs Inc., 2009a,b) and 0.3 µl of each restriction enzyme. The mixture
was incubated at 37◦C for 1-2 hours and the sample was afterwards analysed using
analytical agarose gel electrophoresis (section 11.1.2).
Preparative cleavage
84 µl plasmid DNA was mixed with 10 µl of the appropriate NEBuffer (New
England Biolabs Inc., 2009a,b) and 3 µl of each restriction enzyme. The mixture
was incubated at 37◦C for 4 hours or overnight. To avoid self-ligation 1 µl CIP (calf
intestinal alkaline phosphatase) was added to the digested vector plasmid mixture
and incubation continued for another hour.
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Digested fragments were exposed to preparative agarose gel electrophoresis
(section 11.1.2) in order to isolate the correct fragments.
11.1.11 Ligation of insert and vector DNA
After digestion with the same restriction enzymes both insert and vector DNA were
purified as described in section 11.1.3. To estimate the ratio between concentration
of insert and vector DNA 2 µl samples of each were analysed with analytical agarose
gel electrophoresis (section 11.1.2).
T4 DNA Ligase (New England Biolabs #M0202S) was used for the ligation
reaction: 8 µl DNA (insert:vector volume ratio determined from analytical gel to
achieve 2-6 times molar excess of the insert DNA) was mixed with 1 µl 10X T4
DNA ligase buffer and 1 µl T4 DNA ligase. The mixture was incubated for 1 hour
at room temperature followed by transformation in DH5α cells (section 11.1.5).
11.2 General maintenance of Drosophila Melanogaster
Schneider 2 cells
Work with D. melanogaster S2 cells was always conducted in a laminar air flow
bench using sterile equipment and solutions/reagents. The protocol for handling
of the cells is a modified version of Invitrogen’s manuals for S2 cells (Invitrogen
life technologies, 2002, 2003a). The procedure is described in the following sec-
tions 11.2.1-11.2.4.
11.2.1 Culturing of S2 cells
For the initial culturing and experiments (including stable transfections) of S2
cells complete Schneider’s Drosophila medium (cSDM, described below) were used.
As stable cell lines were obtained all lines (transfected and untransfected) were
accustomed to a serum free medium, EX-CELL 420 (Sigma #14420C).
The complete Schneider’s Drosophila medium consist of Schneider’s Drosophila
medium (Invitrogen #21720) containing 10 % heat-inactivated fetal bovine serum
(FBS) and 5 ml/l (50 units) penicillin/streptomycin (pen/strep).
For selection of stably transfected cell lines (section 11.3.2) 10 or 25 µg/ml
blasticidin was added to the growth medium (either cSDM or EX-CELL 420).
S2 cells were incubated at 28◦C in a non-humidified incubator with loosened
caps to allow oxygenation (hereafter incubation at 28◦C).
11.2.2 Thawing cells from frozen stock
Stocks (section 11.2.4) of S2 cells were stored in liquid nitrogen. To thaw them
and start a culture, the vial with cells were removed from liquid nitrogen and
quickly thawed in hands and the outside of the vial were decontaminated with
70 % ethanol.
The entire content of the vial were then transferred into a sterile tube containing
4 ml of medium (cSDM or EX-CELL 420) at room temperature and centrifuged
at 280×g for 5-10 minutes. The dimethylsulfoxide (DMSO) containing medium
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(see section 11.2.4) was decanted and the cells were resuspended in 10 ml of fresh
medium and transferred into a T-25 cm2 flask. Cells were then incubated at 28◦C.
When the culture reached confluency (after 4 to 6 days) cells were subcultured
in new flasks (section 11.2.3).
11.2.3 Subculturing of cells
For general maintenance or when experiments were initiated cells were split into
new flasks. To loosen cells flasks were tapped and the surface was flushed with
conditioned medium (“used” medium) to remove the remaining cells. Part of the
cell suspension was then distributed to new flasks with fresh medium and the flasks
(T-25 or T-75 cm2) were incubated at 28◦C. Successful subculturing was possible
at ratios as low as 1:25.
11.2.4 Freezing S2 cells for stock
In order to keep the passage number low and to have back-up of cells in case of
contamination, aliquots of the used cell lines were regularly frozen. S2 cells were
stored in a freezing medium composed of 45 % fresh growth medium (cSDM or
EX-CELL 420) and 45 % conditioned medium with DMSO added to a final concen-
tration of 10 %. The freezing medium was prepared just before use. Conditioned
medium was included in the freezing medium to provide growth factors secreted
from the cells during culturing. These are to ensure optimal recovery of cells when
thawed and seeded for culture (Invitrogen life technologies, 2002, 2003a).
When passaging the cells determined for freezing, the suspension of loosened
cells was centrifuged at 280×g for 5-10 minutes, the supernatant decanted (and
collected for preparation of freezing medium) and cells were resuspended in freezing
medium to a density of approximately 1×107 cells/ml. Aliquots of this suspension
were distributed into cryovials and frozen at -80◦C. A few days later the frozen
vials were moved to liquid nitrogen storage.
11.3 Experiments with S2 cells
Wild type S2 cells were used for transient and stable transfection with dopamine β-
hydroxylase and tryptophan hydroxylase genes (section 10.3 and 11.3.1-11.3.2) and
for testing of blasticidin effect on cell survival (section 11.3.3). Stable transfected
cell lines were cultivated in spinner flasks to produce protein (section 13.1).
11.3.1 Transient transfection of S2 cells
Transient transfection of the S2 cells was done using the calcium phosphate trans-
fection procedure based on the protocol provided by Invitrogen (Invitrogen life
technologies, 2002, 2003a). The adjusted procedure is shown below:
Day 1: In 35 mm petri-dishes 3×106 cells were seeded in 3 ml cSDM or EX-
CELL 420 (1×106 cells/ml). Cells were incubated at 28◦C for 5 hr to allow
growth and adherence to the surface of the petri-dishes.
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After approximately 4 hr the transfection mix were prepared (volumes per
plate):
Solution A (mixed in a microcentrifuge tube):
36 µl 2 M CaCl2, recombinant DNA corresponding to 19 µg and sterile milliQ
water to a final volume of 300 µl
Solution B (in a second microcentrifuge tube):
300 µl 2X HEPES buffered saline (HBS; 50 mM HEPES, 1.5 mM Na2HPO4,
280 mM NaCl, pH 7.1)
Solution A was slowly (1 to 2 minutes) added to solution B with continuous
mixing (pipetting up and down). Continuous mixing ensured the production
of a fine precipitate which is necessary for efficient transfection.
The resulting solution was incubated at room temperature for 30-40 minutes
while the fine precipitate was formed.
The solutions (one for each gene construct) were mixed again and added
dropwise to each plate of cells where it was gently blended into the growth
medium.
Cells were incubated with the transfection mixture at 28◦C overnight (ap-
proximately 19 hr).
Day 2-5: The calcium phosphate containing medium was removed and the cells
were washed with fresh medium. Afterwards 3 ml fresh medium was supplied
to the cells and incubation at 28◦C was continued. At various timepoints (see
section 12.5) expression in different plates was induced by addition of copper
sulfate to a final concentration of 500 µM. Cells were then grown in the
presence of CuSO4 until harvested.
Day 5-8: Cells were flushed of the surface with medium and the cell suspension
transferred to microcentrifuge tubes and centrifuged at approximately 230×g
for 10 minutes.
The supernatants (containing secreted proteins) were transferred to new mi-
crocentrifuge tubes and stored at -20◦C until testing for expression (sec-
tion 11.4.1).
Pellets were resuspended in 1 ml phosphate buffered saline (PBS) and again
centrifuged at 230×g for 10 minutes. The new supernatants were discarded
and cell pellets resuspended in 50 µl lysis buffer (50 mM Tris, pH 7.8, 150 mM
NaCl, 1 % Nonidet P-40) and incubated for 10 minutes at room temperature,
whereafter it was vortexed and centrifuged at 230×g for 10 minutes. Su-
pernatants from this centrifugation (containing intra-cellular proteins) were
transferred to new microcentrifuge tubes and stored at -20◦C until testing
for expression using western blotting (section 11.4.1).
11.3.2 Stable transfection of S2 cells
S2 cells were stably transfected with the genes encoding DβH and TPH2 with or
without BiP signal sequence (see sections 10.3.1-10.3.4) in order to establish cell
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lines which only needed induction with copper sulfate to express the given proteins.
The expression vectors were co-transfected with the selection vector pCoBlast for
later selection using blasticidin (see section 10.3.6).
The procedure for stable transfection of S2 cells is very similar to the transient
transfection procedure (see section 11.3.1, Day 1) with the exception that 1 µg of
the selection vector pCoBlast is included in the transfection mix, solution A (sec-
tion 11.3.1, Day 1). Stable transfections were carried out in complete Drosophila
Schneider’s medium and not until stable cell lines were reached they were adapted
to serum free medium (11.2.1 and 11.3.4).
2-3 days post-transfection the medium was replaced by selective medium (com-
plete Drosophila medium containing 25 µg/ml blasticidin). Fresh selective medium
was added every 4-5 days (no subculturing of cells) until resistant colonies appeared
after 1-2 weeks. Hereafter cells were expanded until appropriate amounts of cells
were reached and stocks of the new cell-lines were frozen (see section 11.2.4).
11.3.3 Testing blasticidin effect
In order to test the effect of blasticidin on untransfected S2 cells, 3×106 cells in 3 ml
cSDM were seeded in 35 mm petri dishes and exposed to different concentrations
of blasticidin 0-50 µg/ml for a week. After that cell viability was determined using
the trypan blue exclusion method. When cells are exposed to the trypan blue
diazo dye cells which are dead or has damaged membranes are selectively colored
by the dye, whereas living cells exclude the dye (Strober, 2001).
Cells were flushed of the surfaces and 750 µl cell suspension were mixed with
750 µl 0.4 % trypan blue solution. After 5 minutes incubation at room temperature
cells were counted using a hemocytometer and the amount of unstained, viable cells
was compared to cell number a the beginning of the experiment.
11.3.4 Adaption of cells to serum free medium
As soon as back ups of stable transfected cell lines were frozen both the transfected
and untransfected S2 cell lines were adapted to serum free EX-CELL 420 medium.
To begin with 1/3 of the cSDM was replaced by EX-CELL 420. After 3 days
growth in this mixture medium was changed into 2/3 EX-CELL 420 and 1/3
cSDM and after further 3 days cells were supplied with 100% EX-CELL 420. As
this change of medium did not affect the cell viability, cells were expanded for
freezing of back up stocks in EX-CELL 420 (section 11.2.4).
For stably transfected cell lines 25 µg/ml blasticidin was added to the growth
medium (cSDM, EX-CELL 420 or a mixture of these).
11.4 Detection of protein expression
Expression of proteins from the S2 cell lines was analysed with western blotting.
11.4.1 Western blotting
For western blotting (WB) a tank blotting system was used for the transfer step.
For detection of protein a colorimetric alkaline phosphatase (AP) system was used.
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Electrophoresis
When analysing by WB 7.5 % precast Tris/HCl gels from Bio-Rad were used. The
marker was 20 µl BenchMarkTM pre-stained protein standard (Invitrogen #10748-
010). 20 µl samples were mixed with 5 µl uncolored 5X sample buffer and only
samples were heated to 80◦C for 10 min followed by a brief centrifugation before
loading in the wells next to the marker. Running buffer was used in both the
inner and the outer chamber. 100 V constant voltage was applied to the gel for
around 80 min allowing the proteins to separate (All solutions for WB are listed
in table 11.1).
Transfer
After electrophoresis the gels were soaked in transfer buffer for 45 min and PVDF
membranes (Bio-Rad #162-0174) were wetted in 100 % methanol and incubated
in transfer buffer for 5-10 min. Two fiber-pads and two filterpapers per membrane
Table 11.1: Buffers for western blotting. Composition of the buffers used for WB.
Buffer Composition
5X sample buffer 200 mM Tris/HCl pH 6.8
uncolored 2 % SDS
40 % glycerol
Just before use 28 µl β-mercaptoethanol was added
to an aliquot of 190 µl uncolored 5X sample buffer
Running buffer 25 mM Tris base
192 mM glycine
0.1 % SDS
Transfer buffer 25 mM Tris base
192 mM glycine
20 % methanol
0.05 % SDS
TBS 20 mM Tris/HCl pH 7.5
500 mM NaCl
TTBS 0.05 % Tween-20 in TBS
Blocking buffer 30 g/l gelatine in TBS
Antibody buffer 10 g/l gelatine in TTBS
Color development buffer AP Conjugate substrate kit (Bio-Rad #170-6432)
4 % AP color development buffer
1 % AP color reagent A
1 % AP color reagent B
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were soaked in transfer buffer and the casettes were assembled with a sandwich of
fiber-pad, filterpaper, the gel, the membrane, filterpaper and a fiber-pad (Bands
from the marker were drawed on the membrane to ensure them being visible) and
placed in a blotting tank containing transfer buffer at 4◦C, a cooling unit and a
magnetic stirrer. 100 V constant voltage was applied for 90 min, whereafter the
membranes were incubated in TBS for 10 min followed by blocking overnight in
blocking solution at 25◦C.
Blotting
Membranes were washed 10 minutes in TTBS followed by 90 min incubation with
the primary antibody (PH8/mouse-anti-TPH/TH/PAH, Chemicon International
#MAB5278 1:50 for TPH2 and sheep-anti-DβH, Novus Biologicals #MB300-112
1:500 for DβH) in antibody buffer. After another rinsing for 2×5 min in TTBS
membranes were incubated for 45 min with the secondary antibody (goat-anti-
mouse-AP, Bio-Rad #170-6520 1:3000 for TPH2 and rabbit-anti-sheep-AP, Acris
Antibodies #R1456AP 1:2000 for DβH) in antibody buffer. The membranes were
washed 2×5 min in TTBS and 1×5 min in TBS and incubated with color develop-
ment solution until bands were visible (max. 30 min). The membranes were then
washed in milliQ water for at least 2×5 min and allowed to dry.
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12 Construction of
eukaryotic expression
strains
In the following sections results from the construction of the eukaryotic expression
strains will be presented. These include preparation of the recombinant DNA in
E. coli, transient and stable transfections of D. Melanogaster S2 cells and the test
of blasticidin concentration for stable transfected cells.
12.1 Creation of TPH2 vector for expression in S2 cells
The gene encoding TPH2 for expression in S2 cells was constructed by PCR with
HC744 (Ub-huTPH2(SacII/XhoI)-pET26 in DH5α, 30 µg/ml kanamycin sulfate
(30 Kan) resistance) as the template and the primers HCP621 and HCP622 as
shown in section 10.3.2, table 10.1. The resulting 1487 bp fragment (see figure 12.2)
2000
1650
1000
huTPH2 (KpnI/XhoI) fragment 
Figure 12.2: huTPH2 gene-fragment created by PCR. The 1487 bp DNA fragment corresponding to the
gene for huTPH2 flanked by KpnI and XhoI sites was created by PCR, agarose gel electrophoresed and visualized
by illumination with UV-light.
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was purified and ligated into the PCR Script vector. The ligated plasmid was trans-
formed into DH5α cells to produce the strain HC1500 (huTPH2(KpnI/XhoI)-PCR
Script vector in DH5α, 100 µg/ml ampicillin resistance (100 Amp)). DNA from
this strain was analytically cleaved with the restriction enzymes KpnI and XhoI
resulting in the two expected DNA fragments, and moreover the DNA was junction
sequenced with T7/T3 primers confirming that the HC1500 vector contained the
correct huTPH2 sequence (data not shown).
The gene encoding huTPH2 was preparatively cleaved from HC1500 using
KpnI/XhoI and ligated to the pMT/V5-His A vector (internal number HC1440)
likewise cleaved with KpnI/XhoI and dephosphorylated with CIP. Preparative gels
from the cleavages are shown in figure 12.3.
5000
2000
1650
1000
huTPH2 fragment 
pMT/V5 His A vector fragment 
Figure 12.3: Insert and vector-fragments to create HC2027. Left: The 1478 bp band corresponding to
the huTPH2 gene-fragment. Right: The ∼3.5 kb band corresponding to the pMT/V5-His A vector. Both bands
were cut free, extracted from gel material and ligated together creating the plasmid for expression of huTPH2 in
D. Melanogaster S2 cells.
The ligated plasmid was transformed into DH5α cells resulting in strain HC2027
(huTPH2(KpnI/XhoI)-pMT/V5-His A in DH5α, 100 Amp resistance). DNA from
this strain was tested by analytical cleavage with KpnI/XhoI and the two expected
fragments appeared (not shown), afterwards DNA was junction sequenced using
primers MT forward and BGH reverse confirming that the insert sequence was
correct.
12.2 Construction of DβH vector for expression in S2 cells
The first step of the construction of the vector containing the gene encoding DβH
for eukaryotic expression was the removal of the internal NcoI restriction site by a
silent mutation. This was done by PCR with HC1147 (DβH(NdeI/HindIII)-pUC57
in DH5α, 100 Amp resistance) as the template and primers HCP623/HCP624 as
shown in section 10.3.2, table 10.1. The resulting 1788 bp fragment (not shown)
was purified and ligated into the PCR Script vector. The ligated plasmid was
transformed into DH5α cells to produce the strain HC1502 (DβH(NdeI/HindIII,
no internal NcoI)-PCR Script vector in DH5α, 100 Amp resistance).
Afterwards new restriction sites were introduced by another PCR reaction with
HC1502 as the template and primers HCP625/HCP626 as shown in section 10.3.2,
table 10.1. The resulting 1741 bp fragment (shown in figure 12.4) was purified and
ligated into the PCR Script vector.
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DH fragment 
2000
1650
1000
Figure 12.4: DβH fragment created by two PCR reactions. In the first step the internal NcoI restriction
site was removed whereupon new restriction sites were introduced upstream (NcoI) and downstream (XhoI) of
the gene encoding DβH resulting in the 1741 bp fragment shown here. For unknown reasons the apparent size of
the DNA does not correspond to 1741 bp, but the sequence of the fragment was later confirmed.
Transformation of the ligated plasmid into DH5α cells resulted in strain HC1849
(DβH(NcoI/XhoI)-PCR Script vector in DH5α, 100 Amp resistance). Since ana-
lytical cleavage with NcoI/XhoI resulted in the expected DNA fragments, HC1849
DNA was sequenced with T7/T3 primers and the insert sequence was confirmed
(data not shown).
HC1849 was preparatively cleaved with NcoI/XhoI and ligated to HC2027
(huTPH2(KpnI/XhoI)-pMT/V5-His A in DH5α, 100 Amp resistance) also cleaved
with NcoI/XhoI and dephosphorylated with CIP. Preparative gels from the cleav-
age are shown in figure 12.5.
The resulting plasmid was transformed into DH5α cells resulting in strain
HC1903 (DβH(NcoI/XhoI)-pMT/V5-His A in DH5α, 100 Amp resistance). DNA
from this strain was analytically cleaved with NcoI/XhoI resulting in the expected
fragments and sequenced with MT forward and BGH reverse primers. It was
thereby confirmed that HC1903 contained the correct DβH DNA sequence flanked
by NcoI and XhoI restriction sites (data not shown).
DH fragment 
5000
2000
1650
1000
pMT/V5 His A fragment
5000
2000
1650
1000
Figure 12.5: Insert and vector-fragments to create HC1903. Left: The 1741 bp band corresponding to
the DβH gene-fragment. Right: The ∼3.5 kb band corresponding to the pMT/V5-His A vector. Both bands
were cut free, extracted from gel material and ligated together creating the plasmid for expression of DβH in D.
Melanogaster S2 cells.
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12.3 Construction of BiP-TPH2 and BiP-DβH vectors for
transfection of S2 cells
Drosophila Melanogaster optimized genes for TPH2 and DβH with an upstream
BiP secretion signal (see section 10.3 and 10.3.4) were ordered from GenScript.
These plasmids were transformed into DH5α cells creating strain HC2006 (BiP-
TPH2(NcoI/XhoI)-pUC57 in DH5α, 100 Amp resistance) and strain HC2002 (BiP-
DβH(NcoI/XhoI)-pUC57 in DH5α, 100 Amp resistance).
The plasmid containing the gene for BiP-TPH2 (HC2006) was cleaved with
NcoI/XhoI and ligated to HC1903 (DβH(NcoI/XhoI)-pMT/V5-His A in DH5α,
100 Amp resistance) likewise cleaved with NcoI/XhoI and dephosphorylated with
CIP. Preparative gels from the cleavages are shown in figure 12.6. The ligated
plasmid was transformed into DH5α cells and the resulting strain HC2018 (BiP-
TPH2(NcoI/XhoI)-pMT/V5-His A in DH5α, 100 Amp resistance) was analytically
cleaved with NcoI/XhoI and the expected fragments were seen. Sequencing with
primers MT forward/BGH reverse confirmed the sequence of HC2018 (data not
shown).
BiP-TPH2 fragment 
5000
2000
1650
1000
pMT/V5 His A vector fragment 
5000
2000
1650
1000
Figure 12.6: Vector and insert to create HC2018. Left: The 1535 bp fragment corresponding to the gene
encoding BiP-TPH2. Right: The The ∼3.5 kb band corresponding to the pMT/V5-His A vector. Both bands
were cut free, extracted from gel material and ligated together creating the plasmid for expression of BiP-TPH2
in D. Melanogaster S2 cells.
BiP-DH fragment 
5000
2000
1650
1000
Figure 12.7: Insert to create HC2016. The 1799 bp fragment corresponding to the gene encoding BiP-DβH.
The band was cut free, extracted from gel material and ligated together with the pMT/V5-His A fragment shown
in figure 12.6, right. This ligation created the plasmid for expression of BiP-DβH in D. Melanogaster S2 cells.
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HC2002 DNA was cleaved with NcoI/XhoI and the fragment corresponding
to BiP-DβH was ligated to HC1903 (DβH(NcoI/XhoI)-pMT/V5-His A in DH5α,
100 Amp resistance), which was also cleaved with NcoI/XhoI and dephosphory-
lated with CIP. Figure 12.7 shows the preparative gels from these cleavages. The
ligation product was transformed into DH5α cells resulting in strain HC2016 (BiP-
DβH(NcoI/XhoI)-pMT/V5-His A in DH5α, 100 Amp resistance). DNA from this
strain was analytically cleaved with NcoI/XhoI revealing the correct sized frag-
ments and sequenced with MT forward and BGH reverse primers confirming the
correct sequence of the insert (data not shown).
12.4 Overview of prepared E. coli strains
Construction of E. coli strains containing recombinant DNA for transfection of D.
Melanogaster S2 cells with TPH2, BiP-TPH2, DβH and BiP-DβH was successfully
achieved. Table 12.2 shows an overview of the bacterial strains used/constructed
to achieve this recombinant DNA. The strains HC2027 (TPH2), HC1903 (DβH),
HC2018 (BiP-TPH2) and HC2016 (BiP-DβH) were cultured in 50 ml cultures
and DNA purified using Midiprep (see section 11.1.8). DNA concentration was
determined and the DNA was used for transient and stable transfections of S2
cells (see sections 12.5-12.6).
Table 12.2: Bacterial strains for production of recombinant DNA for transfection in S2 cells.
Bacterial strains constructed and/or used to make recombinant DNA for expression of TPH2, BiP-TPH2, DβH
and BiP-DβH in S2 cells. The strains containing DNA used for transfections are written in bold.
Number Plasmid Cell type Resistance
HC744 Ub-huTPH2(SacII/XhoI)-pET26 DH5α 100 Amp
HC1440 pMT/V5-His A DH5α 100 Amp
HC1500 huTPH2(KpnI/XhoI)-PCR Script vector DH5α 100 Amp
HC2027 huTPH2(KpnI/XhoI)-
pMT/V5-His A DH5α 100 Amp
HC1502 DβH(NdeI/HindIII, no internal NcoI)- DH5α 100 Amp
PCR Script vector
HC1849 DβH(NcoI/XhoI)-PCR Script vector DH5α 100 Amp
HC1903 DβH(NcoI/XhoI)-pMT/V5-His A DH5α 100 Amp
HC2006 BiP-TPH2 (NcoI/XhoI)-pUC57 DH5α 100 Amp
HC2018 BiP-TPH2(NcoI/XhoI)-
pMT/V5-His A DH5α 100 Amp
HC2002 BiP-DβH(NcoI/XhoI)-pUC57 DH5α 100 Amp
HC2016 BiP-DβH(NcoI/XhoI)-
pMT/V5-His A DH5α 100 Amp
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12.5 Transient transfection results
Transient transfections of S2 cells were conducted with both TPH2, BiP-TPH2,
DβH and BiP-DβH constructs. All transfections were done with 19 µg DNA
except control cells which were untransfected and uninduced. One, two, three
and four days after transfection one dish with each construct were induced with
500 µM CuSO4 and after seven days all cells were harvested, meaning that protein
expression had been induced for six, five, four and three days respectively. Both
cells and media from each condition were analysed by WB.
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Figure 12.8: Transient transfection of S2 cells
with TPH2. Lane 1 is the marker, lanes 2-3 are un-
transfected controls cells and media respectively. Lane
4 is media from cells that were induced for three days
and lanes 5-10 are cells and media from cells that were
induced for four, five or six days. TPH2 is detected in
all media samples including the control media and in
all cell fractions except the control cells.
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Figure 12.9: Transient transfection of S2 cells
with BiP-TPH2. Lane 1 is the marker, lanes 2-3
are untransfected controls cells and media respectively.
Lane 4 is media from cells that were induced for three
days and lanes 5-10 are cells and media from cells that
were induced for four, five or six days. BiP-TPH2 is
detected in all media samples including the control me-
dia.
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Figure 12.10: Transient transfection of S2 cells
with DβH. Lane 1 is the marker, lanes 2-3 are un-
transfected controls cells and media respectively. Lane
4 is media from cells that were induced for three days
and lanes 5-10 are cells and media from cells that were
induced for four, five or six days. In spite of the not
very intense bands DβH is detected in all media sam-
ples including the control media.
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Figure 12.11: Transient transfection of S2 cells
with BiP-DβH. Lane 1 is the marker, lanes 2-3
are untransfected controls cells and media respectively.
Lane 4 is media from cells that were induced for three
days and lanes 5-10 are cells and media from cells that
were induced for four, five or six days. Even though
bands are not very intense, BiP-DβH is detected in all
media samples including the control media.
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12.5 Transient transfection results
Western blots from the transient transfections are shown in figures 12.8-12.11.
Media from both TPH2, BiP-TPH2, DβH and BiP-DβH transfected cells contained
the respective protein according to the WB. This was not expected since only BiP-
TPH2 and BiP-DβH should be secreted to the media whereas TPH2 and DβH
were expected to be expressed inside the cells. Moreover media from control cells
apparently also contained protein.
Also other conditions were tried e.g. the proteins were used as negative controls
for each other such that TPH2 transfected cells were analysed for DβH expression
and vice versa, or cells were induced at different timepoints and then harvested
three days later such that all cells had been exposed to CuSO4 for the same period
of time. The results from these experiments were not different from the results
shown in figures 12.8-12.11, therefore data are not shown.
Since media from control cells apparently contained protein, serum added to
the media were suspected to interfere with WB, and fresh media with and without
serum added, serum alone and conditioned serum-containing media were therefore
analysed with WB for both TPH2 and DβH. Figure 12.12 shows that serum at
least interfered with the DβH antibody (lanes 3-5) whereas no labeling were seen
with the TPH2 antibody (lanes 7-10).
To overcome the problem with serum interference cells were adapted to the
serum free medium EX-CELL 420 (see section 11.3.4) and the cells in EX-CELL
420 were transiently transfected using the same conditions as described for cells
cultured with serum. In these experiments cells died prior to induction with CuSO4
indicating that cells was not able to withstand the transfection mix when no serum
was present (data not shown).
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Figure 12.12: Analysis of serum interference with antibodies. Lanes 1 and 6 are the markers, lanes 2
and 7 are medium without serum, lanes 3 and 8 are serum alone and lanes 4, 5, 9 and 10 are complete medium
which is fresh in lanes 4 and 9 and conditioned in lanes 5 and 10. Lanes 1-5 are labeled with an antibody against
DβH and lanes 6-10 are labeled for TPH2.
Even though transient transfections did not give an unambiguous answer if
TPH2, BiP-TPH2, DβH and BiP-DβH were expressed it was decided to carry on
with stable transfections. First of all stable transfections were already on the way
at this point of time and secondly it was not ruled out that stable transfected cells
could survive in serum free medium even though wildtype cells did not survive
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transient transfections when no serum was present.
12.6 Stable transfected cell lines
Stable transfections with TPH2, BiP-TPH2, DβH and BiP-DβH recombinant DNA
were done as described in section 11.3.2. No increase in cell death were observed
upon addition of 25 µg/ml blasticidin to the growth medium and after approxi-
mately two weeks cells were subcultured to promote expansion until the amount
of cells was high enough to freeze stocks of the stable transfected cell lines.
To ensure that the low number of dead cells was due to successful transfection
the influence of different blasticidin concentrations was tested on untransfected
cells. Already after one days incubation with blasticidin many cells were loosened
and looked unhealthy and edged compared to the control cells which were round.
Figure 12.13 shows the number of cells at each blasticidin concentration at day 0
and day 7. It is very clear that untransfected cells cannot survive in the presence
of even low blasticidin concentrations and therefore the cells surviving normal
culturing in the presence of 25 µg/ml blasticidin must be transfected.
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Figure 12.13: Untransfected S2 cells cultured with blasticidin. Control cells expanded from 3·106 to
14.4·106 cells from day 0 to day 7 whereas the presence of 8.3 µg/ml blasticidin resulted in a reduction of cell
number from 3·106 to 0.96·106 during the week and with higher blasticidin concentrations cell numbers after 7
days were even lower. Moreover the cells which were cultured in the presence of blasticidin were not viable.
Since it was observed that serum interfered with the antibodies used for WB
(see section 12.5) and transient transfection was impossible in serum free medium,
it was decided to adapt the stable transfected cell lines to the serum free medium
EX-CELL 420 and try expression of proteins at a larger scale.
12.7 Conclusion of transfections
Transient transfections were done with both TPH2, BiP-TPH2, DβH and BiP-
DβH constructs. Cells and media were tested for protein expression with western
blots but serum interfered with the antibodies used. Therefore it cannot be con-
cluded if any of the protein were expressed as a result of transient transfection.
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Moreover transient transfection of cells cultured in serum free medium was tried,
but the cells did not survive this treatment when serum was not present.
Stable transfections were successful resulting in four new cell lines: S2/TPH2,
S2/BiP-TPH2, S2/DβH and S2/BiP-DβH. These cells grew in the presence of
25 µg/ml blasticidin and after expansion of cells, stocks of all four new cell lines
were obtained.
The stable transfected lines were afterwards adapted to serum free medium
(EX-CELL 420) and stocks of S2/TPH2, S2/BiP-TPH2, S2/DβH and S2/BiP-
DβH in EX-CELL 420 were also obtained.
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13 Eukaryotic production
of TPH2 and Dβ H
- experimental
This section describes the procedure for culturing of the stable transfected S2 cell
lines in spinner cultures. Also the protocol for SDS-page used for detection of
expressed protein are included.
13.1 Transfected S2 cells in spinner cultures
In order to produce protein stable transfected S2 cells were grown in 300-400 ml
spinner cultures.
Cells were seeded in 500 ml spinner flasks at a density of 1·106 cells/ml in
300-400 ml growth medium, either EX-CELL 420 or 1:1 EX-CELL 420/cSDM
supplemented with 10 or 25 µg/ml blasticidin. Cells were incubated at 28◦C on
a heatless operating Multi-Point Stepper-Drive Stirrer at 80 rpm and allowed to
grow to a density higher than 6·106 viable cells/ml (3-4 days). When this cell
density was reached, protein production was induced by addition of CuSO4 to a
final concentration of 500 µM.
Cell densities were determined using hemocytometer counts. For counting of
total cell number 10 µl culture were mixed with 10 µl milliQ water, and for count-
ing of viable cell number 10 µl culture was mixed with 10 µl 0.4 % trypan blue
solution and incubated at room temperature for 5 minutes before counting (see
also section 11.3.3).
Culturing was continued for 9-20 days in total until cell viability was around
60 %. During culturing samples were collected on a regular basis. 1.5 ml cell
suspension was centrifuged at 416×g for 5 minutes and supernatants transferred
to new tubes. Both cell pellet and supernatants were frozen at -20◦ until testing
for expression levels (see sections 11.4.1 and 13.2.1).
Proteins were harvested by transferring cell suspensions to centrifuge tubes and
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Figure 13.14: Transfected S2 cells in spinner cultures. Two 300 ml spinner cultures on the heatless
Multi-Point Stepper-Drive Stirrer placed in the incubator.
centrifuging at 3500×g for 15 minutes at 4◦C. The resulting supernatant i.e. the
conditioned medium containing secreted proteins was transferred to 200 ml flasks
and immediately frozen at -20◦C. After some days the frozen medium was moved
to -80◦C.
Pellets were resuspended in 20 ml of cold PBS, transferred to 50 ml tubes
and centrifuged again at 3500×g for 10 minutes at 4◦C. Supernatants from this
centrifugation were discarded and pellets again resuspended in lysis buffer (50 mM
Tris pH 7.8, 150 mM NaCl, 1% Nonidet P-40). After 10 minutes incubation at
room temperature the solution was centrifuged at 3500×g for 10 minutes at 4◦C.
Supernatants were decanted and supernatants i.e. cell lysate and in some cases
pellets (insoluble fraction) were immediately frozen at -20◦C and after some days
moved to -80◦C.
13.2 Detection of proteins
In most cases western blotting (protocol in section 11.4.1) was used for analysis of
protein expression, but in some cases SDS-page, as described here, was used.
13.2.1 Sodium dodecyl sulfate polyacrylamide gel electrophoresis
For sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-page) 7.5 %
precast Tris/HCl gels from Bio-Rad were used. The marker was 0.5 µl low range
protein-standard (Bio-Rad #161-0304) mixed with 19.5 µl milliQ water and 5 µl
5X sample buffer (see table 13.3). 20 µl samples were mixed with 5 µl 5X sample
buffer and both marker and samples were heated to 80◦C for 10 min followed
by a brief centrifugation before loading in the wells. Running buffer (table 13.3)
was used in both the inner and the outer chamber. 100 V constant voltage was
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applied to the gel for around 80 min allowing the proteins to separate. The gels
were afterwards soaked in fixative solution for 30 min followed by 1 hr in staining
solution and destaining overnight (solutions are described in table 13.3).
Table 13.3: Buffers for SDS-page. Composition of the buffers used for SDS-page.
Buffer Composition
5X sample buffer 200 mM Tris/HCl pH 6.8
2 % SDS
40 % glycerol
0.04 % Coomassie G-250
Just before use 28 µl β-mercaptoethanol was added to an
aliquot of 190 µl 5X sample buffer
Running buffer 25 mM Tris base
192 mM glycine
0.1 % SDS
Fixative solution 500 ml milliQ water
400 ml 96 % ethanol
100 ml glacial acetic acid
Staining solution 900 ml milliQ water
100 ml glacial acetic acid
0.25 g Coomassie blue G-250
Destaining solution 900 ml milliQ water
100 ml glacial acetic acid
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14 Eukaryotic production
of TPH2 and Dβ H
Results from the eukaryotic production of TPH2 and DβH are presented and
briefly discussed in the following sections. Since it was decided to order new genes
with BiP secretion signal (see section 10.3) these were codon optimized for D.
melanogaster, but due to differences in expression pattern (secreted versus intra-
cellular protein) no comparisons are made between the E. coli and D. melanogaster
codon optimized genes for TPH2 and DβH, respectively.
14.1 TPH2 production in S2 cells
Since the S2/BiP-TPH2 cells should secrete TPH2 the first attempt to produce
TPH2 was done with these cells.
S2/BiP-TPH2 cells were cultured in serum free medium (see figure 14.15) and
samples from both cell lysate and medium were analysed with WB for TPH2
content. However no bands appeared on the membrane even after 10× upconcen-
tration of media samples (data not shown).
Most TPH2 is often found in the insoluble fraction when expressing in a bac-
terial system (see part II, section 8) which indicate that the cells may try to avoid
this protein or survive better without it. To compensate for an eventually negative
effect of TPH2 expression S2/BiP-TPH2 cells were therefore cultured with serum
in 1:1 EX-CELL 420/cSDM supplemented with blasticidin. During both experi-
ments the percentage of viable S2/BiP-TPH2 cells after induction was comparable
to the number of S2/BiP-DβH cells when cultured in serum free medium (compare
figure 14.15 with figure 14.19 in section 14.2).
Figures 14.16 and 14.17 shows the SDS-page and WB from the spinner culture
of S2/BiP-TPH2 supplemented with serum. The very intense bands in figure 14.16
lanes 2-4 correspond to the serum added to the medium. Bands are also seen in
the cell lysate, figure 14.16 lanes 5-7, but since no bands are seen in the WB,
figure 14.17 lanes 5-7, it was precluded that these bands correspond to TPH2.
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Figure 14.15: Growth curve for S2/BiP-TPH2 cells in spinner culture. 1·106 cells/ml were seeded in
the spinner flask and after 5 days the cell density was high enough to add 500 µM CuSO4 to induce expression
of BiP-TPH2. After this point the cell viability continued decreasing until harvest at day 20. pH of the growth
medium was only slightly lowered during the experiment.
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Figure 14.16: SDS-page for S2/BiP-TPH2 spin-
ner culture. Lane 1 is the marker, lanes 2-4 are media
from day 1, 7 and 17, lanes 5-7 are cell lysate from day
1, 7 and 17 and lanes 8-10 are the rest i.e. the insolu-
ble fraction from day 1, 7 and 17. The intense bands
in the media stem from serum, whereas the bands in
lanes 5-7 are unidentified since no bands appear in the
corresponding western blot (figure 14.17).
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Figure 14.17: WB for S2/BiP-TPH2 spinner
culture. Lane 1 is the marker, lanes 2-4 are media
from day 1, 7 and 17, lanes 5-7 are cell lysate from day
1, 7 and 17 and lanes 8-10 are the rest i.e. the insoluble
fraction from day 1, 7 and 17. No bands are detected
in any of the samples. Lane 1 is the marker, lanes 2-4
are media from day 1, 7 and 17, lanes 5-7 are cell lysate
from day 1, 7 and 17 and lanes 8-10
Since expression of secreted TPH2 did not work out, culturing of S2/TPH2 cells
in spinner cultures was tried. These cells were cultured in EX-CELL 420 medium
and WB analysis revealed that TPH2 was present in the insoluble fractions (see
figure 14.18). Moreover a band is seen in the medium sample from day 5 but at
a lower weight than TPH2 (56 kDa), this band could be a breakdown product of
TPH2, but it is only seen at day 5 (one single experiment).
These results indicate that the eukaryotic D. melanogaster system does not
stabilize TPH2 or increase its solubility. Unfortunately it is not known whether
TPH2 is found in the insoluble fractions because it is harmful to the cells or if it
is destabilized by some component of the medium.
Shin et al. (2003) reported expression and secretion of human interleukin-2
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Figure 14.18: WB from S2/TPH2 spinner culture. Lane 1 is the marker, lanes 2-5 are cell lysate from day
5, 9, 15 and 20. Lanes 6-9 are media from day 5, 9, 15 and 20 and lane 10 is the insoluble fraction/rest from day
20. A breakdown product from TPH2 is seen in the medium from day 5 and TPH2 is detected in the insoluble
fraction from day 20.
with a green fluorescent partner in S2 cells. A similar experimental design could
be helpful for TPH2 or even better with a green fluorescent folding reporter like
the ones used in E. coli (Pe´delacq et al., 2006; Waldo et al., 1999).
14.2 DβH production in S2 cells
DβH was only produced from the S2/BiP-DβH cell line in spinner cultures. These
cells were cultured in serum free EX-CELL 420 medium (figure 14.19). The cell
density was highest when inducing with CuSO4 and hereafter decreasing until
harvest at day 20. This is probably a combination of the presence of CuSO4 and
the fact that decreasing amounts of nutrients are available with incubation time.
The same tendency was also seen by Lim et al. (2004), Kim et al. (2005) and
by Valle et al. (2001) when inducing at higher cell densities, but when inducing at
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Figure 14.19: Growth curve for S2/BiP-DβH cells in spinner culture. 1·106 cells/ml were seeded in
the spinner flask and after 5 days the cell density was high enough to add 500 µM CuSO4 to induce expression
of BiP-DβH. After this point cell viability continued decreasing until harvest at day 20. pH of the medium was
only slightly lowered during the experiment.
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a similar cell density their cell density increased for some days before a decrease
was observed. Moreover the maximum cell density obtained in this study was low
compared to the 1·108 cells/ml reached by Li et al. (1996), on the other hand they
used a constitutively expressing cell line which was grown in a bioreactor with
nutrient feed.
Samples from both cell lysate and medium were analysed with WB for DβH
content showing that DβH was present both in the lysate and in media samples
(shown in figures 14.20 and 14.21, respectively), and most of it was secreted to
the medium as expected. Cells were induced with CuSO4 at day 3 where the DβH
production becomes markedly higher compared to day 2. Moreover the amount
of DβH in the medium becomes higher with incubation time. Attempts were
done to determine DβH concentration in the media at harvest using UV/visible
spectrophotometry, this were unfortunately not possible due to a high background
around 280 nm.
The same high secretion efficiencies were also reported by Kim et al. (2005)
and Shin et al. (2003), who expressed other human proteins in S2 cells using the
BiP secretion signal.
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Figure 14.20: WB for cell lysates of S2/BiP-
DβH spinner culture. Lane 1 is the marker and
lanes 2-10 are cell lysates from day 1-9 respectively.
DβH is detected in low amounts from day 2 to day 9,
but approximately the same amount all days.Lane 1
is the marker, lanes 2-10 are cell lysates from day 1-9
respectively. DβH is detected in low amounts
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Figure 14.21: WB for media samples of S2/BiP-
DβH spinner culture. Lane 1 is the marker and
lanes 2-10 are media samples from day 1-9 respectively.
DβH is detected in increasing amounts every day from
day 2 to day 9. Cells were induced with CuSO4 at day
3 which is seen as a markedly higher band intensity at
day 3 compared to day 2.
Because of the fine DβH production in S2/BiP-DβH cells the S2/DβH cell
line was not analysed for DβH production. Since cell viabilities were around 60 %
after 20 days (see figure 14.19), it was decided to grow S2/BiP-DβH cells in spinner
cultures for 20 days compared to the 9 days experiment shown in figures 14.20-
14.21 and use the DβH produced for purification experiments as described in the
chapters 15-16.
14.3 Conclusion
No expression of TPH2 was detected with the S2/BiP-TPH2 cell line. Instead
tryptophan hydroxylase 2 was expressed in S2/TPH2 cells but was found in the
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insoluble fraction. Due to time limitation no attempts were done to solubilise the
protein.
Dopamine β-hydroxylase was successfully expressed in S2/BiP-DβH cells and
was efficiently secreted to the growth medium in increasing amounts with incu-
bation time. DβH containing medium was recovered after 20 days and used for
purification.
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15 Protocols for purification
and characterisation of
eukaryotic produced Dβ H
In the following sections the strategy for purification of eukaryotic produced DβH
is described. This strategy includes deglycosylation of DβH in preparation for
crystallization attempts and separation of DβH from the deglycosylation enzyme.
Moreover crystallization screens for deglycosylated DβH and mass spectrometry
analysis of the glycosylated protein are outlined.
All protein purifications were performed on an A¨KTA Purifier 100 High Perfor-
mance Liquid Chromatography (HPLC) system using columns from GE Health-
care.
15.1 Strategy for purification of DβH produced in S2 cells
The purification protocol for DβH is an extension of the strategy presented by Li
et al. (1996).
Dopamine β-hydroxylase was purified in two or three steps dependent if the pro-
tein was deglycosylated or not. First step was cation exchange on a RESOURCE S,
6 ml column. The fractions containing DβH was collected, pooled and upconcen-
trated whereupon the proteins in the concentrate were separated using gel filtration
on a Superdex 200 column. Glycosylated DβH was recovered after the gel filtration
and concentrated. This concentrate was either saved for further analysis or degly-
cosylated followed by another cation exchange on a RESOURCE S, 6 ml column.
After this purification step deglycosylated DβH was recovered.
During the purification samples for analysis with SDS-page and/or western
blotting were collected and frozen at -20◦C.
The buffers used for the different steps of the purification are shown in
table 15.4.
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Table 15.4: Buffers for purification of DβH. The buffers used for cation exchange and gel filtration of DβH.
The same buffers were used for both the first cation exchange and the cation exchange of deglycosylated DβH.
Buffer A Buffer B
Cation exchange 20 mM 20 mM
CH3COONa/CH3COOH, CH3COONa/CH3COOH
pH 5.6 + 1 M NaCl, pH 5.6
Gel filtration 0.1 M
CH3COONH4/CH3COOH,
pH 5.6
15.2 Purification of glycosylated DβH
The medium collected from S2/BiP-DβH spinner cultures was thawed overnight
at +4◦C. pH of the medium was adjusted to pH 5.6 with diluted acetic acid and
the medium was filtered through 0.45 µm GHP Acrodisc GF syringe filters from
Pall. The filtered solution was then diluted with 20 mM CH3COONa/CH3COOH,
pH 5.6 until the conductivity of the diluted solution was below 6.5 mS/cm.
In preliminary purifications the diluted solution was loaded on an SP Sepharose
HP 16/10 column equilibrated with 20 mM CH3COONa/CH3COOH, pH 5.6. Pro-
teins were eluted with a two step gradient: A linear gradient of 0-50 % buffer B
(0-0.5 M NaCl) over 10 column volumes (CV) followed by a linear gradient from
50-100 % buffer B over 3 CV.
Further investigations revealed that the diluted solution could be loaded with
a P960 pump at 18 ml/min on a RESOURCE S, 6 ml column equilibrated with
20 mM CH3COONa/CH3COOH, pH 5.6, and that the gradient rather should be
in three steps: 0 % buffer B isocratic over 1 CV, 0-20 % buffer B (0-0.2 M NaCl)
linear over 9 CV and 20-100 % buffer B (0.2-1 M NaCl) linear over 2 CV.
Fractions with conductivity 4-16 mS/cm were collected taking care to avoid
the following peak containing a D. Melanogaster protein of the same size as DβH
(see section 16.2).
The pooled fractions were concentrated to approximately 2 ml using a Vi-
vacell 70 with 30,000 molecular weight cut off (MWCO) polyethersulfone (PES)
membrane and afterwards loaded on a Superdex 200 26/60 column equilibrated
with 0.1 M CH3COONH4/CH3COOH, pH 5.6. Proteins in the concentrate were
separated according to size and eluted in five peaks of which DβH was present
in the peaks around KAV∼0.17 (peak 2) and KAV∼0.29 (peak 3). DβH in these
peaks was concentrated using a Vivacell 70 with 30,000 MWCO PES membrane
to approximately 2 ml and further concentrated with Amicon Ultra-0.5 3K 3,000
nominal molecular weight limit (NMWL) Milipore Ultracel low binding regener-
ated cellulose membrane.
The approximate molecular weight of the proteins eluting in the gel filtration
was determined from the calibration curve of the Superdex 200 26/60 column
which have been determined in the Metalloprotein Chemistry and Engineering
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Group (Haahr, 2008). According to this curve the molecular weight can be deter-
mined from the gel phase distribution coefficient KAV using the following equation:
KAV = −0.323 · log(MW) + 1.928
where MW is the molecular weight in Da and KAV is defined from the elution
volume (V e), the column void volume (V 0) and the geometric column volume
(V c) (GE Healthcare, 2006):
KAV =
Ve − V0
Vc − V0
Protein concentration was determined using UV/visible spectrophotometry at
280 nm with DβH,280nm=82,125 M
−1cm−1, assuming all Cys are involved in disul-
fide bridges (Gasteiger et al., 2003).
In some cases DβH from peak 2 was afterwards deglycosylated as described in
section 15.3.
15.3 Deglycosylation of DβH
Deglycosylation was performed either in small scale to test if DβH was glycosylated
at all or in larger scale to deglycosylate DβH during purification. The PNGase F
kit from New England Biolabs (# P0705S) was used for the deglycosylations.
Small scale deglycosylations were performed both with and without denaturing
conditions:
Denaturing conditions Non-denaturing conditions
Mixing of: Mixing of:
1 µl DβH concentrate 1 µl DβH concentrate
8 µl milliQ 9 µl milliQ
1 µl 10X denaturing buffer
Incubate 10 min at 100◦C, mix Incubate 12 min at room temperature
Incubate 2 min at room temperature
Addition of: Addition of:
2 µl 10X G7 reaction buffer 2 µl 10X G7 reaction buffer
2 µl 10 % NP40 6 µl milliQ
4 µl milliQ 2 µl PNGase F
2 µl PNGase F
All samples were incubated 1 hr at 37◦C and afterwards kept at -20◦C un-
til analysed by western blotting. For comparison a control sample of 1 µl DβH
concentrate mixed with 19 µl milliQ was also analysed.
During purifications DβH was deglycosylated in larger scale using non-denatu-
ring conditions.
100 µl DβH concentrate was mixed with 20 µl 10X G7 reaction buffer, 65 µl
milliQ and 15 µl PNGase F and mixed. The mixture was incubated 1 hr at 37◦C.
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A sample of 2 µl deglycosylated DβH was mixed with 38 µl milliQ and kept for
WB analysis. DβH in the remaining mixture was separated from PNGase F using
cation exchange as described in section 15.4.
15.4 Separation of DβH from deglycosylation enzyme
To separate DβH from PNGase F a cation exchange similar to the first step was
performed.
The 200 µl mixture from deglycosylation was diluted with 800 µl 20 mM
CH3COONa/CH3COOH, pH 5.6 to ensure that the conductivity was below
6.5 mS/cm.
The diluted solution was loaded at 2.5 ml/min with a P960 pump on a RE-
SOURCE S, 6 ml column equilibrated with 20 mM CH3COONa/CH3COOH,
pH 5.6. Proteins were eluted with a gradient in three steps: 0 % buffer B iso-
cratic over 1 CV, 0-20 % buffer B (0-0.2 M NaCl) linear over 9 CV and 20-100 %
buffer B (0.2-1 M NaCl) linear over 2 CV.
Afterwards fractions with conductivity 10-17 mS/cm were collected, pooled
and concentrated using a Vivacell 70 with 30,000 MWCO PES membrane until
approximately 2 ml and further concentrated with Amicon Ultra-0.5 3K 3,000
NMWL Milipore Ultracel low binding regenerated cellulose membrane.
Protein concentration were determined spectrophotometrically at 280 nm using
DβH,280nm=82,125 M
−1cm−1, assuming all Cys are involved in disulfidebridges
(Gasteiger et al., 2003).
15.5 Crystallization screens
Crystallization screens were set up at the Max-lab Crystallization Facility at
Lund University, Sweden. JCSG+ and PACT Premier screens (Molecular Di-
mensions) were set up in 96-well plates using the program MRC 1 well for the
Mosquito robot (TTP Labtech, UK). Both screens were set up at 4◦C and for
the JCSG+ screen (see table 15.5) drops were combined from 100 nl deglycosy-
lated DβH (∼0.8 mg/ml) and 100 nl of the reservoir solution. For the PACT
Premier screen (see table 15.6) drops were combined from 100 nl deglycosylated
DβH (∼0.9 mg/ml) and 50 nl of the reservoir solution.
15.6 Mass spectrometry
Mass spectrometric analysis was performed using a LCT Premier mass spectrom-
eter (Waters) with a nanoflow electrospray ionization source and a time-of-flight
analyser operating in V mode. Au/Pd coated borosilicate glass capillary tips
(Proxeon #ES-380) were used. Spectra were recorded in positive ion mode using
a source temperature of 30◦C, sample cone voltage of 50 V, capillary voltage of
1500-1700 V and ion guide voltage of 80-120 V.
The protein samples of 12.5 µM were sprayed from either 0.55 M or 1 M am-
monium acetate.
The data was processed using the MassLynx v4.1 software. The obtained m/z
(mass-to-charge ratio) spectrum was smoothed, background subtracted and cen-
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tered. Charge states were assigned and the protein masses calculated using the
component analysis algorithm.
Samples from peak 2 and peak 3 of the gel filtration (glycosylated DβH, see
section 16.4, figure 16.32B) were analysed.
Table 15.5: JCSG+ 96 well crystallization screen. Contents of the JCSG+ crystallization screen from
Molecular Dimensions. Abbreviations: bis-tris; bis-(2-hydroxyethyl)imino-tris(hydroxymethyl)methane, CAPS;
N-cyclohexyl-3-aminopropanesulfonic acid, CHES; 2-(N-cyclohexylamino)ethane sulfonic acid, HEPES; 2-(4-(2-
hydroxyethyl)-1-piperazinyl)ethanesulfonic acid, Na HEPES; 2-(4-(2-hydroxyethyl)-1-piperazinyl)ethanesulfonic
acid sodium salt, MES; 2-(N-morpholino)ethanesulfonic acid, MPD; 2,4-methyl pentanediol, PEG; polyethylene
glycol (2K, 6K , 8K and 10K correspond to the molecular weight, in thousands of Da, of PEG), tris; 2-Amino-2-
(hydroxymethyl)propane-1,3-diol.
Well Salt Buffer pH Precipitant
A1 0.2 M lithium sulfate 0.1 M sodium acetate 4.5 50 % v/v PEG 400
A2 None 0.1 M citrate 5.5 20 % w/v PEG 3K
A3 0.2 M di-ammonium None - 20 % w/v PEG 3350
hydrogen citrate
A4 0.02 M calcium chloride 0.1 M sodium acetate 4.6 30 % v/v MPD
A5 0.2 M magnesium formate None - 20 % w/v PEG 3350
A6 0.2 M lithium sulfate 0.1 M phosphate/citrate 4.2 20 % w/v PEG 1K
A7 None 0.1 M CHES 9.5 20 % w/v PEG 8K
A8 0.2 M ammonium formate None - 20 % w/v PEG 3350
A9 0.2 M ammonium chloride None - 20 % w/v PEG 3350
A10 0.2 M potassium formate None - 20 % w/v PEG 3350
A11 0.2 M ammonium 0.1 M tris 8.5 50 % v/v MPD
dihydrogen phosphate
A12 0.2 M potassium nitrate None - 20 % w/v PEG 3350
B1 None 0.1 M Na citrate 4.0 0.8 M ammonium sulfate
B2 0.2 M sodium thiocyanate None - 20 % w/v PEG 3350
B3 None 0.1 M bicine 9.0 20 % w/v PEG 6K
B4 None 0.1 M HEPES 7.5 10 % w/v PEG 8K/
8 % v/v ethylene glycol
B5 None 0.1 M sodium cacodylate 6.5 40 % v/v MPD
5 % w/v PEG 8000
B6 None 0.1 M phosphate/citrate 4.2 40 % v/v ethanol
5 % w/v PEG 1000
B7 None 0.1 M sodium acetate 4.6 8 % w/v PEG 4K
B8 0.2 M magnesium chloride 0.1 M Tris 7.0 10 % w/v PEG 8K
B9 None 0.1 M Na citrate 5.0 20 % w/v PEG 6K
B10 0.2 M magnesium chloride 0.1 M sodium cacodylate 6.5 50 % v/v PEG 200
B11 None None 6.5 1.6 M tri-sodium citrate
B12 0.2 M tri-potassium citrate None - 20 % w/v PEG 3350
C1 0.2 M sodium chloride 0.1 M phosphate/citrate 4.2 20 % w/v PEG 8K
C2 1.0 M lithium chloride 0.1 M Na citrate 4.0 20 % w/v PEG 6K
C3 0.2 M ammonium nitrate None - 20 % w/v PEG 3350
C4 None 0.1 M HEPES 7.0 10 % w/v PEG 6K
C5 None 0.1 M Na HEPES 7.5 0.8 M NaH2PO4
0.8 M KH2PO4
C6 None 0.1 M phosphate/citrate 4.2 40 % v/v PEG 300
C7 0.2 M zinc acetate 0.1 M sodium acetate 4.5 10 % w/v PEG 3K
C8 None 0.1 M tris 8.5 20 % v/v ethanol
C9 None 0.1 M Na/K phosphate 6.2 25 % v/v 1,2-propanediol
10 % v/v glycerol
C10 None 0.1 M bicine 9.0 10 % w/v PEG 20,000
2 % v/v dioxane
C11 None 0.1 M sodium acetate 4.6 2.0 M ammonium sulfate
C12 None None - 10 % w/v PEG 1000
10 % w/v PEG 8000
D1 None None - 24 % w/v PEG 1500
20 % v/v glycerol
D2 0.2 M magnesium chloride 0.1 M Na HEPES 7.5 30 % v/v PEG 400
D3 0.2 M sodium chloride 0.1 M Na/K phosphate 6.2 50 % v/v PEG 200
D4 0.2 M lithium sulfate 0.1 M sodium acetate 4.5 30 % w/v PEG 8K
D5 None 0.1 M HEPES 7.5 70 % v/v MPD
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Well Salt Buffer pH Precipitant
D6 0.2 M magnesium chloride 0.1 M tris 8.5 20 % w/v PEG 8K
D7 0.2 M lithium sulfate 0.1 M tris 8.5 40 % v/v PEG 400
D8 None 0.1 M tris 8.0 40 % v/v MPD
D9 0.17 M ammonium sulfate None - 25.5 % w/v PEG 4K
15 % v/v glycerol
D10 0.2 M calcium acetate 0.1 M sodium cacodylate 6.5 40 % v/v PEG 300
D11 0.14 M calcium chloride 0.07 M sodium acetate 4.6 14 % v/v 2-propanol
30 % v/v glycerol
D12 0.04 M potassium None - 16 % w/v PEG 8K
dihydrogen phosphate 20 % v/v glycerol
E1 None 0.1 M sodium cacodylate 6.5 1.0 M tri-sodium citrate
E2 0.2 M sodium chloride 0.1 M sodium cacodylate 6.5 2.0 M ammonium sulfate
E3 0.2 M sodium chloride 0.1 M HEPES 7.5 10 % v/v 2-propanol
E4 0.2 M lithium sulfate 0.1 M tris 8.5 1.26 M ammonium sulfate
E5 None 0.1 M CAPS 10.5 40 % v/v MPD
E6 0.2 M zinc acetate 0.1 M imidazole 8.0 20 % w/v PEG 3K
E7 0.2 M zinc acetate 0.1 M sodium cacodylate 6.5 10 % v/v 2-propanol
E8 None 0.1 M sodium acetate 4.5 1.0 M di-ammonium
hydrogen phosphate
E9 None 0.1 M MES 6.5 1.6 M magnesium sulfate
E10 None 0.1 M bicine 9.0 10 % w/v PEG 6K
E11 0.16 M calcium acetate 0.08 M sodium cacodylate 6.5 14.4 % w/v PEG 8K
20 % v/v glycerol
E12 None 0.1 M imidazole 8.0 10 % w/v PEG 8K
F1 0.05 M caesium chloride 0.1 M MES 6.5 30 % v/v jeffamine M-600
F2 None 0.1 M Na Citrate 5.0 3.2 M ammonium sulfate
F3 None 0.1 M tris 8.0 20 % v/v MPD
F4 None 0.1 M HEPES 7.5 20 % v/v jeffamine M-600
F5 0.2 M magnesium chloride 0.1 M tris 8.5 50 % v/v ethylene glycol
F6 None 0.1 M bicine 9.0 10 % v/v MPD
F7 None None 7.0 0.8 M succinic acid
F8 None None 7.0 2.1 M DL-malic acid
F9 None None 7.0 2.4 M sodium malonate
F10 1.1 M sodium malonate 0.1 M HEPES 7.0 0.5 % v/v jeffamine
ED-2001
F11 1.0 M succinic acid 0.1 M HEPES 7.0 1 % w/v PEG 2000 MME
F12 None 0.1 M HEPES 7.0 30 % v/v jeffamine M-600
G1 None 0.1 M HEPES 7.0 30 % v/v jeffamine ED-2001
G2 0.02 M magnesium chloride 0.1 M HEPES 7.5 22 % w/v polyacrylic acid
5100 sodium salt
G3 0.01 M cobalt chloride 0.1 M tris 8.5 20 % w/v polyvinyl-
pyrrolidone K15
G4 0.2 M tri-methylamine 0.1 M tris 8.5 20 % w/v PEG 2K MME
N-oxide
G5 0.005 M cobalt chloride 0.1 M HEPES 7.5 12 % w/v PEG 3350
0.005 M cadmium chloride
0.005 M magnesium chloride
0.005 M nickel chloride
G6 0.2 M sodium malonate None 7.0 20 % w/v PEG 3350
G7 0.1 M succinic acid None 7.0 15 % w/v PEG 3350
G8 0.15 M DL-malic acid None 7.0 20 % w/v PEG 3350
G9 0.1 M potassium thiocyanate None - 30 % w/v PEG 2K MME
G10 0.15 M potassium bromide None - 30 % w/v PEG 2K MME
G11 None 0.1 M bis-tris 5.5 2.0 M ammonium sulfate
G12 None 0.1 M bis-tris 5.5 3.0 M sodium chloride
H1 None 0.1 M bis-tris 5.5 0.3 M magnesium formate
H2 1.0 M ammonium sulfate 0.1 M bis-tris 5.5 1 % w/v PEG 3350
H3 None 0.1 M bis-tris 5.5 25 % w/v PEG 3350
H4 0.2 M calcium chloride 0.1 M bis-tris 5.5 45 % v/v MPD
H5 0.2 M ammonium acetate 0.1 M bis-tris 5.5 45 % v/v MPD
H6 0.1 M ammonium acetate 0.1 M bis-tris 5.5 17 % w/v PEG 10K
H7 0.2 M ammonium sulfate 0.1 M bis-tris 5.5 25 % w/v PEG 3350
H8 0.2 M sodium chloride 0.1 M bis-tris 5.5 25 % w/v PEG 3350
H9 0.2 M lithium sulfate 0.1 M bis-tris 5.5 25 % w/v PEG 3350
H10 0.2 M ammonium acetate 0.1 M bis-tris 5.5 25 % w/v PEG 3350
H11 0.2 M magnesium chloride 0.1 M bis-tris 5.5 25 % w/v PEG 3350
H12 0.2 M ammonium acetate 0.1 M HEPES 7.5 45 % v/v MPD
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Table 15.6: PACT Premier 96 well crystallization screen. Contents of the PACT Premier crys-
tallization screen from Molecular Dimensions. Abbreviations: HEPES; N-(2-hydroxyethyl)-piperazine-N’-2-
ethanesulfonic acid, MES; 2-(N-morpholino)ethanesulfonic acid, PEG; polyethylene glycol, tris; 2-Amino-2-
(hydroxymethyl)propane-1,3-diol, SPG buffer; succinic acid, phosphate, glycine, MIB buffer; malonic acid, im-
idazole, boric acid, PCTP buffer; propionic acid, cacodylate, bis-tris propane, MMT buffer; malic acid, MES,
tris.
Well Buffer/Salt Buffer/Salt pH Precipitant
A1 0.1 M SPG buffer None 4.0 25 % w/v PEG 1500
A2 0.1 M SPG buffer None 5.0 25 % w/v PEG 1500
A3 0.1 M SPG buffer None 6.0 25 % w/v PEG 1500
A4 0.1 M SPG buffer None 7.0 25 % w/v PEG 1500
A5 0.1 M SPG buffer None 8.0 25 % w/v PEG 1500
A6 0.1 M SPG buffer None 9.0 25 % w/v PEG 1500
A7 0.2 M sodium chloride 0.1 M sodium acetate 5.0 20 % w/v PEG 6000
A8 0.2 M ammonium chloride 0.1 M sodium acetate 5.0 20 % w/v PEG 6000
A9 0.2 M lithium chloride 0.1 M sodium acetate 5.0 20 % w/v PEG 6000
A10 0.2 M magnesium chloride 0.1 M sodium acetate 5.0 20 % w/v PEG 6000
A11 0.2 M calcium chloride 0.1 M sodium acetate 5.0 20 % w/v PEG 6000
A12 0.01 M zinc chloride 0.1 M sodium acetate 5.0 20 % w/v PEG 6000
B1 0.1 M MIB buffer None 4.0 25 % w/v PEG 1500
B2 0.1 M MIB buffer None 5.0 25 % w/v PEG 1500
B3 0.1 M MIB buffer None 6.0 25 % w/v PEG 1500
B4 0.1 M MIB buffer None 7.0 25 % w/v PEG 1500
B5 0.1 M MIB buffer None 8.0 25 % w/v PEG 1500
B6 0.1 M MIB buffer None 9.0 25 % w/v PEG 1500
B7 0.2 M sodium chloride 0.1 M MES 6.0 20 % w/v PEG 6000
B8 0.2 M ammonium chloride 0.1 M MES 6.0 20 % w/v PEG 6000
B9 0.2 M lithium chloride 0.1 M MES 6.0 20 % w/v PEG 6000
B10 0.2 M magnesium chloride 0.1 M MES 6.0 20 % w/v PEG 6000
B11 0.2 M calcium chloride 0.1 M MES 6.0 20 % w/v PEG 6000
B12 0.01 M zinc chloride 0.1 M MES 6.0 20 % w/v PEG 6000
C1 0.1 M PCTP buffer None 4.0 25 % w/v PEG 1500
C2 0.1 M PCTP buffer None 5.0 25 % w/v PEG 1500
C3 0.1 M PCTP buffer None 6.0 25 % w/v PEG 1500
C4 0.1 M PCTP buffer None 7.0 25 % w/v PEG 1500
C5 0.1 M PCTP buffer None 8.0 25 % w/v PEG 1500
C6 0.1 M PCTP buffer None 9.0 25 % w/v PEG 1500
C7 0.2 M sodium chloride 0.1 M HEPES 7.0 20 % w/v PEG 6000
C8 0.2 M ammonium chloride 0.1 M HEPES 7.0 20 % w/v PEG 6000
C9 0.2 M lithium chloride 0.1 M HEPES 7.0 20 % w/v PEG 6000
C10 0.2 M magnesium chloride 0.1 M HEPES 7.0 20 % w/v PEG 6000
C11 0.2 M calcium chloride 0.1 M HEPES 7.0 20 % w/v PEG 6000
C12 0.01 M zinc chloride 0.1 M HEPES 7.0 20 % w/v PEG 6000
D1 0.1 M MMT buffer None 4.0 25 % w/v PEG 1500
D2 0.1 M MMT buffer None 5.0 25 % w/v PEG 1500
D3 0.1 M MMT buffer None 6.0 25 % w/v PEG 1500
D4 0.1 M MMT buffer None 7.0 25 % w/v PEG 1500
D5 0.1 M MMT buffer None 8.0 25 % w/v PEG 1500
D6 0.1 M MMT buffer None 9.0 25 % w/v PEG 1500
D7 0.2 M sodium chloride 0.1 M tris 8.0 20 % w/v PEG 6000
D8 0.2 M ammonium chloride 0.1 M tris 8.0 20 % w/v PEG 6000
D9 0.2 M lithium chloride 0.1 M tris 8.0 20 % w/v PEG 6000
D10 0.2 M magnesium chloride 0.1 M tris 8.0 20 % w/v PEG 6000
D11 0.2 M calcium chloride 0.1 M tris 8.0 20 % w/v PEG 6000
D12 0.002 M zinc chloride 0.1 M tris 8.0 20 % w/v PEG 6000
E1 0.2 M sodium fluoride None - 20 % w/v PEG 3350
E2 0.2 M sodium bromide None - 20 % w/v PEG 3350
E3 0.2 M sodium iodide None - 20 % w/v PEG 3350
E4 0.2 M potassium thiocyanate None - 20 % w/v PEG 3350
E5 0.2 M sodium nitrate None - 20 % w/v PEG 3350
E6 0.2 M sodium formate None - 20 % w/v PEG 3350
E7 0.2 M sodium acetate None - 20 % w/v PEG 3350
E8 0.2 M sodium sulfate None - 20 % w/v PEG 3350
E9 0.2 M potassium/ None - 20 % w/v PEG 3350
sodium tartrate
E10 0.02 M sodium/ None - 20 % w/v PEG 3350
potassium phosphate
E11 0.2 M sodium citrate None - 20 % w/v PEG 3350
E12 0.2 M sodium malonate None - 20 % w/v PEG 3350
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Well Salt Buffer pH Precipitant
F1 0.2 M sodium fluoride 0.1 M bis-tris propane 6.5 20 % w/v PEG 3350
F2 0.2 M sodium bromide 0.1 M bis-tris propane 6.5 20 % w/v PEG 3350
F3 0.2 M sodium iodide 0.1 M bis-tris propane 6.5 20 % w/v PEG 3350
F4 0.2 M potassium thiocyanate 0.1 M bis-tris propane 6.5 20 % w/v PEG 3350
F5 0.2 M sodium nitrate 0.1 M bis-tris propane 6.5 20 % w/v PEG 3350
F6 0.2 M sodium formate 0.1 M bis-tris propane 6.5 20 % w/v PEG 3350
F7 0.2 M sodium acetate 0.1 M bis-tris propane 6.5 20 % w/v PEG 3350
F8 0.2 M sodium sulfate 0.1 M bis-tris propane 6.5 20 % w/v PEG 3350
F9 0.2 M potassium/ 0.1 M bis-tris propane 6.5 20 % w/v PEG 3350
sodium tartrate
F10 0.02 M sodium/ 0.1 M bis-tris propane 6.5 20 % w/v PEG 3350
potassium phosphate
F11 0.2 M sodium citrate 0.1 M bis-tris propane 6.5 20 % w/v PEG 3350
F12 0.2 M sodium malonate 0.1 M bis-tris propane 6.5 20 % w/v PEG 3350
G1 0.2 M sodium fluoride 0.1 M bis-tris propane 7.5 20 % w/v PEG 3350
G2 0.2 M sodium bromide 0.1 M bis-tris propane 7.5 20 % w/v PEG 3350
G3 0.2 M sodium iodide 0.1 M bis-tris propane 7.5 20 % w/v PEG 3350
G4 0.2 M potassium thiocyanate 0.1 M bis-tris propane 7.5 20 % w/v PEG 3350
G5 0.2 M sodium nitrate 0.1 M bis-tris propane 7.5 20 % w/v PEG 3350
G6 0.2 M sodium formate 0.1 M bis-tris propane 7.5 20 % w/v PEG 3350
G7 0.2 M sodium acetate 0.1 M bis-tris propane 7.5 20 % w/v PEG 3350
G8 0.2 M sodium sulfate 0.1 M bis-tris propane 7.5 20 % w/v PEG 3350
G9 0.2 M potassium/ 0.1 M bis-tris propane 7.5 20 % w/v PEG 3350
sodium tartrate
G10 0.02 M sodium/ 0.1 M bis-tris propane 7.5 20 % w/v PEG 3350
potassium phosphate
G11 0.2 M sodium citrate 0.1 M bis-tris propane 7.5 20 % w/v PEG 3350
G12 0.2 M sodium malonate 0.1 M bis-tris propane 7.5 20 % w/v PEG 3350
H1 0.2 M sodium fluoride 0.1 M bis-tris propane 8.5 20 % w/v PEG 3350
H2 0.2 M sodium bromide 0.1 M bis-tris propane 8.5 20 % w/v PEG 3350
H3 0.2 M sodium iodide 0.1 M bis-tris propane 8.5 20 % w/v PEG 3350
H4 0.2 M potassium thiocyanate 0.1 M bis-tris propane 8.5 20 % w/v PEG 3350
H5 0.2 M sodium nitrate 0.1 M bis-tris propane 8.5 20 % w/v PEG 3350
H6 0.2 M sodium formate 0.1 M bis-tris propane 8.5 20 % w/v PEG 3350
H7 0.2 M sodium acetate 0.1 M bis-tris propane 8.5 20 % w/v PEG 3350
H8 0.2 M sodium sulfate 0.1 M bis-tris propane 8.5 20 % w/v PEG 3350
H9 0.2 M potassium/ 0.1 M bis-tris propane 8.5 20 % w/v PEG 3350
sodium tartrate
H10 0.02 M sodium/ 0.1 M bis-tris propane 8.5 20 % w/v PEG 3350
potassium phosphate
H11 0.2 M sodium citrate 0.1 M bis-tris propane 8.5 20 % w/v PEG 3350
H12 0.2 M sodium malonate 0.1 M bis-tris propane 8.5 20 % w/v PEG 3350
128
16 Purification and
characterisation of
eukaryotic expressed DβH
In the following sections results from the purification of DβH are presented and
discussed. Also results from deglycosylations are presented and discussed followed
by a conclusion of the purifications and deglycosylations.
16.1 Preliminary purification of DβH
Preliminary purifications of dopamine β-hydroxylase were performed on a SP
Sepharose HP 16/10 cation exchange column with the buffers 20 mM CH3COONa/
CH3COOH, pH 5.6 and 20 mM CH3COONa/CH3COOH + 1 M NaCl, pH 5.6. Pro-
teins were eluted with a linear gradient of 0-50 % buffer B over 10 CV followed by
a linear gradient from 50-100 % buffer B over 3 CV. A chromatogram is showed
in figure 16.22.
As the chromatogram shows, the highest absorbances are seen in the flow-
through fractions (0-245 ml) and in addition four small peaks are seen at conduc-
tivities 14.7 mS/cm, 16.7 mS/cm, 28.5 mS/cm and 49.8 mS/cm. To clarify where
DβH elutes all fractions were collected. Fractions corresponding to the flowthrough
and the peaks respectively were pooled and the remaining fractions were pooled in
portions of approximately eight subsequent fractions. Figure 16.23 shows the WB
analysis of the fractions from the cation exchange in figure 16.22. WB revealed
that DβH elutes in the fractions 51-88 (7.5-29.6 mS/cm) which does not correspond
to any of the peaks in the chromatogram. The elution range is probably so broad
because several forms of DβH are present, these could be different multimers of
DβH for instance dimers and tetramers (section 3.4.1), it could be DβH with Cu(I)
or Cu(II) in the active site or the apoprotein (sections 3.2 and 3.5.2), moreover
variants with different glycosylation patterns could be present (section 3.2).
Fractions 51-88 were pooled, concentrated ∼25 times in a Vivacell 70 and di-
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 Cond  Conc  UV1_280nm (2)
  0
 20
 40
 60
 80
100
120
mAU
0.0
20.0
40.0
60.0
80.0
mS/cm
  0
 20
 40
 60
 80
%B
  0 100 200 300 400 500 ml
Fraction 66 
14.7 mS/cm 
Fraction 70 
16.7 mS/cm 
Fraction 100 
30.5 mS/cm 
Fraction 135 
49.8 mS/cm 
Figure 16.22: Cation exchange chromatogram from the preliminary purification of DβH. In prelimi-
nary experiments DβH was purified on a SP Sepharose HP 16/10 cation exchange column with the buffers 20 mM
CH3COONa/CH3COOH, pH 5.6 and 20 mM CH3COONa/CH3COOH + 1 M NaCl, pH 5.6. Four small peaks
are seen in the chromatogram.
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Figure 16.23: WB from preliminary cation exchange of DβH. Left membrane: Lane 1 is the marker,
lane 2 is the sample loaded on the column, lane 3 is the flowthrough fractions 3-26 and lanes 4-10 are samples
from fractions 27-34, fractions 35-42, fractions 43-50, fractions 51-58, fractions 59-64, fractions 65-66 and fractions
67-69 respectively. Right membrane: Lane 1 is the marker and lanes 2-10 are samples from fraction 70, fractions
71-79, fractions 80-88, fractions 89-97, fractions 98-106, fractions 107-115, fractions 116-124, fractions 125-132
and fractions 133-137 respectively. Together the two membranes show that DβH elutes in the fractions 51-88.
luted 1:1 with 0.1 M CH3COONH4/CH3COOH pH 5.6 prior t loading n a Su-
perdex 200 26/60 column for gel filtration. The resulting chromatogram (shown in
figure 16.24) consist of five peaks including the void volume (peak 1). Figure 16.25
shows the western blot for this gel filtration revealing that DβH elutes in the peaks
2 and 3. According to the gel phase distribution coefficient KAV∼0.17 for peak 2,
130
16.1 Preliminary purification of DβH
the molecular weight of proteins in this peak is around 277 kDa (see section 15.2)
which indicates that tetrameric DβH (MW of 260 kDa without glycosylations)
elutes in this peak. The KAV for peak 3 is ∼0.29 corresponding to a molecular
weight of 118 kDa, therefore DβH in this peak is assigned to dimeric DβH (MW
of 130 kDa without glycosylations).
  
 UV2_280nm (2)
0.0
1.0
2.0
3.0
4.0
mAU
100 150 200 ml
Peak 4 
KAV = 0.40 
Peak 1 
Peak 2 
KAV = 0.17 
Peak 3 
KAV = 0.29 
Peak 5 
KAV = 0.54 
Figure 16.24: Gel filtration chromatogram for the preliminary purification of DβH. DβH eluted from
the cation exchange column was further purified on a Superdex 200 26/60 column and resulted in a chromatogram
with five peaks.
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Figure 16.25: WB for the preliminary gel filtration of DβH. Lane 1 is the marker, lane 2 is the DβH
concentrate from cation exchange, lane 3 is the sample loaded on the gel filtration column and lanes 4-8 are
samples from the five peaks in the chromatogram. The DβH concentrate was diluted with buffer prior to loading
which explain the difference in band intensity between lanes 2 and 3.
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16 Purification and characterisation of eukaryotic expressed DβH
Upon repurification of tetrameric DβH (peak 2) or dimeric DβH (peak 3) on
the Superdex 200 26/60 column a single peak at the same KAV was observed both
at pH 5, pH 5.6 and pH 6 (data not shown). This indicates that dimers and
tetramers of human DβH are not in rapid equilibrium under the conditions of the
experiment and that a change of pH does not result in conversion from dimeric
to tetrameric DβH or vice versa (see section 3.4.1). This is in agreement with
the observations by Li et al. (1996), who also found that dimers and tetramers of
human DβH are not rapidly interconverted.
16.2 Changed column and gradient in DβH purification
In order to obtain better separation of the proteins in the chromatogram it was
decided to use the smaller RESOURCE S, 6 ml column. When using this column
the area where DβH elutes was split up in four small peaks (data not shown).
Therefore it was decided to change the gradient in order to achieve even better
separation of these peaks.
 UV1_280nm  Cond  Conc
-50
  0
 50
100
mAU
0.0
20.0
40.0
60.0
80.0
mS/cm
  0
 20
 40
 60
 80
%B
1840 1860 1880 1900 ml
Fraction D2 
12.1 mS/cm 
Fraction D6 
13.5 mS/cm 
Fraction E3 
17.6 mS/cm 
Fraction E11 
20.9 mS/cm 
Fraction F4 
22.6 mS/cm 
Fraction F8 
24.4 mS/cm 
Fraction G2 
26.6 mS/cm 
Fraction H8 
33.7 mS/cm 
5  
100 
50 
0 
Figure 16.26: Cation exchange of DβH on a RESOURCE S, 6 ml column. A RESOURCE S, 6 ml
column was used for purification of DβH and the gradient of 0.025 M NaCl per CV resulted in eight peaks between
12-34 mS/cm.
The gradient was lowered to 100 % buffer B over 40 CV (0.025 M NaCl per CV)
compared to 50 % buffer B over 10 CV (0.05 M NaCl per CV). The chromatogram
from this purification is shown in figure 16.26, it contains several small peaks and
their contents were analysed by SDS-page and WB as shown in figures 16.27 and
16.28. The pattern of bands in the SDS-page and WB was very different, the
SDS-page has intense bands of ∼65 kDa in fractions E3 and F8, less intense bands
132
16.3 Small scale deglycosylation of DβH
of the same size in fractions D2 and F4 but this band was not present in the
intermediate fractions. In the WB on the other hand there are intense bands in
fractions D2 and D6 which are also present in fractions E3, E11, F4 and F8 but in
lower intensity.
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Figure 16.27: SDS-page from purification on
RESOURCE S, 6 ml column. Lane 1 is the
marker, lane 2 is the sample that was loaded, lanes
3-10 are samples from fractions D2, D6, E3, E11, F4,
F8, G2 and H8 respectively. Intense bands are seen at
∼65 kDa in fractions E3 and F8, less intense bands at
the same size are seen in fractions D2 and F4, but in
the remaining fractions there are no bands at this size.
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Figure 16.28: WB from purification on RE-
SOURCE S, 6 ml column. Lane 1 is the marker,
lane 2 is the sample that was loaded, lanes 3-10 are
samples from fractions D2, D6, E3, E11, F4, F8, G
and H8 respectively. Inte se DβH ba ds are seen in
fractions D2 and D6, b nds re lso seen in the follow-
ing fractions with decreasing intensity until fraction
F8.D2 and D6, bands are also seen in the following
fractions
Because of these differences the ∼65 kDa bands in fractions D2, E3 and F8
in the SDS-page were subjected to protein identification by mass spectrometry
(performed by Alphalyse A/S). The analysis revealed that fraction D2 primari-
ly contained human dopamine β-hydroxylase whereas fraction E3 contained the
D. melanogaster protein hexosaminidase 2 and fraction F8 contained immune-
regulated catalase, another protein from D. melanogaster. These results could
explain the differences between the SDS-page and WB (figures 16.27 and 16.28) and
it was decided to collect fractions with conductivity 4-16 mS/cm in the subsequent
purifications and avoid the following peak (fraction E3 in figure 16.26) containing
hexosaminidase 2.
Gel filtration of fractions with conductivity 4-16 mS/cm resulted in an extra
peak at KAV∼0.08 (118 ml in gel filtration chromatogram in section 16.4, fig-
ure 16.32B) and the absorbances at 280 nm of peaks 2 and 3 were changed: The
absorbance of peak 2 was increased and the absorbance of peak 3 was decreased
(see figure 16.32B).
16.3 Small scale deglycosylation of DβH
To analyse whether DβH produced in D. melanogaster S2 cells was glycosylated
and if deglycosylation was possible under non-denaturing conditions, concentrated
samples of tetrameric DβH (peak 2) and dimeric DβH (peak 3) from gel filtration
were deglycosylated under denaturing and non-denaturing conditions and analysed
with WB comparing with a non-deglycosylated sample from the same peak. The
western blot is shown in figure 16.29.
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Figure 16.29: Deglycosylation of DβH under denaturing and non-denaturing conditions. Lane 1 is
the marker, lanes 3-5 are DβH from gel filtration peak 2 control and deglycosylated under denaturing or non-
denaturing conditions respectively, lanes 7-9 are similar samples from gel filtration peak 3. DβH from both peaks
were glycosylated to begin with and deglycosylation was possible both under denaturing and non-denaturing
conditions.
As the WB shows the DβH in both peak 2 and peak 3 were glycosylated and
could be deglycosylated under both denaturing and non-denaturing conditions.
The glycosylations account for approximately 8 kDa of the total mass. Li et al.
(1996) also found that DβH produced in S2 cells was glycosylated, but they only
analysed the pool assigned to dimeric DβH.
Since deglycosylation of DβH was possible under non-denaturing conditions it
was decided to deglycosylate a larger portion of DβH in preparation for crystal-
lization experiments. Therefore different ratios of DβH and the deglycosylation
enzyme PNGase F were analysed and it was tested whether deglycosylation was
possible in 1 hr or if an overnight experiment was necessary.
The WB from these tests is shown in figure 16.30, it shows that DβH was
deglycosylated in all the conditions tested and that deglycosylation was possible
in 1 hr even with 0.125 µl PNGase F per 1 µl DβH (6.15 µM). This allows for
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Figure 16.30: Ratios between DβH and PNGase F for deglycosylation. Lane 1 is the marker, lane 2
is the control sample, lanes 3-6 are 1 hr deglycosylations with decreasing amounts of PNGase F and lanes 7-10
are overnight (o.n.) deglycosylations with decreasing amounts of PNGase F. DβH was deglycosylated under all
conditions, meaning that 0.125 µl PNGase F per µl DβH (6.15 µM) was enough for deglycosylation in 1 hr.
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a fast deglycosylation of DβH during the purification process and moreover when
scaling up only small amounts of PNGase F is needed compared to the volumes
recommended by the deglycosylation kit.
16.4 Final purification procedure for deglycosylated DβH
Since small scale deglycosylations were successful it was decided to scale up degly-
cosylations and add a third step in the purification procedure, namely separation
of deglycosylated DβH from the deglycosylation enzyme PNGase F.
The final purification procedure for a full purification of deglycosylated DβH
and the results hereof are presented here: To begin with pH of the DβH con-
taining medium was adjusted to pH 5.6 and the medium was diluted with 20 mM
CH3COONa/CH3COOH, pH 5.6 until the conductivity was below 6.5 mS/cm.
DβH in this solution were purified on a RESOURCE S, 6 ml column and after
cation exchange fractions with conductivity 4-16 mS/cm were collected and con-
centrated. The resulting concentrate was loaded on a Superdex 200 26/60 column
and after gel filtration the fractions of peak 2 (KAV∼0.17) were collected and con-
centrated. Tetrameric DβH in this concentrate was deglycosylated as described
in section 15.3 and afterwards separated from PNGase F using cation exchange
chromatography on a RESOURCE S, 6 ml column. Fractions with conductivity
10-17 mS/cm were collected and concentrated.
A schematic overview of the final purification procedure for deglycosylated
DβH is shown in figure 16.31. This procedure includes the three purification steps
also shown in figure 16.32 as well as the steps in between the actual purifications to
Dilution to conductivity
Cation exchange on a 
Collection and concentration of fractions 
Collection and concentration of peak 2
Cation exchange on a 
Collection and concentration of fractions 
Adjustment to pH 5.6 
 < 6.5 mS/cm 
RESOURCE S, 6 ml column 
                            
with conductivity 4-16 mS/cm 
Size exclusion chromatography on                               
Superdex 200 26/60 column 
Deglycosylation 
RESOURCE S, 6 ml column 
                                                   
with conductivity 10-17 mS/cm 
Figure 16.31: Schematic overview of the final purification procedure for deglycosylated DβH. The
individual steps in the DβH purification procedure. After the gel filtration step glycosylated DβH can be obtained
whereas some extra steps are needed to obtain purified and deglycosylated DβH.
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Figure 16.32: Chromatograms from a full purification of DβH. Chromatograms from cation exchange,
gel filtration and the second cation exchange of deglycosylated DβH. The collected fractions are marked with
dashed lines. A: Chromatogram from the initial cation exchange on a RESOURCE S, 6 ml column. DβH was
collected in the fractions with conductivity 4-16 mS/cm. B: Chromatogram from the gel filtration (Superdex 200
26/60 column) of the upconcentrated fractions with DβH. Tetrameric DβH eluting in peak 2 was collected and
deglycosylated. C: Chromatogram from the cation exchange of deglycosylated DβH (RESOURCE S, 6 ml column).
Deglycosylated DβH elutes between 10-17 mS/cm.
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prepare the samples for the next step.
Figure 16.32 shows the chromatograms from all three purification steps. Degly-
cosylated DβH elutes at higher conductivity compared to DβH with glycosylations
but in a narrower area. This is probably due to the loss of glycosylations and the
fact that only tetrameric DβH was deglycosylated and repurified. Therefore most
of the deglycosylated DβH will be tetrameric unless the conditions of the cation
exchange are preferable for conversion between dimers and tetramers.
 
  
 
kDa 
 
180 
 
115 
 
82 
 
64 
 
49 
 
37 
 
 
1 2 3 4 5 6 7 8 9 10 
 
62
M
ar
ke
r
   
   
Lo
ad
ed
, C
E1
   
   
   
   
Fi
ltr
at
e,
 C
E1
 4
-1
6 
m
S/
cm
   
   
   
   
   
   
C
on
ce
nt
ra
te
, C
E1
 4
-1
6 
m
S/
cm
   
   
   
   
   
   
   
   
Fi
ltr
at
e,
 G
F 
pe
ak
 2
   
   
   
   
   
   
   
   
   
   
C
on
ce
nt
ra
te
, G
F 
pe
ak
 2
   
   
   
   
   
   
   
   
   
   
   
   
D
eg
ly
co
sy
la
te
d 
pe
ak
 2
   
   
   
   
   
   
   
   
   
   
   
   
   
   
C
E2
, 2
-1
0 
m
S/
cm
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
Fi
ltr
at
e,
 C
E2
 1
0-
17
 m
S/
cm
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
C
on
ce
nt
ra
te
, C
E2
 1
0-
17
 m
S/
cm
Figure 16.33: WB from the three steps of DβH purification. Lane 1 is the marker, lane 2 is the
sample loaded on the first cation exchange column (CE1) and lanes 3 and 4 are filtrate and concentrate from the
upconcentration of fractions with conductivity 4-16 mS/cm. Lanes 5 and 6 are filtrate and concentrate from the
upconcentration of peak 2 in the gel filtration (GF), lane 7 is the deglycosylated DβH from GF peak 2. Lanes
8-10 are samples from the second cation exchange (CE2), 2-10 mS/cm conductivity in lane 8 and filtrate and
concentrate from the upconcentration of fractions with conductivity 10-17 mS/cm in lanes 9 and 10. DβH is
present in the 4-16 mS/cm concentrate from CE1, in the peak 2 concentrate from GF and in the 10-17 mS/cm
concentrate from CE2.
Figure 16.33 shows the WB from the three steps of DβH purification. DβH
is present in the concentrate from the first cation exchange and peak 2 of the gel
filtration, hereafter DβH was deglycosylated resulting in the band at lower mass
in lane 7. In the second cation exchange DβH was found in the fractions with
conductivity 10-17 mS/cm.
Average yields from the different steps of the purification procedure are listed
in table 16.7. Up to 1.4 mg/l culture tetrameric DβH was recovered in peak 2
and up to 1.0 mg/l culture dimeric DβH was recovered in peak 3. The yields are
not very high but according to the WB in figure 16.25 most DβH is captured in
the collected peaks which means that the expression step needs optimization to
obtain higher yields. Off course some DβH is lost to avoid contamination with
the D. melanogaster protein hexosaminidase 2 but this loss is unavoidable. A
total yield of 2.4 mg/l culture is comparable to the 16 mg dopamine β-hydroxylase
per l culture reported by Li et al. (1996). The difference in these yields can be
explained by the cell densities during these studies. Where I obtained a maximum
of 6·106 cells/ml per batch (see figure 14.19 in section 14.2), cell densities in the
fed batch experiments by Li et al. (1996) reached 1·108 cells/ml.
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Table 16.7: Average DβH yields during purifications. DβH concentration in the BiP-DβH medium was
not determined since the background around 280 nm was too high. Yields after the first cation exchange (CE1),
gel filtration (GF), deglycosylation and the second cation exchange (CE2) are given. The mass for glycosylated
DβH is estimated according to the different sizes of nondeglycosylated and deglycosylated DβH seen on western
blots.
Sample Volume (ml) Protein (mg) Mass used for
calculation
BiP-DβH medium 200 ml - -
CE1, 4-16 mS/cm 30 ml 0.58 mg ∼72,000 g/mol
GF, peak 2 22 ml 0.20 mg ∼72,000 g/mol
GF, peak 3 16 ml 0.14 mg ∼72,000 g/mol
Deglycosylated peak 2 0.2 ml 0.26 mg 64,940 g/mol
(incl. PNGase F)
CE2, 10-17 mS/cm 14 ml 0.04 mg 64,940 g/mol
16.5 Crystallization of deglycosylated DβH
JCSG+ and PACT Premier screens were set up at 4◦C with 100 nl of the DβH
solution (0.8-0.9 mg/ml) and 100 nl or 50 nl of the reservoir solutions, respectively.
At the same day the screens were set up, phase separation were seen as very small
droplets in all conditions of the PACT Premier screen, whereas the drops of the
JCSG+ screen were clear. After two weeks no crystal growth were observed. Due
to time limitations no further results from the crystallization screens are included
in this dissertation.
16.6 Mass spectrometric analysis of DβH
Glycosylated DβH from peak 2 and peak 3 from the gel filtration shown in fig-
ure 16.32B was analysed using mass spectrometry. The main species in peak 2 has
an apparent mass of 281,035±68 Da corresponding to tetrameric glycosylated DβH.
A small amount of a species assigned to dimeric DβH is also seen (figure 16.34).
The theoretical apparent mass of tetrameric holo-DβH without glycosylations is
m/z
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Figure 16.34: Mass spectrum of the DβH eluting in peak 2 of gel filtrations. The main species in
peak 2 has an apparent mass of 281,035±68 Da corresponding to tetrameric glycosylated DβH. Moreover a small
amount of a species assigned to dimeric DβH is also seen. The assigned charge states are given.
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260,208 Da. Glycosylations therefore account for around 5.2 kDa per monomer
which is consistent with the difference in bands from glycosylated and deglycosy-
lated DβH seen in figure 16.33, lanes 6 and 7.
Two species which have the masses 281,933±46 Da and 140,450±52 Da are
found in peak 3. These masses correspond to tetrameric and dimeric glycosylated
DβH, respectively (see figure 16.35).
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Figure 16.35: Mass spectrum of the DβH eluting in peak 3 of gel filtrations. Peak 3 contains two
species which are assigned to tetrameric and dimeric glycosylated DβH, respectively. The apparent masses of the
two species are 281,933±46 Da and 140,450±52 Da. The assigned charge states are given.
In the gel filtration (see section 16.1) a conversion between dimeric and tetra-
meric DβH was not seen upon repurification. Whether the conversion observed in
the mass spectrometry experiments stems from the storage of the sample at 4◦C
or the high ionic strength used is not clear.
16.7 Overall discussion of the purification and
characterisation of DβH
A detailed simple purification procedure for glycosylated DβH was established.
This procedure was further extended to obtain deglycosylated DβH for crystalliza-
tion experiments.
The development of the purification procedure was based on the findings by
Li et al. (1996), but in the procedure described here two steps are needed to
purify glycosylated DβH whereas Li et al. (1996) used three steps. Moreover
deglycosylated DβH was also purified with the procedure described here.
The yields of purified DβH was not very high but could possibly be increased
by optimization of the expression step. As discussed in section 14.2 the use of a
constitutively expressing cell line in a fed batch system would probably increase
both cell densities and the amount of DβH produced. Some DβH was lost dur-
ing the first cation exchange purification, but this loss is unavoidable in order to
prevent contamination with the D. melanogaster protein hexosaminidase 2.
Crystallization conditions for deglycosylated DβH have been investigated but
so far no crystal growth was seen. More protein is needed to do further crystal-
lization experiments, therefore an optimization of the expression step would also
be advantageous for this step.
DβH eluting in peaks 2 and 3 in the gel filtrations was analysed with mass
spectrometry showing that peak 2 contains tetrameric DβH and peak 3 contains
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dimeric DβH. This is consistent with the masses estimated from KAV of these
peaks. Mass spectrometric analysis moreover shows that glycosylations account
for around 5.2 kDa per monomer which is in agreement with the band differences
seen in western blots of glycosylated and deglycosylated DβH.
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Expression plasmids for TPH2, BiP-TPH2, DβH and BiP-DβH, respectively, were
successfully prepared and stable transfected D. melanogaster S2 cell lines for these
proteins were obtained.
TPH2 was only found in the insoluble fractions from S2/TPH2 cells and not
at all in S2/BiP-TPH2 cells or medium, therefore no further attempts were done
to express soluble TPH2 in this project.
DβH on the other hand was successfully expressed and secreted from S2/BiP-
DβH cells in increasing amounts with incubation time. As an inducible system was
used due to the problematic nature of TPH2 CuSO4 was added to the cultures.
Addition of CuSO4 induced protein production but at the same time it shortened
the survival period for the cells. The presence of CuSO4 together with the fact
that no fresh medium were fed to the cells shortened their survival and thereby
set an upper limit for the cell density. With this system the maximum cell density
reached was ∼6·106 cells/ml around the time of induction and afterwards decreased
(see section 14.2). Li et al. (1996) reports cell densities up to 2·107 cells/ml in their
batch experiments and up to 1·108 cells/ml in fed batch experiments (both with
constitutively expressing cells). This is probably the reason why these researchers
obtained higher yields of DβH (16 mg/l culture) compared to the yields obtained
in this project. Up to 1.4 mg/l culture tetrameric DβH was obtained in peak 2
from the gel filtration and up to 1.0 mg/l dimeric DβH was obtained in peak 3.
The dopamine β-hydroxylase concentrations determined in this project were
all measured by UV/visible spectrophotometry at 280 nm. This method is of
course not as precise as an assay for DβH since it does not distinguish between
different proteins. Much time has been spent on a modified version (overviewed
by Theilmann (2009)) of the colorimetric assay for DβH reported by Li et al.
(1996), however this assay did not reflect the presence of DβH in my hands. During
culturing increasing activity were seen with incubation time corresponding to the
increasing amounts of DβH verified by WB, but when analysing during the first
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cation exchange all activity were found in the flowthrough whereas no activity
were seen in the fractions containing DβH. The assay is an indirect assay based on
the oxidation of the electron donor N,N’-dimethyl-1,4-phenylenediamine (DMPD),
therefore other species than DβH could be responsible for the oxidation resulting
in the apparent activity seen. In this case the apparent activity was presumably
caused by increasing amounts of reactive oxidative species secreted by the S2 cells
with increasing cell death.
Unfortunately time limitations prevented me from trying to establish another
assay for DβH as for example the HPLC based assay reported by Li et al. (1996)
or an assay based on mass spectrometry.
In conclusion a detailed purification procedure for dopamine β-hydroxylase is
presented with this project. This procedure is important for the further character-
ization of DβH in regards of the three-dimensional structure, regulation of activity
and deducing the reaction mechanism (sections 3.4.1-3.6).
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In this project E. coli expression strains for tryptophan hydroxylase 2 and solu-
bility and stability optimized variants hereof were created and the proteins were
expressed and purified. Unfortunately it turned out that the introduction of mu-
tations did not improve the solubility or stability of TPH2 and thereby the purifi-
cation procedure was not improved either.
Instead stable transfected D. melanogaster S2 cell lines expressing intracellular
or secreted TPH2, respectively, were established. I was not able to detect secreted
TPH2 in the medium from the S2/BiP-TPH2 cells and for the S2/TPH2 cell line
TPH2 were only detected in the insoluble fractions. Therefore some more work
needs to be done on TPH2.
In order to investigate if secreted full length TPH2 ever exist, it could be a
possibility to establish another S2 cell line expressing TPH2 fused to a fluorescent
folding reporter (similar to Cabantous et al. (2005) or Shin et al. (2003)). Such a
system would allow one to see if correctly folded full length TPH2 is produced, if
it is secreted or not and how fast it is degraded. These informations would be very
useful when trying to optimize the TPH2 expression system. Moreover it would be
nice to know if TPH2 is destabilized/degraded by the S2 cells or if some content of
the medium causes this degrad If possible these suggestions require huge amounts
of medium and another equipment for the cell cultures are necessary.
I have been able to establish a stable transfected S2 cell line expressing and
secreting dopamine β-hydroxylase upon induction with CuSO4, to purify glycosy-
lated DβH from the medium and afterwards deglycosylate DβH for crystallization
experiments.
In order to improve these results more protein is needed, therefore another
stable transfected S2 cell line which express DβH constitutively would be very
useful. With such a cell line addition of CuSO4 can be avoided, and a higher density
of viable cells and thereby increased concentration of DβH would be possible. Even
though 500 µM CuSO4 should not influence cell growth (Santos et al., 2007), other
researchers have also seen decreasing cell number upon induction with 0.5-1 mM
CuSO4 (Lim et al., 2004; Valle et al., 2001). In this project the inducible system was
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chosen because of the concurrent creation of a tryptophan hydroxylase 2 expressing
cell line since the previous findings of insoluble TPH2 in bacterial systems could
indicate that this protein is harmful to growing cells. Creation of a constitutively
expressing DβH cell line could be done similar to the creation of the inducible
cell line described in this dissertation, only another expression vector should be
used. Such vector could be the pAc5.1/V5-His vector (Invitrogen) which allows
constitutively expression and contains the cloning sites which were also used in this
project. Moreover higher cell densities could be obtained in fed batch experiments
instead of the batch cultures used in this project.
Both on dopamine β-hydroxylase and tryptophan hydroxylase 2 more work
needs to be done in order to increase the possibility of developing a cure for some
of the neurological disorders caused by the dysfunction of these enzymes or the
neurotransmitters, which levels they regulate.
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Abstract Tryptophan hydroxylase exists in two isoforms:
Isoform 1 catalyses the first and rate-limiting step in the
synthesis of serotonin in the peripheral parts of the body
while isoform 2 catalyses this step in the brain. The cata-
lytic domains of human tryptophan hydroxylase 1 and 2
have been expressed, purified and the kinetic properties
have been studied and are compared. Substrate inhibition
by tryptophan is observed for isoform 1 but not for isoform
2. Large differences are observed in the Km,tetrahydrobiopterin
values for the two isoforms, being[10 times larger for
isoform 1 compared to isoform 2.
Keywords Tryptophan hydroxylase  Aromatic amino
acid hydroxylases  Enzyme kinetics  Enzymatic
properties  Iron-containing enzymes  Tetrahydrobiopterin
Abbreviations
BH4 6R-5,6,7,8-Tetrahydrobiopterin
TPH Tryptophan hydroxylase
cTPH1 Catalytic domain of human tryptophan
hydroxylase isoform 1
cTPH2 Catalytic domain of human tryptophan
hydroxylase isoform 2
LB Luria-Bertani
E. coli Escherichia coli
HEPES 4-(2-Hydroxyethyl)-piperazine-1-ethanesulfonic
acid
1 Introduction
Tryptophan hydroxylase (TPH, EC 1.14.16.4) catalyses the
first and rate-limiting step in the biosynthesis of serotonin
[14]. Serotonin is an important neurotransmitter and dys-
function of the central serotonergic system is observed in
psychiatric disorders such as depression, obsessive-com-
pulsive disorder (OCD) and schizophrenia [15].
TPH is part of the enzyme family of iron and tetrahy-
drobiopterin (BH4) dependent aromatic amino acid
hydroxylases. In addition to TPH this family constitutes
phenylalanine hydroxylase (EC 1.14.16.1) and tyrosine
hydroxylase (EC 1.14.16.2) [5]. All three enzymes use BH4
and O2 to hydroxylate the respective aromatic amino acids
and are believed to follow the same reaction mechanism [6,
23]. The eukaryotic aromatic amino acid hydroxylases all
form homotetramers and each monomer can be divided in
an N-terminal regulatory domain, a catalytic domain and a
small tetramerization domain in the C-terminal [5].
Two isoforms of TPH exists: Isoform 1 (TPH1) is found
in the pineal gland [14], cancer cells [1, 8] and the
peripheral parts of the body such as the enterochromaffin
cells [9] and mast cells [12]. The recently identified iso-
form 2 (TPH2) is found in the brain [14, 28, 31]. The
sequence identity of human TPH1 and human TPH2 is
65% while the sequence identity and sequence homology
of the catalytic domains are 81% and 91%, respectively.
TPH is notoriously known for its instability and it has
proven difficult to produce recombinant soluble and active
TPH [16, 17]. However, expression of the catalytic domain
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of TPH have been more successful yielding active and
stable enzyme suitable for thorough characterization
[3, 19–21]. Crystal structures are available of the catalytic
domain of human TPH1 with bound 7,8-dihydrobiopterin
[29] and of the catalytic domain of chicken TPH1 with
bound tryptophan substrate [30].
Recently, interest has been turned toward designing
inhibitors for TPH1 in the gastrointestinal tract which
could be used in the treatment of irritable bowel syndrome
and emesis associated with chemotheraphy [13, 25]. These
inhibitors are not isoform-specific but do not cross the
blood–brain barrier and these inhibitors therefore deplete
serotonin in the gastrointestinal tract and not in the brain.
In order to elucidate the possibility of isoform-specific
inhibitors, the kinetic properties of the catalytic domains
of human TPH1 (cTPH1) and TPH2 (cTPH2) have to be
compared.We have therefore cloned, expressed and purified
the cTPH1 and cTPH2 and determined the kinetic parame-
ters for both variants under identical conditions using a
continuous fluorimetric assay [18]. The apparentKm value of
one substrate is often dependable on the concentration of the
substrates held at fixed concentrations. It is therefore difficult
to compareKm values determined at different concentrations
of the fixed substrates. Comparison of kinetic parameters
also requires that they are obtained under identical condi-
tions e.g. ionic strength, pH and temperature. The Km and
Vmax values in this study are determined at the same condi-
tions and the values are therefore directly comparable.
2 Materials and Methods
Ultrapure glycerol was obtained from Invitrogen. Sodium
dodecyl sulfate polyacrylamide 12% Tris–HCl gels were
from Bio-Rad. (6R)-5,6,7,8-tetrahydro-L-biopterin dihy-
drochloride (BH4) was from Schircks Laboratories, Jona,
Switzerland. Luria Bertani (LB) media and all other
chemicals used were analytical grade obtained from
Sigma–Aldrich. All solutions were prepared using
18.2 MX cm water from a Milli-Q synthesis A10 Q-Gard
system (Millipore).
2.1 Protein Expression
2.1.1 Creation of Expression Strains
The genes for human TPH1 and TPH2 were codon opti-
mized for expression in Escherichia coli (E. coli) and
obtained from GenScript Corp., USA. For the protein
sequences the ExPASy accession numbers are P17752 for
TPH1 and Q8IWU9 for TPH2.
The genes encoding the catalytic domain of TPH1 (D1-
99 TPH1 D414-444) (cTPH1) and TPH2 (D1-145 TPH2
D460-490) (cTPH2) were amplified by PCR. Flanking
restriction enzyme sites were incorporated in the PCR
primers. The forward primer incorporates an NdeI site
encoding a start methionine and the reverse primer incor-
porates a stop codon followed by an XhoI site. The gene
sequences covered by the primers were amplified by Pfx
DNA polymerase (Invitrogen) and cloned into the pPCR-
Script Amp SK vector (Stratagene), using the protocols
provided by the manufacturer. The DNA sequences were
confirmed using the MWG Biotech sequencing service.
The cTPH/NdeI/XhoI genes were cloned into the pET26
(Novagen) expression vector [26] using T4 DNA ligase.
The obtained cTPH expression vectors were transformed
into E. coli BL21(DE3) cells (Novagen) for expression.
2.1.2 Expression
From a frozen stock, the E. coli BL21(DE3) strain harboring
the cTPH1 (or the cTPH2) expression plasmid was plated
on a LB 30 lg/mL kanamycin sulfate (30 Kan) agar plate.
The plate was incubated overnight at 37 °C. A single colony
was used to inoculate 50 mL LB 30 Kan media and incu-
bated at 37 °C in a 250 mL shake flask at 250 rpm. This
pre-culture was incubated for approximately 4 h until an
optical density at 600 nm (OD600) of 0.6–1.0 was reached.
The pre-culture was stored overnight at 4 °C. The cells were
then sedimented by centrifugation at 4 °C, 1,800g for
10 min. The cells were resuspended in 50 mL fresh LB 30
Kan media. 6.5 mL cell resuspension was used to inoculate
650 mL LB 30 Kan media in a 2 L triple baffled shake flask.
The culture was incubated at 30 °C, 250 rpm for approxi-
mately 5 h. When an OD600 of 0.4–0.6 was attained the
cTPH1 expression was induced by addition of isopropyl-b-
D-thiogalactopyranoside (IPTG) to a final concentration
of 0.1 mM. After incubation at 30 °C, 250 rpm for 4 h the
cells were harvested by centrifugation at 4 °C, 3000g for
15 min. Cells from 650 mL culture were resuspended in
25 mL ice-cold 20 mM Tris/H2SO4, pH 8.5 and transferred
to 50 mL polypropylene tubes. The cells were again cen-
trifuged at 4 °C, 3000g for 15 min. The supernatant was
discarded and the cells stored at -80 °C until further use.
Expression of cTPH2 was done using the same proce-
dure except that expression was done at 20 °C for 14 h as
described previously [21] and during harvesting, the cells
were resuspended in 20 mM Bis-Tris Propane/HCl, 5%
(w/v) glycerol, pH 7.2.
2.2 Protein Purification
2.2.1 Purification of cTPH1
Cells from 3 9 650 mL culture containing cTPH1 were
resuspended in 3 9 40 mL 20 mM Tris/H2SO4, pH 8.5.
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The cells were lysed on ice by sonication for 3 9 30 s
using a Satorius Labsonic P at 80% amplitude. The cell
extract was centrifuged at 4 °C, 18,000g for 20 min. The
supernatant was collected, diluted with ice-cold water to a
conductivity of 0.7 mS/cm and filtered through 0.45 lm
GHP Acrodisc GF syringe filters from Pall. The superna-
tant was loaded onto a Q Sepharose High Performance 26/
10 column which was equilibrated in buffer A: 20 mM
Tris/H2SO4, pH 8.5. Buffer B is 20 mM Tris/NaOH, 0.8 M
(NH4)2SO4, pH 8.5. The column was washed with 2 col-
umn volume (CV) of buffer A. A linear gradient of 0–7.5%
buffer B (0–60 mM (NH4)2SO4) over 7.5 CV was applied
to the column. The selected fractions containing cTPH1
were collected and pooled. The buffer of the collected
fractions was changed to 20 mM HEPES/NaOH, 200 mM
(NH4)2SO4, 10% (w/v) glycerol, pH 7.2 and concentrated
by ultrafiltration in an Amicon stirred pressure cell with
an Ultracel PL-3 membrane. Approximately 7 mL of
concentrated cTPH1 solution was then filtered through a
0.45 lm filter and loaded onto a HiLoad Superdex 75 26/
60 prep grade column. Prior to loading the column was
equilibrated in 20 mM HEPES/NaOH, 200 mM (NH4)2SO4,
10% (w/v) glycerol, pH 7.2. Fractions containing cTPH1
were collected. The cTPH1 concentration was determined
using the theoretical absorption coefficient [22] of
e280 = 33350 M
-1 cm-1. Samples were stored in aliquots
of 1 mL at -80 °C.
2.2.2 Purification of cTPH2
Cells from 3 9 650 mL culture containing cTPH2 were
resuspended in 3 9 40 mL 20 mM Bis-Tris Propane/HCl,
5%(w/v) glycerol, pH 7.2. The cells were lysed and cen-
trifuged as described above. The filtered supernatant was
loaded onto a Q Sepharose HP 26/10 column which was
equilibrated in buffer A: 20 mM Bis-Tris Propane/HCl,
5%(w/v) glycerol, pH 7.2. Buffer A and buffer B: 20 mM
Bis-Tris Propane/HCl, 5% (w/v) glycerol, 0.8 M (NH4)2SO4,
pH 7.2, were flushed with argon for 1 h/L buffer prior to
column equilibration. The column was washed with
1.5 CV of buffer A. A linear gradient of 0–4% buffer B
(0–32 mM (NH4)2SO4) over one CV was applied to the
column followed by a gradient from 4 to 12% buffer B
(32–96 mM (NH4)2SO4) over 5 CV. The selected fractions
containing cTPH2 were collected and pooled. The col-
lected fractions were then concentrated by ultrafiltration.
Approximately 7 mL of concentrated cTPH2 solution was
then filtered through a 0.45 lm filter and loaded onto
the Superdex 75 column. Prior to loading the column
was equilibrated in 20 mM HEPES/NaOH, 100 mM
(NH4)2SO4, 5%(w/v) glycerol, pH 7.2. Fractions contain-
ing cTPH2 were collected. The cTPH2 concentration was
determined using the theoretical absorption coefficient [22]
of e280 = 39310 M
-1 cm-1. Samples were stored in ali-
quots of 0.5 mL at -80 °C.
2.3 Determination of Kinetic Parameters
2.3.1 The TPH Activity Assay
The formation of 5-hydroxytryptophan was monitored
using fluorescence spectrophotometry essentially as
described by Moran et al. [18] and Nielsen et al. [21]. The
assay conditions were 50 mM HEPES/NaOH, 200 mM
(NH4)2SO4, pH 7.0, 7 mM dithiothreitol (DTT), 25 lM
(NH4)2Fe(SO4)2, and 0.025 g/L catalase. All measurements
were done at 15 °C in order to ensure the stability of the
enzyme [18]. The standard substrate concentrations were
70 lM tryptophan, 300 lM BH4 and 500 lM O2. The
dioxygen concentration is achieved by equilibration of the
solution with a mixture of dioxygen and dinitrogen gas (for
details see [21]). For each substrate concentration at least
three measurements were made.
2.3.1.1 Preparation of Enzyme Samples The cTPH1
solution was prepared as follows: Stocks of the cTPH1
were thawed and diluted with an equal volume of 20 mM
HEPES/NaOH 10% w/v glycerol, 200 mM (NH4)2SO4, pH
7.2, 4 mM DTT, 0.1 g/L catalase and 0.16 mM tryptophan.
The mixture was stored in 3–6 polypropylene tubes closed
under argon. 0.221 units of cTPH1 (measured at 70 lM
tryptophan, 300 lM BH4 and 500 lM O2) was used in the
measurements which equals *1.26 lM cTPH1.
The cTPH2 solution was prepared as follows: Stocks of
cTPH2 were thawed. The cTPH2 was diluted with 20 mM
HEPES/NaOH, 100 mM (NH4)2SO4, 5% (w/v) glycerol, pH
7.2 to give a concentration of 125 lM. Equal volumes of
the cTPH2 solution and 1.2 mM tryptophan, 4 mM DTT,
0.1 g/L catalase in 60 mM HEPES/NaOH, 15% (w/v)
glycerol, 300 mM (NH4)2SO4, pH 7.0 were mixed. The
mixture was stored in 3–6 polypropylene tubes closed under
argon. Diluting the cTPH2 sample with buffer solution
containing tryptophan, DTT, catalase, extra (NH4)2SO4,
extra glycerol prevents loss of activity. In the cTPH2
experiments 0.256 units (measured at 60 lM tryptophan,
300 lM BH4 and 300 lM O2) of cTPH2 was used which is
equal to*0.50 lM.
2.3.2 Enzyme Kinetic Data Analysis
The Michaelis–Menten equation (Eq. 1) was fitted to the
kinetic data for varied concentrations of BH4, O2 and
tryptophan, except in the case of varied tryptophan con-
centrations in the cTPH1 reaction where substrate inhibi-
tion was taken into account and Eq. 2 [4] was fitted to the
kinetic data. For each fitted curve, the sum of squares
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divided by the degrees of freedom (SS/DoF) and the
coefficient of determination (R2) are given. The fitting was
done using OriginPro 7.5 from OriginLab Corp.
vi ¼
Vmax½S
Km þ ½S
ð1Þ
vi ¼
Vmax½S
Km þ ½S þ
½S2
Ki
ð2Þ
3 Results
3.1 Expression and Purification
3.1.1 cTPH1
A high level of cTPH1 expression is achieved as seen on
the SDS–PAGE in Fig. 1a lane 1. The supernatant (Fig. 1a
lane 2) was loaded on a Q Sepharose HP column and
cTPH1 eluted at a conductivity of 1.5 mS/cm. A sample of
the collected fractions is seen in the SDS–PAGE Fig. 1a
lane 4. cTPH1 eluted from the 26/60 Superdex 75 gel fil-
tration column at 147 mL. A sample of the collected
fractions is shown in Fig. 1a lane 5. The cTPH1 band
corresponds to the expected molecular weight of 36.1 kDa.
The yield was 10 mg/L culture with a specific activity of
70 lmol 5-hydroxytryptophan/(min lmol cTPH1) (mea-
sured with 70 lM tryptophan, 300 lM BH4 and 500 lM
O2).
3.1.2 cTPH2
High level expression of cTPH2 is achieved as seen on the
SDS–PAGE in Fig. 1b lane 1. The supernatant (Fig. 1b
lane 2) was loaded on a Q Sepharose HP column and
cTPH2 eluted at conductivity of 9.5 mS/cm. A sample of
the collected fractions is seen in the SDS–PAGE Fig. 1b
lane 4. cTPH2 eluted from the 26/60 Superdex 75 gel
filtration column at 137 mL. A sample of the collected
fractions is shown in Fig. 1b lane 5. The cTPH2 band
corresponds to the expected molecular weight of 36.2 kDa.
The yield was 69 mg/L culture with a specific activity of
214 lmol 5-hydroxytryptophan/(min lmol cTPH2) (mea-
sured with 70 lM tryptophan, 300 lM BH4 and 500 lM
O2).
3.2 The Kinetic Parameters of cTPH1 and cTPH2
Plots of the initial rates as function of varied tryptophan,
BH4 and O2 concentrations for cTPH1 and cTPH2 are
shown in Fig. 2. The determined kinetic parameters are
summarized in Table 1.
4 Discussion
As seen on the SDS–PAGE in Fig. 1 the cTPH1 (a lane 1)
and cTPH2 (b lane 1) bands are clearly the dominant
proteins in the cell lysate. Judging from the thickness of the
cTPH1 and cTPH2 bands, the expression of cTPH2 is
significantly higher than that of cTPH1. Both genes coding
for cTPH1 and cTPH2 were codon optimized for expres-
sion in E. coli and one would therefore expect the same
expression level. However, differences in the translation
initiation region downstream of initiation codon could be
the reason for the difference in expression levels observed
[24].
The purifications of cTPH1 and cTPH2 were done in
two simple steps: An anion exchange followed by a gel
filtration as described and discussed by Nielsen et al. [21].
The anion exchange of cTPH1 was performed at pH 8.5
while the anion exchange of cTPH2 was done at pH 7.2.
The cTPH1 does not bind to the anion exchange media at
pH 7.2, most likely due to its higher pI compared to
cTPH2. The theoretical pI of cTPH1 is 6.6 and the pI of
cTPH2 is 5.6. The cTPH2 can be purified at pH above 8 but
a tendency to precipitate was observed, which is not the
case at pH 7.2. In the purification of the catalytic domain of
chicken TPH1 [21] we observe that the chicken cTPH1
elutes in three pools from the anion exchange column
depending on the charge of the iron and we use argon
flushed buffers and dithionite to keep the chicken cTPH1
iron in the ferrous form. In the case of human cTPH1 the
fractions containing ferric cTPH1 are more pure than the
fractions of ferrous cTPH1. Therefore, no attempt was done
to keep the cTPH1 in the ferrous form. Some cTPH1 is lost
in fractions containing ferrous cTPH1 and this partially
explains the lower yield of cTPH1 compared to cTPH2.
Determination of the true kinetic parameters for a ter
reactant enzyme like TPH demands saturating concentra-
tions of the fixed substrates. However, this is not possible
in the case of TPH. One reason is that TPH is inhibited at
oxygen concentrations above 500 lM (data not shown).
Two obvious explanations for this inhibition are that it is
either due to oxidation of ferrous iron to the inactive ferric
form or by oxidation of BH4 to the inactive dihydrobiop-
terin form.
We have determined the apparent Km values for all three
substrates of cTPH1 and cTPH2 (see Fig. 2; Table 1) at the
same conditions (i. e. same buffer concentration and pH,
same salt and ionic strength, same temperature and same
concentration of the fixed substrates) and the data are
therefore directly comparable.
Substrate inhibition by tryptophan is observed for
cTPH1 and chicken cTPH1 [21] but is not observed for
cTPH2 (see Fig. 2a, d). The Ki,tryptophan of cTPH1 is
72 ± 7 lM while for chicken cTPH1 it is 164 ± 24 lM
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[21]. Substrate inhibition by tryptophan have been reported
for TPH1 with a Ki,tryptophan of 282–740 lM with assay
conditions: 40 mM HEPES pH 7.0, 250 lM BH4, 2 mM
DTT, 10 lM (NH4)2Fe(SO4)2 and 30 °C [17]. These con-
ditions differ significantly from ours in the temperature and
the ionic strength of the solution and can therefore not be
directly compared. At conditions similar to ours (50 mM
MES, 100 mM (NH4)2SO4, 6 mM DTT, pH 7.0, 15 °C) a
Ki,tryptophan of 146 ± 14 lM have been reported for the
catalytic domain of rabbit TPH1 [19]. This Ki,tryptophan is in
the same range as the 72 ± 7 lM of cTPH1 and
164 ± 24 lM of chicken cTPH1. Further studies will be
undertaken to determine the mechanism of inhibition as
well as determining why tryptophan inhibition is not
observed for cTPH2, which is unexpected in view of the
high sequence identity.
Fig. 1 SDS–PAGE of samples from the purification of cTPH. a
cTPH1 samples. Lane 1 is 2 lL of the cell raw extract. Lane 2 is 2 lL
of the supernatant. Lane 3 is the molecular weight standard. Lane 4 is
the collected fractions from the anion exchange column. Lane 5 is the
collected fractions from the gel filtration column b cTPH2 samples
from the purification. Lane 1 is 2 lL of the cell raw extract. Lane 2 is
2 lL of the supernatant. Lane 3 is the molecular weight standard.
Lane 4 is the collected fractions from the anion exchange column.
Lane 5 is the collected fractions from the gel filtration column
Fig. 2 The initial rates for cTPH1 (a–c) and cTPH2 (d–f) as a function of substrate concentrations. (a, d) varied tryptophan concentration. (b, e)
varied BH4 concentration. (c, f) varied O2 concentration
404 M. S. Windahl et al.
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The Km,tryptophan values for the two isoforms are similar,
22.8 ± 0.9 lM for cTPH1 and 15.0 ± 0.4 lM for cTPH2.
These values are in line with the value for chicken cTPH1
(7.7 ± 0.7 lM) determined at the same conditions [21].
For human TPH1 the reported Km,tryptophan values are in the
range of 10.6–33 lM [16, 17, 27] while for TPH2 the
reported Km,tryptophan values are in the range of 20.1–77 lM
[3, 17, 27]. It should be noted that the assay conditions in
[3, 16, 17] differ significantly from ours by using a higher
temperature and lower ionic strength, and the experiments
by Tenner et al. [27] were done on crude lysates and it is
unclear if it is actually the initial rates that have been
measured. It is known that the catalytic domain is unstable
at low ionic strength [19, 21] and we therefore have
200 mM (NH4)2SO4 in our assay. No (NH4)2SO4 have
been added to the assay used in [3, 16, 17] and this may
yield an unstable catalytic domain. From our results we
conclude that the Km,tryptophan values for the two isoforms
are similar and within a quite narrow range.
Large differences in kinetic parameters is observed for
Km;BH4 : The Km;BH4 for cTPH1 is 315 ± 37 lM which
is similar to the chicken cTPH1 Km;BH4 which is
324 ± 10 lM. These values are more than a factor 10
higher than the Km;BH4 ¼ 26:5 1:3 lM for cTPH2. Cur-
rently, two possible explanations for this large difference
between the two isoforms can be envisioned. This large
difference might be a result of the substrate inhibition by
tryptophan observed for TPH1 or it might be rooted in
some structural difference in the BH4 binding pocket
resulting in a higher affinity of cTPH2 for BH4. For TPH1
reported Km;BH4 values are in the range of 27–50.8 lM [16,
17] and for TPH2 reported Km;BH4 values are in the range of
6.2–20.2 lM [3, 17].
The Km;O2 value of cTPH1 is 109 ± 7 lM while cTPH2
is 272 ± 9 lM. We have reported Km;O2 ¼ 39 2 lM for
chicken cTPH1 [21], otherwise Km;O2 have only been
reported for partially purified TPH from natural sources
(rabbit hindbrain [7], neoplastic murine mast cells [10] and
human carcinoid tumor [11]). The assay conditions used
in [7, 10, 11] differ greatly from ours, either by using
6-methyl-5,6,7,8-tetrahydropterin or 6,7-dimethyl-tetra-
hydropterin [10, 11] and/or by not measuring initial rates
[7, 10, 11]. A comparison with these values is therefore
pointless. For oxygenases such as TPH it is very unusual
that the Km;O2 have any relationship to the dissociation
constant of the (TPHBH4Trp)O2 complex. Instead the
Km;O2 generally corresponds to the relative magnitudes of
the second order rate constant for combination of dioxygen
with the enzyme complex and the first-order rate constant
for the rate-limiting step in the reaction [2]. So the enzyme
with the higher Km;O2; i.e. cTPH2, would also likely have
the higher kcat which is also the case. We have determined
kcat for cTPH2 to 274–404 min
-1 while for cTPH1 kcat is in
the range 83–160 min-1 and this follows the trend indi-
cated by the Km;O2 values. This suggests that cTPH2
hydroxylates tryptophan somewhat faster than cTPH1.
In conclusion we have cloned, expressed and purified
cTPH1 and cTPH2. Overall, large differences are
observed in the enzyme kinetic parameters of cTPH1 and
cTPH2 despite the high primary sequence identity (81%)
and homology (91%) between the catalytic domains of
the two TPH isoforms. Just a few amino acid substitu-
tions probably lead to subtle structural differences caus-
ing these large differences in enzyme kinetic parameters.
These differences hold promises for future identification
of isoform-specific compounds that selectively can target
either TPH1 or TPH2 in contrast to the recently pub-
lished inhibitors which inhibits both isoforms. Further
structural and enzymatic studies will be carried out to
elucidate the differences in the catalytic domains of the
two enzymes.
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Table 1 The apparent enzyme kinetic parameters of cTPH1 and cTPH2
Enzyme Varied substrate Km ± SE (lM) Vmax ± SE (lM min
-1) Ki ± SE (lM) Kcat ± SE (min
-1)a
cTPH1 Tryptophan 22.8 ± 0.9 201 ± 11 72 ± 7 160 ± 15
cTPH2 Tryptophan 15.0 ± 0.4 151 ± 1 – 302 ± 18
cTPH1 BH4 315 ± 37 164 ± 10 – 130 ± 13
cTPH2 BH4 26.5 ± 1.3 137 ± 2 – 274 ± 17
cTPH1 O2 109 ± 7 105 ± 2 – 83 ± 7
cTPH2 O2 273 ± 9 202 ± 3 – 404 ± 25
Measured at 15 °C with the fixed substrate concentration being: 70 lM tryptophan, 300 lM BH4 and 500 lM O2. Assay conditions were 50 mM
HEPES/NaOH, 200 mM (NH4)2SO4, pH 7.0, 7 mM dithiothreitol (DTT), 25 lM (NH4)2Fe(SO4)2, and 0.025 g/L catalase. Standard error (SE) at
95% confidence interval
a The kcat values are calculated by dividing the Vmax with the enzyme concentration given in sect. 2.3.1.1
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